

CITATION REPORT

List of articles citing

Angiotensin-converting enzyme 2 is a functional receptor for the SARS coronavirus

DOI: 10.1038/nature02145
Nature, 2003, 426, 450-4.

Source: <https://exaly.com/paper-pdf/35276913/citation-report.pdf>

Version: 2024-04-19

This report has been generated based on the citations recorded by exaly.com for the above article. For the latest version of this publication list, visit the link given above.

The third column is the impact factor (IF) of the journal, and the fourth column is the number of citations of the article.

#	Paper	IF	Citations
2284	Angiotensin converting enzyme-2 (ACE2) and its possible roles in hypertension, diabetes and cardiac function. 2003 , 10, 377-385		9
2283	The SARS-CoV S glycoprotein: expression and functional characterization. 2003 , 312, 1159-64		290
2282	Angiotensin Converting Enzyme-2 (ACE2) and its Possible Roles in Hypertension, Diabetes and Cardiac Function. 2003 , 10, 377-385		9
2281	The secret life of ACE2 as a receptor for the SARS virus. 2003 , 115, 652-3		107
2280	Molecular advances in severe acute respiratory syndrome-associated coronavirus (SARS-CoV). 2003 , 1, 247-62		17
2279	[Current topics on SARS coronavirus]. 2004 , 54, 97-105		1
2278	Coronaviruses and Toroviruses. 379-397		8
2277	On the origin of the super-spreading events in the SARS epidemic. 2004 , 68, 147-152		2
2276	Advancements in the battle against severe acute respiratory syndrome. 2004 , 5, 1687-93		13
2275	Plasma proteome of severe acute respiratory syndrome analyzed by two-dimensional gel electrophoresis and mass spectrometry. 2004 , 101, 17039-44		94
2274	Identification of immunodominant sites on the spike protein of severe acute respiratory syndrome (SARS) coronavirus: implication for developing SARS diagnostics and vaccines. 2004 , 173, 4050-7		128
2273	pH-dependent entry of severe acute respiratory syndrome coronavirus is mediated by the spike glycoprotein and enhanced by dendritic cell transfer through DC-SIGN. 2004 , 78, 5642-50		389
2272	ACE2 X-ray structures reveal a large hinge-bending motion important for inhibitor binding and catalysis. 2004 , 279, 17996-8007		424
2271	Protective humoral responses to severe acute respiratory syndrome-associated coronavirus: implications for the design of an effective protein-based vaccine. 2004 , 85, 3109-3113		57
2270	What have we learnt from SARS?. 2004 , 359, 1137-40		20
2269	Cleavage and serum reactivity of the severe acute respiratory syndrome coronavirus spike protein. 2004 , 190, 91-8		26
2268	Retroviral vectors pseudotyped with severe acute respiratory syndrome coronavirus S protein. 2004 , 78, 9007-15		114

2267	Identification of an antigenic determinant on the S2 domain of the severe acute respiratory syndrome coronavirus spike glycoprotein capable of inducing neutralizing antibodies. 2004 , 78, 6938-45	115
2266	Structure of a proteolytically resistant core from the severe acute respiratory syndrome coronavirus S2 fusion protein. 2004 , 101, 17958-63	104
2265	Severe acute respiratory syndrome: developing a research response. 2004 , 189, 634-41	11
2264	Comparison of cystine determination in mixed leukocytes vs polymorphonuclear leukocytes for diagnosis of cystinosis and monitoring of cysteamine therapy. 2004 , 50, 1686-8	34
2263	ACE2 gene polymorphisms do not affect outcome of severe acute respiratory syndrome. 2004 , 50, 1683-6	65
2262	Receptor-dependent coronavirus infection of dendritic cells. 2004 , 78, 5486-90	24
2261	Efficient replication of severe acute respiratory syndrome coronavirus in mouse cells is limited by murine angiotensin-converting enzyme 2. 2004 , 78, 11429-33	139
2260	Discovery of novel human and animal cells infected by the severe acute respiratory syndrome coronavirus by replication-specific multiplex reverse transcription-PCR. 2004 , 42, 3196-206	67
2259	Structural characterization of the fusion-active complex of severe acute respiratory syndrome (SARS) coronavirus. 2004 , 101, 8709-14	75
2258	A 193-amino acid fragment of the SARS coronavirus S protein efficiently binds angiotensin-converting enzyme 2. 2004 , 279, 3197-201	528
2257	Generation of synthetic severe acute respiratory syndrome coronavirus pseudoparticles: implications for assembly and vaccine production. 2004 , 78, 12557-65	106
2256	A subcutaneously injected UV-inactivated SARS coronavirus vaccine elicits systemic humoral immunity in mice. 2004 , 16, 1423-30	88
2255	Treatment of severe acute respiratory syndrome. 2004 , 126, 670-4	16
2254	Severe acute respiratory syndrome coronavirus pathogenesis, disease and vaccines: an update. 2004 , 23, S207-14	35
2253	Induction of IL-8 release in lung cells via activator protein-1 by recombinant baculovirus displaying severe acute respiratory syndrome-coronavirus spike proteins: identification of two functional regions. 2004 , 173, 7602-14	94
2252	Mechanisms of host defense following severe acute respiratory syndrome-coronavirus (SARS-CoV) pulmonary infection of mice. 2004 , 173, 4030-9	253
2251	S protein of severe acute respiratory syndrome-associated coronavirus mediates entry into hepatoma cell lines and is targeted by neutralizing antibodies in infected patients. 2004 , 78, 6134-42	153
2250	Severe acute respiratory syndrome: review and lessons of the 2003 outbreak. 2004 , 33, 628-34	39

2249	Synthesis and characterization of a native, oligomeric form of recombinant severe acute respiratory syndrome coronavirus spike glycoprotein. 2004 , 78, 10328-35	94
2248	Structure-based discovery of a novel angiotensin-converting enzyme 2 inhibitor. 2004 , 44, 903-6	142
2247	Retroviruses pseudotyped with the severe acute respiratory syndrome coronavirus spike protein efficiently infect cells expressing angiotensin-converting enzyme 2. 2004 , 78, 10628-35	197
2246	Small molecules targeting severe acute respiratory syndrome human coronavirus. 2004 , 101, 10012-7	368
2245	Inhibition of severe acute respiratory syndrome-associated coronavirus (SARSCoV) by calpain inhibitors and beta-D-N4-hydroxycytidine. 2004 , 15, 15-22	110
2244	CD209L (L-SIGN) is a receptor for severe acute respiratory syndrome coronavirus. 2004 , 101, 15748-53	456
2243	Structure, evolutionary conservation, and functions of angiotensin- and endothelin-converting enzymes. 2004 , 239, 47-97	27
2242	Novel and re-emerging respiratory infections. 2004 , 2, 405-12	4
2241	Inhibition of severe acute respiratory syndrome virus replication by small interfering RNAs in mammalian cells. 2004 , 78, 7523-7	96
2240	Assessment of synthetic peptides of severe acute respiratory syndrome coronavirus recognized by long-lasting immunity. 2004 , 64, 600-7	15
2239	Childhood severe acute respiratory syndrome, coronavirus infections and asthma. 2004 , 15, 206-9	48
2238	Severe acute respiratory syndrome. 2004 , 10, S88-97	714
2237	Virus entry: molecular mechanisms and biomedical applications. 2004 , 2, 109-22	367
2236	Antivirals and antiviral strategies. 2004 , 2, 704-20	275
2235	Development and characterisation of neutralising monoclonal antibody to the SARS-coronavirus. 2004 , 120, 87-96	92
2234	SARS corona virus peptides recognized by antibodies in the sera of convalescent cases. 2004 , 324, 251-6	110
2233	Development of a safe neutralization assay for SARS-CoV and characterization of S-glycoprotein. 2004 , 326, 140-9	54
2232	Importance of Akt signaling pathway for apoptosis in SARS-CoV-infected Vero E6 cells. 2004 , 327, 169-74	60

2231	Interferon-beta and interferon-gamma synergistically inhibit the replication of severe acute respiratory syndrome-associated coronavirus (SARS-CoV). 2004 , 329, 11-7	137
2230	Coronavirus replication and pathogenesis: Implications for the recent outbreak of severe acute respiratory syndrome (SARS), and the challenge for vaccine development. 2004 , 10, 75-85	40
2229	[Relevance of coronaviruses. The SARS example]. 2004 , 47, 647-52	
2228	Infection of cultured intestinal epithelial cells with severe acute respiratory syndrome coronavirus. 2004 , 61, 2100-12	59
2227	Angiotensin-converting enzyme-2: a molecular and cellular perspective. 2004 , 61, 2704-13	105
2226	Angiotensin-converting enzyme 2: a functional receptor for SARS coronavirus. 2004 , 61, 2738-43	159
2225	The SARS-CoV S glycoprotein. 2004 , 61, 2428-30	22
2224	Organ distribution of severe acute respiratory syndrome (SARS) associated coronavirus (SARS-CoV) in SARS patients: implications for pathogenesis and virus transmission pathways. 2004 , 203, 622-30	722
2223	Tissue distribution of ACE2 protein, the functional receptor for SARS coronavirus. A first step in understanding SARS pathogenesis. 2004 , 203, 631-7	3418
2222	Exploring the pathogenesis of severe acute respiratory syndrome (SARS): the tissue distribution of the coronavirus (SARS-CoV) and its putative receptor, angiotensin-converting enzyme 2 (ACE2). 2004 , 203, 740-3	164
2221	Severe acute respiratory syndrome and the liver. 2004 , 39, 291-4	16
2220	Evaluation of antibody responses against SARS coronaviral nucleocapsid or spike proteins by immunoblotting or ELISA. 2004 , 73, 338-46	55
2219	Persistent infection of SARS coronavirus in colonic cells in vitro. 2004 , 74, 1-7	71
2218	The 3D structure analysis of SARS-CoV S1 protein reveals a link to influenza virus neuraminidase and implications for drug and antibody discovery. 2004 , 681, 137-141	10
2217	Identification of novel small-molecule inhibitors of severe acute respiratory syndrome-associated coronavirus by chemical genetics. 2004 , 11, 1293-9	121
2216	A novel fingerprint map of SARS-CoV with visualization analysis.	
2215	Reconstruction of the most recent common ancestor sequences of SARS-Cov S gene and detection of adaptive evolution in the spike protein. 2004 , 49, 1311-1313	5
2214	Identification of angiotensin converting enzyme 2 in the rodent retina. 2004 , 29, 419-27	64

2213	DC-SIGN and DC-SIGNR interact with the glycoprotein of Marburg virus and the S protein of severe acute respiratory syndrome coronavirus. 2004 , 78, 12090-5	290
2212	Molecular targets for the rational design of drugs to inhibit SARS coronavirus. 2004 , 1, 205-209	3
2211	Identification of six new polymorphisms in the human coronavirus 229E receptor gene (aminopeptidase N/CD13). 2004 , 8, 217-22	12
2210	Severe acute respiratory syndrome coronavirus spike protein expressed by attenuated vaccinia virus protectively immunizes mice. 2004 , 101, 6641-6	341
2209	Suppression of SARS-CoV entry by peptides corresponding to heptad regions on spike glycoprotein. 2004 , 319, 746-746	
2208	Antibody detection of SARS-CoV spike and nucleocapsid protein. 2004 , 314, 931-6	52
2207	Expression cloning of functional receptor used by SARS coronavirus. 2004 , 315, 439-44	122
2206	Characterization of humoral responses in mice immunized with plasmid DNAs encoding SARS-CoV spike gene fragments. 2004 , 315, 1134-9	46
2205	Characterization of SARS main protease and inhibitor assay using a fluorogenic substrate. 2004 , 318, 862-7	131
2204	Assembly of human severe acute respiratory syndrome coronavirus-like particles. 2004 , 318, 833-8	104
2203	Following the rule: formation of the 6-helix bundle of the fusion core from severe acute respiratory syndrome coronavirus spike protein and identification of potent peptide inhibitors. 2004 , 319, 283-8	83
2202	Suppression of SARS-CoV entry by peptides corresponding to heptad regions on spike glycoprotein. 2004 , 319, 746-52	84
2201	Identification of two antigenic epitopes on SARS-CoV spike protein. 2004 , 319, 929-35	34
2200	Susceptibility to SARS coronavirus S protein-driven infection correlates with expression of angiotensin converting enzyme 2 and infection can be blocked by soluble receptor. 2004 , 319, 1216-21	208
2199	Nucleocapsid protein of SARS coronavirus tightly binds to human cyclophilin A. 2004 , 321, 557-65	92
2198	Highly infectious SARS-CoV pseudotyped virus reveals the cell tropism and its correlation with receptor expression. 2004 , 321, 994-1000	87
2197	Oligomerization of the SARS-CoV S glycoprotein: dimerization of the N-terminus and trimerization of the ectodomain. 2004 , 322, 93-9	27
2196	ACE1 polymorphism and progression of SARS. 2004 , 323, 1124-9	69

2195	Receptor-binding domain of SARS-CoV spike protein induces highly potent neutralizing antibodies: implication for developing subunit vaccine. 2004 , 324, 773-81	316
2194	Immunological, structural, and preliminary X-ray diffraction characterizations of the fusion core of the SARS-coronavirus spike protein. 2004 , 324, 761-7	7
2193	Silencing of SARS-CoV spike gene by small interfering RNA in HEK 293T cells. 2004 , 324, 1186-93	39
2192	Inactivated SARS-CoV vaccine elicits high titers of spike protein-specific antibodies that block receptor binding and virus entry. 2004 , 325, 445-52	109
2191	ACE2, a new regulator of the renin-angiotensin system. 2004 , 15, 166-9	230
2190	Cellular entry of the SARS coronavirus. 2004 , 12, 466-72	172
2189	ACE2: from vasopeptidase to SARS virus receptor. 2004 , 25, 291-4	370
2188	SARS: future research and vaccine. 2004 , 5, 300-3	10
2187	Molecular biology of severe acute respiratory syndrome coronavirus. 2004 , 7, 412-9	150
2186	No association of angiotensin-converting enzyme 2 gene (ACE2) polymorphisms with essential hypertension. 2004 , 17, 624-8	58
2185	A model of the ACE2 structure and function as a SARS-CoV receptor. 2004 , 314, 235-41	128
2184	Cloning and characterization of a secreted form of angiotensin-converting enzyme 2. 2004 , 122, 61-7	37
2183	Interaction between heptad repeat 1 and 2 regions in spike protein of SARS-associated coronavirus: implications for virus fusogenic mechanism and identification of fusion inhibitors. 2004 , 363, 938-47	380
2182	Bibliography. Current world literature. Infectious diseases. 2004 , 10, 218-38	
2181	Severe acute respiratory syndrome: an update. 2004 , 17, 287-94	15
2180	Potent neutralization of severe acute respiratory syndrome (SARS) coronavirus by a human mAb to S1 protein that blocks receptor association. 2004 , 101, 2536-41	481
2179	Severe acute respiratory syndrome: public health response and clinical practice update for an emerging disease. 2004 , 16, 61-9	7
2178	Membrane-bound carboxypeptidase E facilitates the entry of eosinophil cationic protein into neuroendocrine cells. 2004 , 382, 841-8	18

2177	New FAcEs to the renin-angiotensin system. 2005 , 20, 91-5	36
2176	ACE2; an ACE up the Sleeve?. 2005 , 1, 51-63	7
2175	History and recent advances in coronavirus discovery. 2005 , 24, S223-7, discussion S226	315
2174	Bibliography Current World Literature. 2005 , 17, 119-164	
2173	Current World Literature. 2005 , 18, 171-196	
2172	SARS-CoV genome polymorphism: a bioinformatics study. 2005 , 3, 18-35	8
2171	Chemokine up-regulation in SARS-coronavirus-infected, monocyte-derived human dendritic cells. 2005 , 106, 2366-74	340
2170	Bcl-xL inhibits T-cell apoptosis induced by expression of SARS coronavirus E protein in the absence of growth factors. 2005 , 392, 135-43	99
2169	Phylogenetic analysis and sequence comparisons of structural and non-structural SARS coronavirus proteins in Taiwan. 2005 , 5, 261-9	13
2168	Microarray and real-time RT-PCR analyses of differential human gene expression patterns induced by severe acute respiratory syndrome (SARS) coronavirus infection of Vero cells. 2005 , 7, 248-59	43
2167	Establishment of Vero E6 cell clones persistently infected with severe acute respiratory syndrome coronavirus. 2005 , 7, 1530-40	17
2166	Production of a monoclonal antibody against SARS-CoV spike protein with single intrasplenic immunization of plasmid DNA. 2005 , 100, 177-81	10
2165	Pathogenesis of severe acute respiratory syndrome. 2005 , 17, 404-10	122
2164	A molecular docking model of SARS-CoV S1 protein in complex with its receptor, human ACE2. 2005 , 29, 254-7	23
2163	Membrane-associated zinc peptidase families: comparing ACE and ACE2. 2005 , 1751, 2-8	64
2162	The severe acute respiratory syndrome (SARS). 2005 , 11, 455-68	9
2161	Antibody to severe acute respiratory syndrome (SARS)-associated coronavirus spike protein domain 2 cross-reacts with lung epithelial cells and causes cytotoxicity. 2005 , 141, 500-8	43
2160	Hypocortisolism in survivors of severe acute respiratory syndrome (SARS). 2005 , 63, 197-202	145

2159	Good ACE, bad ACE do battle in lung injury, SARS. 2005 , 11, 821-2	67
2158	TZDs and diabetes: testing the waters. 2005 , 11, 822-4	15
2157	Angiotensin-converting enzyme is a GPI-anchored protein releasing factor crucial for fertilization. 2005 , 11, 160-6	196
2156	A crucial role of angiotensin converting enzyme 2 (ACE2) in SARS coronavirus-induced lung injury. 2005 , 11, 875-9	2294
2155	Immunopathogenesis of coronavirus infections: implications for SARS. 2005 , 5, 917-27	365
2154	Receptor and viral determinants of SARS-coronavirus adaptation to human ACE2. 2005 , 24, 1634-43	710
2153	Coronaviral hypothetical and structural proteins were found in the intestinal surface enterocytes and pneumocytes of severe acute respiratory syndrome (SARS). 2005 , 18, 1432-9	50
2152	Angiotensin-converting enzyme 2 protects from severe acute lung failure. <i>Nature</i> , 2005 , 436, 112-6	50.4 1770
2151	Identification of critical active-site residues in angiotensin-converting enzyme-2 (ACE2) by site-directed mutagenesis. 2005 , 272, 3512-20	74
2150	Characterization of viral proteins encoded by the SARS-coronavirus genome. 2005 , 65, 69-78	86
2149	Development of antiviral therapy for severe acute respiratory syndrome. 2005 , 66, 81-97	56
2148	From genome to antivirals: SARS as a test tube. 2005 , 10, 345-52	16
2147	A novel cell-based binding assay system reconstituting interaction between SARS-CoV S protein and its cellular receptor. 2005 , 123, 41-8	20
2146	Development of a homogeneous screening assay for automated detection of antiviral agents active against severe acute respiratory syndrome-associated coronavirus. 2005 , 129, 56-63	24
2145	Detection of the nucleocapsid protein of severe acute respiratory syndrome coronavirus in serum: comparison with results of other viral markers. 2005 , 130, 45-50	43
2144	Evaluation of a safe and sensitive Spike protein-based immunofluorescence assay for the detection of antibody responses to SARS-CoV. 2005 , 296, 37-44	21
2143	Assays for the assessment of neutralizing antibody activities against Severe Acute Respiratory Syndrome (SARS) associated coronavirus (SCV). 2005 , 301, 21-30	20
2142	Structural basis of severe acute respiratory syndrome coronavirus ADP-ribose-1''-phosphate dephosphorylation by a conserved domain of nsP3. 2005 , 13, 1665-75	148

2141	Structural insights into SARS coronavirus proteins. 2005 , 15, 664-72	64
2140	Substitutions of conserved amino acids in the receptor-binding domain of the spike glycoprotein affect utilization of murine CEACAM1a by the murine coronavirus MHV-A59. 2005 , 334, 98-110	12
2139	Identification of a critical neutralization determinant of severe acute respiratory syndrome (SARS)-associated coronavirus: importance for designing SARS vaccines. 2005 , 334, 74-82	97
2138	Epitope mapping and biological function analysis of antibodies produced by immunization of mice with an inactivated Chinese isolate of severe acute respiratory syndrome-associated coronavirus (SARS-CoV). 2005 , 334, 134-43	24
2137	Neutralizing antibody and protective immunity to SARS coronavirus infection of mice induced by a soluble recombinant polypeptide containing an N-terminal segment of the spike glycoprotein. 2005 , 334, 160-5	89
2136	Identification of murine CD8 T cell epitopes in codon-optimized SARS-associated coronavirus spike protein. 2005 , 335, 34-45	66
2135	Cells of human aminopeptidase N (CD13) transgenic mice are infected by human coronavirus-229E in vitro, but not in vivo. 2005 , 335, 185-97	31
2134	Long-term protection from SARS coronavirus infection conferred by a single immunization with an attenuated VSV-based vaccine. 2005 , 340, 174-82	135
2133	LSECtin interacts with filovirus glycoproteins and the spike protein of SARS coronavirus. 2005 , 340, 224-36	167
2132	Genetic analysis of the SARS-coronavirus spike glycoprotein functional domains involved in cell-surface expression and cell-to-cell fusion. 2005 , 341, 215-30	57
2131	Serine-scanning mutagenesis studies of the C-terminal heptad repeats in the SARS coronavirus S glycoprotein highlight the important role of the short helical region. 2005 , 341, 122-9	10
2130	Identification of an alternative 5'-untranslated exon and new polymorphisms of angiotensin-converting enzyme 2 gene: lack of association with SARS in the Vietnamese population. 2005 , 136, 52-7	40
2129	Diffusion-weighted MR study of femoral head avascular necrosis in severe acute respiratory syndrome patients. 2005 , 22, 661-4	22
2128	Recurrent mutations associated with isolation and passage of SARS coronavirus in cells from non-human primates. 2005 , 76, 435-40	23
2127	Autoantibodies against human epithelial cells and endothelial cells after severe acute respiratory syndrome (SARS)-associated coronavirus infection. 2005 , 77, 1-7	50
2126	Treatment of severe acute respiratory syndrome. 2005 , 24, 583-91	82
2125	Susceptibility of different eukaryotic cell lines to SARS-coronavirus. 2005 , 150, 1023-31	34
2124	Characterization of neutralizing monoclonal antibodies recognizing a 15-residues epitope on the spike protein HR2 region of severe acute respiratory syndrome coronavirus (SARS-CoV). 2005 , 12, 711-27	32

2123	Molecular evidence of tissue renin-angiotensin systems: a focus on the brain. 2005 , 7, 135-40	39
2122	A combined nucleocapsid vaccine induces vigorous SARS-CD8+ T-cell immune responses. 2005 , 3, 7	16
2121	Antiviral Drug Targets and Strategies for Emerging Viral Diseases and Bioterrorism Threats. 2005 , 83-113	3
2120	An overview on severe acute respiratory syndrome (SARS). 2005 , 63, 149-57	12
2119	Genome organization and structural aspects of the SARS-related virus. 2005 , 101-128	2
2118	. 2005 ,	3
2117	. 2005 ,	6
2116	SARS vaccine development. 2005 , 11, 1016-20	126
2115	Longitudinally profiling neutralizing antibody response to SARS coronavirus with pseudotypes. 2005 , 11, 411-6	123
2114	Current status of anti-SARS agents. 2005 , 16, 23-31	16
2113	Identification of two critical amino acid residues of the severe acute respiratory syndrome coronavirus spike protein for its variation in zoonotic tropism transition via a double substitution strategy. 2005 , 280, 29588-95	119
2112	Design of wide-spectrum inhibitors targeting coronavirus main proteases. 2005 , 3, e324	392
2111	SARS: understanding the virus and development of rational therapy. 2005 , 5, 677-97	16
2110	ACE and ACE2: a tale of two enzymes. 2005 , 26, 322-4	82
2109	Severe acute respiratory syndrome coronavirus infection of human ciliated airway epithelia: role of ciliated cells in viral spread in the conducting airways of the lungs. 2005 , 79, 15511-24	249
2108	Recombinant severe acute respiratory syndrome (SARS) coronavirus nucleocapsid protein forms a dimer through its C-terminal domain. 2005 , 280, 23280-6	60
2107	Structure of SARS coronavirus spike receptor-binding domain complexed with receptor. 2005 , 309, 1864-8	1383
2106	Exogenous ACE2 expression allows refractory cell lines to support severe acute respiratory syndrome coronavirus replication. 2005 , 79, 3846-50	116

2105	Structural biology. Adaptation of SARS coronavirus to humans. 2005 , 309, 1822-3	43
2104	ACE2 receptor expression and severe acute respiratory syndrome coronavirus infection depend on differentiation of human airway epithelia. 2005 , 79, 14614-21	593
2103	Inhibitors of cathepsin L prevent severe acute respiratory syndrome coronavirus entry. 2005 , 102, 11876-81	734
2102	New antiviral drugs, vaccines and classic public health interventions against SARS coronavirus. 2005 , 16, 13-21	9
2101	Vesicular stomatitis virus pseudotyped with severe acute respiratory syndrome coronavirus spike protein. 2005 , 86, 2269-2274	106
2100	Tumor necrosis factor-alpha convertase (ADAM17) mediates regulated ectodomain shedding of the severe-acute respiratory syndrome-coronavirus (SARS-CoV) receptor, angiotensin-converting enzyme-2 (ACE2). 2005 , 280, 30113-9	467
2099	Luxury at a cost? Recombinant mouse hepatitis viruses expressing the accessory hemagglutinin esterase protein display reduced fitness in vitro. 2005 , 79, 15054-63	49
2098	Modulation of the immune response to the severe acute respiratory syndrome spike glycoprotein by gene-based and inactivated virus immunization. 2005 , 79, 13915-23	38
2097	Molecular and biological characterization of human monoclonal antibodies binding to the spike and nucleocapsid proteins of severe acute respiratory syndrome coronavirus. 2005 , 79, 1635-44	130
2096	Object-oriented biological system integration: a SARS coronavirus example. 2005 , 21, 2502-9	8
2095	Chronic liver injury in rats and humans upregulates the novel enzyme angiotensin converting enzyme 2. 2005 , 54, 1790-6	215
2094	Evaluation of human monoclonal antibody 80R for immunoprophylaxis of severe acute respiratory syndrome by an animal study, epitope mapping, and analysis of spike variants. 2005 , 79, 5900-6	129
2093	Characterization of cytokine/chemokine profiles of severe acute respiratory syndrome. 2005 , 171, 850-7	238
2092	Do we need genomic research for the prevention of common diseases with environmental causes?. 2005 , 161, 799-805	118
2091	The immune response to viral lower respiratory tract infection. 2005 , 568, 41-65	1
2090	Human coronavirus NL63 employs the severe acute respiratory syndrome coronavirus receptor for cellular entry. 2005 , 102, 7988-93	518
2089	Identification and antigenic epitope mapping of immunodominant region amino residues 510 to 672 on the spike protein of the severe acute respiratory syndrome coronavirus. 2005 , 24, 503-9	9
2088	Receptor-binding domain of severe acute respiratory syndrome coronavirus spike protein contains multiple conformation-dependent epitopes that induce highly potent neutralizing antibodies. 2005 , 174, 4908-15	202

2087	Humanized mice develop coronavirus respiratory disease. 2005 , 102, 8073-4	7
2086	Severe acute respiratory syndrome and the innate immune responses: modulation of effector cell function without productive infection. 2005 , 174, 7977-85	117
2085	Single amino acid substitutions in the severe acute respiratory syndrome coronavirus spike glycoprotein determine viral entry and immunogenicity of a major neutralizing domain. 2005 , 79, 11638-46	52
2084	Mannose-binding lectin in severe acute respiratory syndrome coronavirus infection. 2005 , 191, 1697-704	208
2083	Quantitative analysis of severe acute respiratory syndrome (SARS)-associated coronavirus-infected cells using proteomic approaches: implications for cellular responses to virus infection. 2005 , 4, 902-13	69
2082	Identification of two neutralizing regions on the severe acute respiratory syndrome coronavirus spike glycoprotein produced from the mammalian expression system. 2005 , 79, 1906-10	72
2081	Nidovirus sialate-O-acetyl esterases: evolution and substrate specificity of coronaviral and toroviral receptor-destroying enzymes. 2005 , 280, 6933-41	67
2080	Angiotensin-converting enzyme 2 (ACE2), but not ACE, is preferentially localized to the apical surface of polarized kidney cells. 2005 , 280, 39353-62	134
2079	Severe acute respiratory syndrome coronavirus infection of golden Syrian hamsters. 2005 , 79, 503-11	222
2078	Protease-mediated enhancement of severe acute respiratory syndrome coronavirus infection. 2005 , 102, 12543-7	241
2077	Proteomic fingerprints for potential application to early diagnosis of severe acute respiratory syndrome. 2005 , 51, 56-64	63
2076	Apical entry and release of severe acute respiratory syndrome-associated coronavirus in polarized Calu-3 lung epithelial cells. 2005 , 79, 9470-9	93
2075	Differential maturation and subcellular localization of severe acute respiratory syndrome coronavirus surface proteins S, M and E. 2005 , 86, 1423-1434	172
2074	Cross-host evolution of severe acute respiratory syndrome coronavirus in palm civet and human. 2005 , 102, 2430-5	508
2073	Molecular interactions in the assembly of coronaviruses. 2005 , 64, 165-230	236
2072	Development and characterization of a severe acute respiratory syndrome-associated coronavirus-neutralizing human monoclonal antibody that provides effective immunoprophylaxis in mice. 2005 , 191, 507-14	128
2071	Fatal severe acute respiratory syndrome is associated with multiorgan involvement by coronavirus. 2005 , 191, 193-7	130
2070	Angiotensin-converting enzyme 2 (ACE2) and ACE activities display tissue-specific sensitivity to undernutrition-programmed hypertension in the adult rat. 2005 , 46, 1169-74	91

2069	Comparative host gene transcription by microarray analysis early after infection of the Huh7 cell line by severe acute respiratory syndrome coronavirus and human coronavirus 229E. 2005 , 79, 6180-93	76
2068	Murine coronavirus with an extended host range uses heparan sulfate as an entry receptor. 2005 , 79, 14451-6	98
2067	Identification and characterization of the putative fusion peptide of the severe acute respiratory syndrome-associated coronavirus spike protein. 2005 , 79, 7195-206	100
2066	Recombinant modified vaccinia virus Ankara expressing the spike glycoprotein of severe acute respiratory syndrome coronavirus induces protective neutralizing antibodies primarily targeting the receptor binding region. 2005 , 79, 2678-88	171
2065	Rapid Response Research - SARS Coronavirus Vaccines and Application of Processes to Other Emerging Infectious Diseases. 2005 , 1, 185-200	10
2064	Evasion of antibody neutralization in emerging severe acute respiratory syndrome coronaviruses. 2005 , 102, 797-801	219
2063	Severe acute respiratory syndrome coronavirus-like virus in Chinese horseshoe bats. 2005 , 102, 14040-5	1108
2062	Assembly of severe acute respiratory syndrome coronavirus RNA packaging signal into virus-like particles is nucleocapsid dependent. 2005 , 79, 13848-55	137
2061	Coronavirus pathogenesis and the emerging pathogen severe acute respiratory syndrome coronavirus. 2005 , 69, 635-64	712
2060	Screening and identification of linear B-cell epitopes and entry-blocking peptide of severe acute respiratory syndrome (SARS)-associated coronavirus using synthetic overlapping peptide library. 2005 , 7, 648-56	53
2059	Folding of the SARS coronavirus spike glycoprotein immunological fragment (SARS_S1b): thermodynamic and kinetic investigation correlating with three-dimensional structural modeling. 2005 , 44, 1453-63	4
2058	Recent highlights in the development of new antiviral drugs. 2005 , 8, 552-60	117
2057	Molecular characterization of a panel of murine monoclonal antibodies specific for the SARS-coronavirus. 2005 , 42, 125-36	15
2056	Development and evaluation of an enzyme-linked immunosorbent assay for detection of antibodies against the spike protein of SARS-coronavirus. 2005 , 33, 12-8	12
2055	JNK and PI3k/Akt signaling pathways are required for establishing persistent SARS-CoV infection in Vero E6 cells. 2005 , 1741, 4-10	70
2054	Implication of proprotein convertases in the processing and spread of severe acute respiratory syndrome coronavirus. 2005 , 326, 554-63	64
2053	Induction of Th1 type response by DNA vaccinations with N, M, and E genes against SARS-CoV in mice. 2005 , 328, 979-86	59
2052	A human SARS-CoV neutralizing antibody against epitope on S2 protein. 2005 , 333, 186-93	86

2051	Susceptibility of human and rat neural cell lines to infection by SARS-coronavirus. 2005 , 334, 79-85	40
2050	Selection of and recombination between minor variants lead to the adaptation of an avian coronavirus to primate cells. 2005 , 336, 417-23	51
2049	Longitudinal alteration of circulating dendritic cell subsets and its correlation with steroid treatment in patients with severe acute respiratory syndrome. 2005 , 116, 225-35	19
2048	Synthetic peptides derived from SARS coronavirus S protein with diagnostic and therapeutic potential. 2005 , 579, 2130-6	16
2047	Pneumonitis and multi-organ system disease in common marmosets (<i>Callithrix jacchus</i>) infected with the severe acute respiratory syndrome-associated coronavirus. 2005 , 167, 455-63	89
2046	Prokaryotic expression, refolding, and purification of fragment 450-650 of the spike protein of SARS-coronavirus. 2005 , 39, 169-74	22
2045	Organ-specific distribution of ACE2 mRNA and correlating peptidase activity in rodents. 2005 , 26, 1270-7	151
2044	Potentiation of bradykinin actions by analogues of the bradykinin potentiating nonapeptide BPP9alpha. 2005 , 26, 1235-47	23
2043	SARS-coronavirus replication in human peripheral monocytes/macrophages. 2005 , 107, 93-101	131
2042	Adenoviral expression of a truncated S1 subunit of SARS-CoV spike protein results in specific humoral immune responses against SARS-CoV in rats. 2005 , 112, 24-31	44
2041	Intranasal immunization with inactivated SARS-CoV (SARS-associated coronavirus) induced local and serum antibodies in mice. 2005 , 23, 924-31	57
2040	The development of vaccines against SARS corona virus in mice and SCID-PBL/hu mice. 2005 , 23, 2269-72	36
2039	Augmentation of immune responses to SARS coronavirus by a combination of DNA and whole killed virus vaccines. 2005 , 23, 4385-91	51
2038	A review of vaccine research and development: human acute respiratory infections. 2005 , 23, 5708-24	125
2037	Molecular mechanisms of severe acute respiratory syndrome (SARS). 2005 , 6, 8	66
2036	Effects of severe acute respiratory syndrome (SARS) coronavirus infection on peripheral blood lymphocytes and their subsets. 2005 , 9, 323-30	146
2035	Coronaviridae: a review of coronaviruses and toroviruses. 2005 , 1-54	22
2034	Amino acids 1055 to 1192 in the S2 region of severe acute respiratory syndrome coronavirus S protein induce neutralizing antibodies: implications for the development of vaccines and antiviral agents. 2005 , 79, 3289-96	88

2033	Severe acute respiratory syndrome (SARS): a year in review. 2005 , 56, 357-81	114
2032	Vaccine design for severe acute respiratory syndrome coronavirus. 2005 , 18, 327-32	32
2031	The SARS coronavirus S glycoprotein receptor binding domain: fine mapping and functional characterization. 2005 , 2, 73	74
2030	Replicative homeostasis II: influence of polymerase fidelity on RNA virus quasispecies biology: implications for immune recognition, viral autoimmunity and other "virus receptor" diseases. 2005 , 2, 70	10
2029	Chloroquine is a potent inhibitor of SARS coronavirus infection and spread. 2005 , 2, 69	1148
2028	Molecular advances in the cell biology of SARS-CoV and current disease prevention strategies. 2005 , 2, 35	5
2027	Newly recognized causes of acute lung injury: transfusion of blood products, severe acute respiratory syndrome, and avian influenza. 2006 , 27, 591-600; abstract viii	9
2026	The molecular biology of coronaviruses. 2006 , 66, 193-292	962
2025	New Concepts of Antiviral Therapy. 2006 ,	
2024	Antiviral applications of RNAi for coronavirus. 2006 , 15, 89-97	22
2023	Cellular immunity and lung injury in respiratory virus infection. 2006 , 19, 147-55	76
2022	The relationship of severe acute respiratory syndrome coronavirus with avian and other coronaviruses. 2006 , 50, 315-20	14
2021	Loss of angiotensin-converting enzyme-2 leads to the late development of angiotensin II-dependent glomerulosclerosis. 2006 , 168, 1808-20	200
2020	Potential antivirals and antiviral strategies against SARS coronavirus infections. 2006 , 4, 291-302	115
2019	Mustela vison ACE2 functions as a receptor for SARS-coronavirus. 2006 , 581, 507-10	9
2018	Core structure of S2 from the human coronavirus NL63 spike glycoprotein. 2006 , 45, 15205-15	37
2017	The renin-angiotensin system in acute respiratory distress syndrome. 2006 , 3, 225-229	21
2016	Progress in Anti-SARS Coronavirus Chemistry, Biology and Chemotherapy. 2007 , 41, 183-196	27

2015	Identification and characterization of a <i>Penaeus monodon</i> lymphoid cell-expressed receptor for the yellow head virus. 2006 , 80, 262-9	50
2014	A trimerizing GxxxG motif is uniquely inserted in the severe acute respiratory syndrome (SARS) coronavirus spike protein transmembrane domain. 2006 , 45, 11349-56	27
2013	Kinetics and synergistic effects of siRNAs targeting structural and replicase genes of SARS-associated coronavirus. 2006 , 580, 2414-20	31
2012	Insulin degrading enzyme is a cellular receptor mediating varicella-zoster virus infection and cell-to-cell spread. 2006 , 127, 305-16	107
2011	Why are HIV-1 fusion inhibitors not effective against SARS-CoV? Biophysical evaluation of molecular interactions. 2006 , 1760, 55-61	11
2010	A single amino acid substitution (R441A) in the receptor-binding domain of SARS coronavirus spike protein disrupts the antigenic structure and binding activity. 2006 , 344, 106-13	25
2009	HLA-A*0201 T-cell epitopes in severe acute respiratory syndrome (SARS) coronavirus nucleocapsid and spike proteins. 2006 , 344, 63-71	48
2008	ACE2 orthologues in non-mammalian vertebrates (<i>Danio</i> , <i>Gallus</i> , <i>Fugu</i> , <i>Tetraodon</i> and <i>Xenopus</i>). 2006 , 377, 46-55	23
2007	Angiotensin-converting enzyme 2 in lung diseases. 2006 , 6, 271-6	272
2006	Age- and gender-related difference of ACE2 expression in rat lung. 2006 , 78, 2166-71	293
2005	Mapping a neutralizing epitope on the SARS coronavirus spike protein: computational prediction based on affinity-selected peptides. 2006 , 359, 190-201	31
2004	Template-based coiled-coil antigens elicit neutralizing antibodies to the SARS-coronavirus. 2006 , 155, 176-94	33
2003	Inhibition of severe acute respiratory syndrome-associated coronavirus (SARS-CoV) infectivity by peptides analogous to the viral spike protein. 2006 , 120, 146-55	59
2002	A double-inactivated whole virus candidate SARS coronavirus vaccine stimulates neutralising and protective antibody responses. 2006 , 24, 652-61	88
2001	A recombinant baculovirus-expressed S glycoprotein vaccine elicits high titers of SARS-associated coronavirus (SARS-CoV) neutralizing antibodies in mice. 2006 , 24, 3624-31	66
2000	Identification and characterization of novel neutralizing epitopes in the receptor-binding domain of SARS-CoV spike protein: revealing the critical antigenic determinants in inactivated SARS-CoV vaccine. 2006 , 24, 5498-508	46
1999	SARS-associated coronavirus replication in cell lines. 2006 , 12, 128-33	86
1998	[Cell entry mechanism of coronaviruses: implication in their pathogenesis]. 2006 , 56, 165-71	0

1997	SARS: clinical presentation, transmission, pathogenesis and treatment options. 2006 , 110, 193-204	34
1996	Severe Acute Respiratory Syndrome (SARS). 2006 ,	
1995	Colonization of severe acute respiratory syndrome-associated coronavirus among health-care workers screened by nasopharyngeal swab. 2006 , 129, 95-101	41
1994	Infectious diseases emerging from Chinese wet-markets: zoonotic origins of severe respiratory viral infections. 2006 , 19, 401-7	114
1993	The tissue renin-angiotensin system and intracellular signalling. 2006 , 15, 8-13	47
1992	A guided tour through the antiviral drug field. 2006 , 1, 19-35	5
1991	Severe Acute Respiratory Syndrome Coronavirus (SARS-CoV). 2006 , 16, 43-95	15
1990	Severe acute respiratory syndrome (SARS) coronavirus: application of monoclonal antibodies and development of an effective vaccine. 2006 , 16, 117-31	21
1989	Hypothesized and found mechanisms for potentiation of bradykinin actions. 2006 , 6, 5-18	5
1988	How the SARS coronavirus causes disease: host or organism?. 2006 , 208, 142-51	42
1987	Expression of elevated levels of pro-inflammatory cytokines in SARS-CoV-infected ACE2+ cells in SARS patients: relation to the acute lung injury and pathogenesis of SARS. 2006 , 210, 288-97	280
1986	Inflammation inhibitors were remarkably up-regulated in plasma of severe acute respiratory syndrome patients at progressive phase. 2006 , 6, 2886-94	42
1985	Hosting the severe acute respiratory syndrome coronavirus: specific cell factors required for infection. 2006 , 8, 1211-8	18
1984	Human coronavirus NL63, a new respiratory virus. 2006 , 30, 760-73	123
1983	Homozygous L-SIGN (CLEC4M) plays a protective role in SARS coronavirus infection. 2006 , 38, 38-46	109
1982	Generating vesicular stomatitis virus pseudotype bearing the severe acute respiratory syndrome coronavirus spike envelope glycoprotein for rapid and safe neutralization test or cell-entry assay. 2006 , 1081, 246-8	9
1981	A convenient cell fusion assay for the study of SARS-CoV entry and inhibition. 2006 , 58, 480-6	7
1980	Propagation of bovine coronavirus in clones of the Caco-2 cell line showing different levels of alkaline phosphatase activity. 2006 , 77, 253-257	78

1979 Towards treatment of viral pathogenesis. **2006**, 16, 135-8

1978 Sialic acids as receptor determinants for coronaviruses. **2006**, 23, 51-8 126

1977 Modification of SARS-CoV S1 gene render expression in *Pichia pastoris*. **2006**, 33, 329-35 3

1976 Upregulation of mitochondrial gene expression in PBMC from convalescent SARS patients. **2006**, 26, 546-54 30

1975 Lessons from SARS: control of acute lung failure by the SARS receptor ACE2. **2006**, 84, 814-20 105

1974 Human memory T cell responses to SARS-CoV E protein. **2006**, 8, 2424-31 23

1973 SARS coronavirus 7a protein blocks cell cycle progression at G0/G1 phase via the cyclin D3/pRb pathway. **2006**, 346, 74-85 95

1972 Murine encephalitis caused by HCoV-OC43, a human coronavirus with broad species specificity, is partly immune-mediated. **2006**, 347, 410-21 54

1971 Identification of critical determinants on ACE2 for SARS-CoV entry and development of a potent entry inhibitor. **2006**, 350, 15-25 138

1970 Furin cleavage of the SARS coronavirus spike glycoprotein enhances cell-cell fusion but does not affect virion entry. **2006**, 350, 358-69 164

1969 Induction of protective immunity against severe acute respiratory syndrome coronavirus (SARS-CoV) infection using highly attenuated recombinant vaccinia virus DIs. **2006**, 351, 368-80 16

1968 Recombinant adeno-associated virus expressing the receptor-binding domain of severe acute respiratory syndrome coronavirus S protein elicits neutralizing antibodies: Implication for developing SARS vaccines. **2006**, 353, 6-16 38

1967 Interferon-gamma and interleukin-4 downregulate expression of the SARS coronavirus receptor ACE2 in Vero E6 cells. **2006**, 353, 474-81 93

1966 Design and biological activities of novel inhibitory peptides for SARS-CoV spike protein and angiotensin-converting enzyme 2 interaction. **2006**, 69, 70-6 44

1965 Inhibition of feline (FIPV) and human (SARS) coronavirus by semisynthetic derivatives of glycopeptide antibiotics. **2006**, 72, 20-33 44

1964 Coronaviruses and their therapy. **2006**, 71, 397-403 36

1963 Association of angiotensin-converting enzyme 2 gene A/G polymorphism and elevated blood pressure in Chinese patients with metabolic syndrome. **2006**, 147, 91-5 52

1962 Adaptive evolution of the spike gene of SARS coronavirus: changes in positively selected sites in different epidemic groups. **2006**, 6, 88 50

1961	Severe acute respiratory syndrome coronavirus entry into host cells: Opportunities for therapeutic intervention. 2006 , 26, 414-33	22
1960	Cytokine regulation in SARS coronavirus infection compared to other respiratory virus infections. 2006 , 78, 417-24	111
1959	Evaluation of a novel vesicular stomatitis virus pseudotype-based assay for detection of neutralizing antibody responses to SARS-CoV. 2006 , 78, 1509-12	33
1958	Structure of severe acute respiratory syndrome coronavirus receptor-binding domain complexed with neutralizing antibody. 2006 , 281, 15829-36	208
1957	[Pharmacotherapy of severe acute respiratory syndrome (SARS)]. 2006 , 60, 694-700	1
1956	Sialic acid is a receptor determinant for infection of cells by avian Infectious bronchitis virus. 2006 , 87, 1209-1216	93
1955	Conformational states of the severe acute respiratory syndrome coronavirus spike protein ectodomain. 2006 , 80, 6794-800	96
1954	Characterization and inhibition of SARS-coronavirus main protease. 2006 , 6, 361-76	66
1953	An overall picture of SARS coronavirus (SARS-CoV) genome-encoded major proteins: structures, functions and drug development. 2006 , 12, 4539-53	17
1952	The Renin-Angiotensin System: Emerging Concepts. 2006 , 2, 219-226	2
1951	Highly conserved regions within the spike proteins of human coronaviruses 229E and NL63 determine recognition of their respective cellular receptors. 2006 , 80, 8639-52	89
1950	Screening and identification of severe acute respiratory syndrome-associated coronavirus-specific CTL epitopes. 2006 , 177, 2138-45	85
1949	Drug design targeting the main protease, the Achilles' heel of coronaviruses. 2006 , 12, 4573-90	123
1948	Conserved receptor-binding domains of Lake Victoria marburgvirus and Zaire ebolavirus bind a common receptor. 2006 , 281, 15951-8	104
1947	Orchitis: a complication of severe acute respiratory syndrome (SARS). 2006 , 74, 410-6	250
1946	Animal origins of the severe acute respiratory syndrome coronavirus: insight from ACE2-S-protein interactions. 2006 , 80, 4211-9	206
1945	New mass spectrometric assay for angiotensin-converting enzyme 2 activity. 2006 , 47, 1010-7	60
1944	Analysis of ACE2 in polarized epithelial cells: surface expression and function as receptor for severe acute respiratory syndrome-associated coronavirus. 2006 , 87, 1691-1695	135

1943	Functional characterization of heptad repeat 1 and 2 mutants of the spike protein of severe acute respiratory syndrome coronavirus. 2006 , 80, 3225-37	19
1942	Emerging respiratory viruses: challenges and vaccine strategies. 2006 , 19, 614-36	118
1941	Important role for the transmembrane domain of severe acute respiratory syndrome coronavirus spike protein during entry. 2006 , 80, 1302-10	61
1940	The Nidoviruses. 2006 ,	1
1939	Identifying epitopes responsible for neutralizing antibody and DC-SIGN binding on the spike glycoprotein of the severe acute respiratory syndrome coronavirus. 2006 , 80, 10315-24	39
1938	Comparative evaluation of two severe acute respiratory syndrome (SARS) vaccine candidates in mice challenged with SARS coronavirus. 2006 , 87, 641-650	116
1937	Monoclonal antibodies targeting the HR2 domain and the region immediately upstream of the HR2 of the S protein neutralize in vitro infection of severe acute respiratory syndrome coronavirus. 2006 , 80, 941-50	76
1936	Preferential infection of mature dendritic cells by mouse hepatitis virus strain JHM. 2006 , 80, 2506-14	28
1935	Specific epitopes of the structural and hypothetical proteins elicit variable humoral responses in SARS patients. 2006 , 59, 468-76	28
1934	The spleen as a target in severe acute respiratory syndrome. 2006 , 20, 2321-8	31
1933	SARS coronavirus, but not human coronavirus NL63, utilizes cathepsin L to infect ACE2-expressing cells. 2006 , 281, 3198-203	261
1932	Production of an anti-severe acute respiratory syndrome (SARS) coronavirus human monoclonal antibody Fab fragment by using a combinatorial immunoglobulin gene library derived from patients who recovered from SARS. 2006 , 13, 594-7	10
1931	Physiology of local renin-angiotensin systems. 2006 , 86, 747-803	1225
1930	Antigenic and immunogenic characterization of recombinant baculovirus-expressed severe acute respiratory syndrome coronavirus spike protein: implication for vaccine design. 2006 , 80, 5757-67	92
1929	7a protein of severe acute respiratory syndrome coronavirus inhibits cellular protein synthesis and activates p38 mitogen-activated protein kinase. 2006 , 80, 785-93	118
1928	Solution structure of the severe acute respiratory syndrome-coronavirus heptad repeat 2 domain in the prefusion state. 2006 , 281, 11965-71	47
1927	Polyvalent inhibitors of anthrax toxin that target host receptors. 2006 , 103, 13509-13	67
1926	Cross-neutralization of human and palm civet severe acute respiratory syndrome coronaviruses by antibodies targeting the receptor-binding domain of spike protein. 2006 , 176, 6085-92	93

1925	Structural basis of neutralization by a human anti-severe acute respiratory syndrome spike protein antibody, 80R. 2006 , 281, 34610-6	174
1924	Development of human monoclonal antibodies against diseases caused by emerging and biodefense-related viruses. 2006 , 4, 57-66	23
1923	Potential therapies for coronaviruses. 2006 , 16, 1269-1288	9
1922	Full-length genome sequences of two SARS-like coronaviruses in horseshoe bats and genetic variation analysis. 2006 , 87, 3355-3359	85
1921	Significant redox insensitivity of the functions of the SARS-CoV spike glycoprotein: comparison with HIV envelope. 2006 , 281, 9200-4	33
1920	Angiotensin-converting enzyme inhibitors versus angiotensin receptor blockers. A mini-symposium held at the British Hypertension Society Meeting, September 2005. 2006 , 7, 104-21	
1919	Severe acute respiratory syndrome coronavirus nsp1 protein suppresses host gene expression by promoting host mRNA degradation. 2006 , 103, 12885-90	296
1918	Molecular Mimicry between SARS Coronavirus Spike Protein and Human Protein. 2007 ,	3
1917	Human immunodeficiency viral vector pseudotyped with the spike envelope of severe acute respiratory syndrome coronavirus transduces human airway epithelial cells and dendritic cells. 2007 , 18, 413-22	24
1916	Comparison of immunoglobulin G responses to the spike and nucleocapsid proteins of severe acute respiratory syndrome (SARS) coronavirus in patients with SARS. 2007 , 14, 839-46	21
1915	Specific asparagine-linked glycosylation sites are critical for DC-SIGN- and L-SIGN-mediated severe acute respiratory syndrome coronavirus entry. 2007 , 81, 12029-39	106
1914	A previously unknown reovirus of bat origin is associated with an acute respiratory disease in humans. 2007 , 104, 11424-9	164
1913	Clathrin-dependent entry of severe acute respiratory syndrome coronavirus into target cells expressing ACE2 with the cytoplasmic tail deleted. 2007 , 81, 8722-9	244
1912	A novel subset of putative stem/progenitor CD34+Oct-4+ cells is the major target for SARS coronavirus in human lung. 2007 , 204, 2529-36	41
1911	Heparan sulfate is a selective attachment factor for the avian coronavirus infectious bronchitis virus Beaudette. 2007 , 51, 45-51	58
1910	The coronavirus spike protein induces endoplasmic reticulum stress and upregulation of intracellular chemokine mRNA concentrations. 2007 , 81, 10981-90	82
1909	The two FACES of the tissue renin-angiotensin systems: implication in cardiovascular diseases. 2007 , 13, 1231-45	48
1908	Pharmacological, immunological, and gene targeting of the renin-angiotensin system for treatment of cardiovascular disease. 2007 , 13, 1199-214	6

1907	Impaired heart contractility in Apelin gene-deficient mice associated with aging and pressure overload. 2007 , 101, e32-42	219
1906	ACE2: a new target for cardiovascular disease therapeutics. 2007 , 50, 112-9	132
1905	Differential expression of neuronal ACE2 in transgenic mice with overexpression of the brain renin-angiotensin system. 2007 , 292, R373-81	280
1904	Type I feline coronavirus spike glycoprotein fails to recognize aminopeptidase N as a functional receptor on feline cell lines. 2007 , 88, 1753-1760	42
1903	Severe acute respiratory syndrome (SARS) coronavirus. 2007 , 28, 201-12	10
1902	Role of Monocytes and Macrophages in Pathogenesis of SARS. 2007 ,	1
1901	Cell entry by enveloped viruses: redox considerations for HIV and SARS-coronavirus. 2007 , 9, 1009-34	71
1900	New and Evolving Infections of the 21st Century. 2007 ,	
1899	SARS-CoV accessory protein 7a directly interacts with human LFA-1. 2007 , 388, 1325-32	16
1898	The novel human coronaviruses NL63 and HKU1. 2007 , 81, 3051-7	179
1897	Immunization by avian H5 influenza hemagglutinin mutants with altered receptor binding specificity. 2007 , 317, 825-8	185
1896	SARS molecular epidemiology: a Chinese fairy tale of controlling an emerging zoonotic disease in the genomics era. 2007 , 362, 1063-81	52
1895	Ribonucleocapsid formation of severe acute respiratory syndrome coronavirus through molecular action of the N-terminal domain of N protein. 2007 , 81, 3913-21	103
1894	Mutational analysis of aminopeptidase N, a receptor for several group 1 coronaviruses, identifies key determinants of viral host range. 2007 , 81, 1261-73	68
1893	Lethal infection of K18-hACE2 mice infected with severe acute respiratory syndrome coronavirus. 2007 , 81, 813-21	591
1892	Interferon-mediated immunopathological events are associated with atypical innate and adaptive immune responses in patients with severe acute respiratory syndrome. 2007 , 81, 8692-706	297
1891	Severe acute respiratory syndrome coronavirus infection of mice transgenic for the human Angiotensin-converting enzyme 2 virus receptor. 2007 , 81, 1162-73	183
1890	Severe acute respiratory syndrome coronavirus as an agent of emerging and reemerging infection. 2007 , 20, 660-94	661

1889	Cholesterol dependence of varicella-zoster virion entry into target cells. 2007 , 81, 7548-58	56
1888	Synthetic reconstruction of zoonotic and early human severe acute respiratory syndrome coronavirus isolates that produce fatal disease in aged mice. 2007 , 81, 7410-23	53
1887	The cytoplasmic tail of the severe acute respiratory syndrome coronavirus spike protein contains a novel endoplasmic reticulum retrieval signal that binds COPI and promotes interaction with membrane protein. 2007 , 81, 2418-28	121
1886	Impaired angiogenesis in aminopeptidase N-null mice. 2007 , 104, 4588-93	103
1885	Association of ICAM3 genetic variant with severe acute respiratory syndrome. 2007 , 196, 271-80	27
1884	Amino acid substitutions in the s2 region enhance severe acute respiratory syndrome coronavirus infectivity in rat angiotensin-converting enzyme 2-expressing cells. 2007 , 81, 10831-4	12
1883	Participation of both host and virus factors in induction of severe acute respiratory syndrome (SARS) in F344 rats infected with SARS coronavirus. 2007 , 81, 1848-57	51
1882	Natural mutations in the receptor binding domain of spike glycoprotein determine the reactivity of cross-neutralization between palm civet coronavirus and severe acute respiratory syndrome coronavirus. 2007 , 81, 4694-700	44
1881	The emerging role of angiotensin-converting enzyme-2 in the kidney. 2007 , 16, 116-21	29
1880	Monoclonal antibodies against viruses and bacteria: a survey of patents. 2007 , 2, 171-7	4
1879	Immunogenicity of a receptor-binding domain of SARS coronavirus spike protein in mice: implications for a subunit vaccine. 2007 , 25, 136-43	60
1878	Antibodies against trimeric S glycoprotein protect hamsters against SARS-CoV challenge despite their capacity to mediate FcγRII-dependent entry into B cells in vitro. 2007 , 25, 729-40	156
1877	SARS-CoV spike protein-expressing recombinant vaccinia virus efficiently induces neutralizing antibodies in rabbits pre-immunized with vaccinia virus. 2007 , 25, 630-7	16
1876	Receptor-binding domain of SARS-CoV spike protein induces long-term protective immunity in an animal model. 2007 , 25, 2832-8	128
1875	Induction of T-cell response by a DNA vaccine encoding a novel HLA-A*0201 severe acute respiratory syndrome coronavirus epitope. 2007 , 25, 6070-7	35
1874	Priming with SARS CoV S DNA and boosting with SARS CoV S epitopes specific for CD4+ and CD8+ T cells promote cellular immune responses. 2007 , 25, 6981-91	53
1873	Enzymatic pathways of the brain renin-angiotensin system: unsolved problems and continuing challenges. 2007 , 143, 15-27	64
1872	A dominant antigenic epitope on SARS-CoV spike protein identified by an avian single-chain variable fragment (scFv)-expressing phage. 2007 , 117, 75-85	19

1871	Up-regulation of IL-6 and TNF-alpha induced by SARS-coronavirus spike protein in murine macrophages via NF-kappaB pathway. 2007 , 128, 1-8	171
1870	Virus-mediated modulation of the host endocrine signaling systems: clinical implications. 2007 , 18, 159-66	10
1869	The SARS-Coronavirus Membrane protein induces apoptosis through modulating the Akt survival pathway. 2007 , 459, 197-207	54
1868	Identification of synthetic vaccine candidates against SARS CoV infection. 2007 , 358, 716-21	9
1867	Characterization of the first angiotensin-converting like enzyme in bacteria: Ancestor ACE is already active. 2007 , 399, 81-90	24
1866	[Lessons from SARS]. 2007 , 36, 299-302	0
1865	The SARS coronavirus spike glycoprotein is selectively recognized by lung surfactant protein D and activates macrophages. 2007 , 212, 201-11	93
1864	Renin-angiotensin system and cardiovascular risk. 2007 , 369, 1208-19	507
1863	Molecular pathology in the lungs of severe acute respiratory syndrome patients. 2007 , 170, 538-45	68
1862	Pathology and pathogenesis of severe acute respiratory syndrome. 2007 , 170, 1136-47	390
1861	Immune responses against severe acute respiratory syndrome coronavirus induced by virus-like particles in mice. 2007 , 122, 496-502	50
1860	The Immunobiology of SARS*. 2007 , 25, 443-72	195
1859	Feline aminopeptidase N is not a functional receptor for avian infectious bronchitis virus. 2007 , 4, 20	7
1858	Local Angiotensin Generation and AT2 Receptor Activation. 2007 , 247-272	
1857	Adenovirus Methods and Protocols. 2007 ,	2
1856	Optimization of a DNA vaccine against SARS. 2007 , 26, 721-6	13
1855	Status presens of antiviral drugs and strategies: Part II: RNA VIRUSES (EXCEPT RETROVIRUSES). 2007 , 5, 59-112	1
1854	Positive rate of serum SARS-CoV immunoglobulin G antibody among healthcare workers. 2007 , 39, 152-6	8

1853	Interaction of a peptide from the pre-transmembrane domain of the severe acute respiratory syndrome coronavirus spike protein with phospholipid membranes. 2007 , 111, 13714-25	19
1852	ProteinProtein Interactions. 2007 , 87-116	
1851	New insights into the roles of metalloproteinases in neurodegeneration and neuroprotection. 2007 , 82, 113-35	56
1850	Recycling of chloroquine and its hydroxyl analogue to face bacterial, fungal and viral infections in the 21st century. 2007 , 30, 297-308	259
1849	Cleavage of spike protein of SARS coronavirus by protease factor Xa is associated with viral infectivity. 2007 , 359, 174-9	96
1848	Bats, civets and the emergence of SARS. 2007 , 315, 325-44	159
1847	Conformational reorganization of the SARS coronavirus spike following receptor binding: implications for membrane fusion. 2007 , 2, e1082	39
1846	Viruses and Viral Diseases. 2007 , 253-293	1
1845	A fluorogenic peptide containing the processing site of human SARS corona virus S-protein: kinetic evaluation and NMR structure elucidation. 2007 , 8, 1029-37	11
1844	Angiotensin converting enzyme 2 is primarily epithelial and is developmentally regulated in the mouse lung. 2007 , 101, 1278-91	66
1843	Quantitative temporal-spatial distribution of severe acute respiratory syndrome-associated coronavirus (SARS-CoV) in post-mortem tissues. 2007 , 79, 1245-53	31
1842	Computational characterization and design of SARS coronavirus receptor recognition and antibody neutralization. 2007 , 31, 129-33	2
1841	Computational simulation of interactions between SARS coronavirus spike mutants and host species-specific receptors. 2007 , 31, 134-7	2
1840	The use of hepatitis C virus NS3/4A and secreted alkaline phosphatase to quantitate cell-cell membrane fusion mediated by severe acute respiratory syndrome coronavirus S protein and the receptor angiotensin-converting enzyme 2. 2007 , 366, 190-6	2
1839	Molecular pathogenesis of severe acute respiratory syndrome. 2007 , 9, 119-26	9
1838	Lipid rafts play an important role in the early stage of severe acute respiratory syndrome-coronavirus life cycle. 2007 , 9, 96-102	113
1837	The emerging role of ACE2 in physiology and disease. 2007 , 212, 1-11	282
1836	Transferrin receptor 1 is a cellular receptor for New World haemorrhagic fever arenaviruses. <i>Nature</i> , 2007 , 446, 92-6	50.4 314

1835	Identification and characterisation of the angiotensin converting enzyme-3 (ACE3) gene: a novel mammalian homologue of ACE. 2007 , 8, 194	21
1834	Towards our understanding of SARS-CoV, an emerging and devastating but quickly conquered virus. 2007 , 30, 309-27	27
1833	Emodin blocks the SARS coronavirus spike protein and angiotensin-converting enzyme 2 interaction. 2007 , 74, 92-101	282
1832	A study on antigenicity and receptor-binding ability of fragment 450-650 of the spike protein of SARS coronavirus. 2007 , 359, 362-70	14
1831	Generation and characterization of human monoclonal neutralizing antibodies with distinct binding and sequence features against SARS coronavirus using Xenomouse. 2007 , 361, 93-102	54
1830	Palmitoylation of the cysteine-rich endodomain of the SARS-coronavirus spike glycoprotein is important for spike-mediated cell fusion. 2007 , 360, 264-74	93
1829	Exosomal vaccines containing the S protein of the SARS coronavirus induce high levels of neutralizing antibodies. 2007 , 362, 26-37	99
1828	Heterologous viral RNA export elements improve expression of severe acute respiratory syndrome (SARS) coronavirus spike protein and protective efficacy of DNA vaccines against SARS. 2007 , 363, 288-302	15
1827	The S proteins of human coronavirus NL63 and severe acute respiratory syndrome coronavirus bind overlapping regions of ACE2. 2007 , 367, 367-74	119
1826	Complete genome sequence of bat coronavirus HKU2 from Chinese horseshoe bats revealed a much smaller spike gene with a different evolutionary lineage from the rest of the genome. 2007 , 367, 428-39	134
1825	Type 1 angiotensin receptor pharmacology: signaling beyond G proteins. 2007 , 113, 210-26	62
1824	Chicken single-chain variable fragments against the SARS-CoV spike protein. 2007 , 146, 104-11	12
1823	Heterologous MVA-S prime Ad5-S boost regimen induces high and persistent levels of neutralizing antibody response against SARS coronavirus. 2007 , 76, 1131-6	12
1822	Angiotensin-converting enzyme 2 in acute respiratory distress syndrome. 2007 , 64, 2006-12	107
1821	Structural proteomics of the SARS coronavirus: a model response to emerging infectious diseases. 2007 , 8, 85-97	30
1820	The functional motif of SARS-CoV S protein involved in the interaction with ACE2. 2007 , 22, 1-7	4
1819	A single amino acid substitution in the S1 and S2 Spike protein domains determines the neutralization escape phenotype of SARS-CoV. 2008 , 10, 908-15	17
1818	Influenza C virus and bovine coronavirus esterase reveal a similar catalytic mechanism: new insights for drug discovery. 2008 , 25, 393-9	7

1817	An improved culture system for virus isolation and detection. 2008 , 23, 345-351	78
1816	siRNA silencing of angiotensin-converting enzyme 2 reduced severe acute respiratory syndrome-associated coronavirus replications in Vero E6 cells. 2008 , 27, 709-15	20
1815	The search for a structural basis for therapeutic intervention against the SARS coronavirus. 2008 , 64, 204-13	3
1814	Design, synthesis and screening of antisense peptide based combinatorial peptide libraries towards an aromatic region of SARS-CoV. 2008 , 21, 122-31	10
1813	Predicting linear B-cell epitopes using string kernels. 2008 , 21, 243-55	447
1812	Thiol-based angiotensin-converting enzyme 2 inhibitors: P1 modifications for the exploration of the S1 subsite. 2008 , 18, 732-7	17
1811	Thiol-based angiotensin-converting enzyme 2 inhibitors: P1' modifications for the exploration of the S1' subsite. 2008 , 18, 1681-7	5
1810	Infection of the tracheal epithelium by infectious bronchitis virus is sialic acid dependent. 2008 , 10, 367-73	45
1809	Residues affecting the chloride regulation and substrate selectivity of the angiotensin-converting enzymes (ACE and ACE2) identified by site-directed mutagenesis. 2008 , 275, 6033-42	27
1808	The discovery of angiotensin-converting enzyme 2 and its role in acute lung injury in mice. 2008 , 93, 543-8	219
1807	Brain angiotensin-converting enzymes: role of angiotensin-converting enzyme 2 in processing angiotensin II in mice. 2008 , 93, 665-75	36
1806	Angiotensin-converting enzyme 2 catalytic activity in human plasma is masked by an endogenous inhibitor. 2008 , 93, 685-93	94
1805	Angiotensin-converting enzyme 2 in the brain: properties and future directions. 2008 , 107, 1482-94	222
1804	Liver disease and the renin-angiotensin system: recent discoveries and clinical implications. 2008 , 23, 1327-38	88
1803	Angiotensin converting enzyme 2 in the kidney. 2008 , 35, 420-5	33
1802	Co-infection of respiratory bacterium with severe acute respiratory syndrome coronavirus induces an exacerbated pneumonia in mice. 2008 , 52, 118-27	24
1801	Analysis of severe acute respiratory syndrome coronavirus structural proteins in virus-like particle assembly. 2008 , 52, 625-30	15
1800	SARS-CoV replicates in primary human alveolar type II cell cultures but not in type I-like cells. 2008 , 372, 127-35	108

1799	SARS vaccine based on a replication-defective recombinant vesicular stomatitis virus is more potent than one based on a replication-competent vector. 2008 , 376, 165-72	51
1798	Dissection and identification of regions required to form pseudoparticles by the interaction between the nucleocapsid (N) and membrane (M) proteins of SARS coronavirus. 2008 , 380, 99-108	23
1797	Rhesus angiotensin converting enzyme 2 supports entry of severe acute respiratory syndrome coronavirus in Chinese macaques. 2008 , 381, 89-97	23
1796	Calmodulin interacts with angiotensin-converting enzyme-2 (ACE2) and inhibits shedding of its ectodomain. 2008 , 582, 385-90	96
1795	Angiotensin-converting enzyme 2 and new insights into the renin-angiotensin system. 2008 , 75, 781-6	80
1794	Thiopurine analogues inhibit papain-like protease of severe acute respiratory syndrome coronavirus. 2008 , 75, 1601-9	71
1793	AT2 receptors: functional relevance in cardiovascular disease. 2008 , 120, 292-316	195
1792	Determination and application of immunodominant regions of SARS coronavirus spike and nucleocapsid proteins recognized by sera from different animal species. 2008 , 331, 1-12	24
1791	Structural and dynamic characterization of the interaction of the putative fusion peptide of the S2 SARS-CoV virus protein with lipid membranes. 2008 , 112, 6997-7007	22
1790	[Angiotensin converting enzyme 2 and its emerging role in the regulation of the renin angiotensin system]. 2008 , 131, 230-6	17
1789	SARS- and other coronaviruses. 2008 , 454, v-vi	5
1788	Overview of Viruses and Virus Infection. 2008 , 1-33	5
1787	Cell type-specific cleavage of nucleocapsid protein by effector caspases during SARS coronavirus infection. 2008 , 376, 23-34	31
1786	Expression of feline angiotensin converting enzyme 2 and its interaction with SARS-CoV S1 protein. 2008 , 84, 494-6	17
1785	Pathogenetic mechanisms of severe acute respiratory syndrome. 2008 , 133, 4-12	117
1784	SARS coronavirus replicase proteins in pathogenesis. 2008 , 133, 88-100	94
1783	A review of studies on animal reservoirs of the SARS coronavirus. 2008 , 133, 74-87	214
1782	SARS-CoV replication and pathogenesis in an in vitro model of the human conducting airway epithelium. 2008 , 133, 33-44	86

1781	Endocytosis of the receptor-binding domain of SARS-CoV spike protein together with virus receptor ACE2. 2008 , 136, 8-15	88
1780	Thrombopoietin levels increased in patients with severe acute respiratory syndrome. 2008 , 122, 473-7	27
1779	Lipid rafts are involved in SARS-CoV entry into Vero E6 cells. 2008 , 369, 344-9	152
1778	Interferon alfacon 1 inhibits SARS-CoV infection in human bronchial epithelial Calu-3 cells. 2008 , 371, 110-3	21
1777	Mouse-passaged severe acute respiratory syndrome-associated coronavirus leads to lethal pulmonary edema and diffuse alveolar damage in adult but not young mice. 2008 , 172, 1625-37	70
1776	Human immunopathogenesis of severe acute respiratory syndrome (SARS). 2008 , 133, 13-9	234
1775	[Structure and function of angiotensin converting enzyme and its inhibitors]. 2008 , 24, 171-6	18
1774	Phase Detection of the Two-Port FPW Sensor for Biosensing. 2008 , 8, 501-507	19
1773	A second SARS-CoV S2 glycoprotein internal membrane-active peptide. Biophysical characterization and membrane interaction. 2008 , 47, 8214-24	29
1772	Bench-to-bedside review: rare and common viral infections in the intensive care unit--linking pathophysiology to clinical presentation. 2008 , 12, 219	14
1771	Persistent replication of severe acute respiratory syndrome coronavirus in human tubular kidney cells selects for adaptive mutations in the membrane protein. 2008 , 82, 5137-44	44
1770	Difference in receptor usage between severe acute respiratory syndrome (SARS) coronavirus and SARS-like coronavirus of bat origin. 2008 , 82, 1899-907	117
1769	Molecular Pathology of Viral Respiratory Diseases. 2008 , 382-396	1
1768	Mechanisms of zoonotic severe acute respiratory syndrome coronavirus host range expansion in human airway epithelium. 2008 , 82, 2274-85	94
1767	Pathology of experimental SARS coronavirus infection in cats and ferrets. 2008 , 45, 551-62	99
1766	Polymorphisms in the C-type lectin genes cluster in chromosome 19 and predisposition to severe acute respiratory syndrome coronavirus (SARS-CoV) infection. 2008 , 45, 752-8	22
1765	Development of human single-chain antibodies against SARS-associated coronavirus. 2008 , 51, 173-81	2
1764	Respiratory viruses other than influenza virus: impact and therapeutic advances. 2008 , 21, 274-90, table of contents	105

1763	Mechanisms of severe acute respiratory syndrome pathogenesis and innate immunomodulation. 2008 , 72, 672-85, Table of Contents	82
1762	Prior immunization with severe acute respiratory syndrome (SARS)-associated coronavirus (SARS-CoV) nucleocapsid protein causes severe pneumonia in mice infected with SARS-CoV. 2008 , 181, 6337-48	181
1761	Inhibition of the interaction between the SARS-CoV spike protein and its cellular receptor by anti-histo-blood group antibodies. 2008 , 18, 1085-93	214
1760	Entry from the cell surface of severe acute respiratory syndrome coronavirus with cleaved S protein as revealed by pseudotype virus bearing cleaved S protein. 2008 , 82, 11985-91	68
1759	Structural analysis of major species barriers between humans and palm civets for severe acute respiratory syndrome coronavirus infections. 2008 , 82, 6984-91	139
1758	Intranasal vaccination of recombinant adeno-associated virus encoding receptor-binding domain of severe acute respiratory syndrome coronavirus (SARS-CoV) spike protein induces strong mucosal immune responses and provides long-term protection against SARS-CoV infection. 2008 , 180, 948-56	102
1757	Modulation of TNF-alpha-converting enzyme by the spike protein of SARS-CoV and ACE2 induces TNF-alpha production and facilitates viral entry. 2008 , 105, 7809-14	367
1756	Structure of coronavirus hemagglutinin-esterase offers insight into corona and influenza virus evolution. 2008 , 105, 9065-9	176
1755	Aromatic amino acids in the juxtamembrane domain of severe acute respiratory syndrome coronavirus spike glycoprotein are important for receptor-dependent virus entry and cell-cell fusion. 2008 , 82, 2883-94	35
1754	Broadening of neutralization activity to directly block a dominant antibody-driven SARS-coronavirus evolution pathway. 2008 , 4, e1000197	64
1753	Angiotensin-converting enzyme 2: cardioprotective player in the renin-angiotensin system?. 2008 , 52, 816-7	7
1752	Angiotensin converting enzyme-2 is protective but downregulated in human and experimental lung fibrosis. 2008 , 295, L178-85	145
1751	ACE2 is expressed in mouse adipocytes and regulated by a high-fat diet. 2008 , 295, R781-8	135
1750	The nucleocapsid protein of SARS-CoV induces transcription of hfgl2 prothrombinase gene dependent on C/EBP alpha. 2008 , 144, 51-62	22
1749	Severe acute respiratory syndrome coronavirus infection causes neuronal death in the absence of encephalitis in mice transgenic for human ACE2. 2008 , 82, 7264-75	829
1748	Identification of residues in the receptor-binding domain (RBD) of the spike protein of human coronavirus NL63 that are critical for the RBD-ACE2 receptor interaction. 2008 , 89, 1015-1024	48
1747	Structural basis for potent cross-neutralizing human monoclonal antibody protection against lethal human and zoonotic severe acute respiratory syndrome coronavirus challenge. 2008 , 82, 3220-35	128
1746	Amiodarone alters late endosomes and inhibits SARS coronavirus infection at a post-endosomal level. 2008 , 39, 142-9	70

1745	Structural and biochemical investigation of heptad repeat derived peptides of human SARS corona virus (hSARS-CoV) spike protein. 2008 , 15, 874-86	1
1744	Antiviral Agents for SARS. 2008 , 184-202	
1743	Introduction: RNA viruses. 1-2	
1742	Neurotropic coronavirus infections. 50-74	
1741	Recent antiviral strategies against human coronavirus-related respiratory illnesses. 2008 , 14, 248-53	10
1740	Clinical features, pathogenesis and immunobiology of severe acute respiratory syndrome. 2008 , 14, 241-7	9
1739	Pathogenesis of severe acute respiratory syndrome. 2008 , 121, 1722-1731	3
1738	Molecular targets for diagnostics and therapeutics of severe acute respiratory syndrome (SARS-CoV). 2008 , 11, 1s-13s	14
1737	Renal Modulation: The Renin-Angiotensin-Aldosterone System (RAAS). 2008 , 107-127	
1736	Peptide mimicking between SARS coronavirus spike protein and human proteins reacts with SARS patient serum. 2008 , 2008, 326464	12
1735	[Cell entry mechanisms of coronaviruses]. 2009 , 59, 215-22	3
1734	Coronaviruses. 2009 , 1155-1171	10
1733	The Bacterial Surface Expression of SARS Viral Epitope using Salmonella typhi Cytolysin A. 2009 , 39, 103	5
1732	Cleavage of the SARS coronavirus spike glycoprotein by airway proteases enhances virus entry into human bronchial epithelial cells in vitro. 2009 , 4, e7870	121
1731	SARS vaccines: where are we?. 2009 , 8, 887-98	143
1730	Antibody binding site mapping of SARS-CoV spike protein receptor-binding domain by a combination of yeast surface display and phage peptide library screening. 2009 , 22, 407-15	8
1729	Activation of the SARS coronavirus spike protein via sequential proteolytic cleavage at two distinct sites. 2009 , 106, 5871-6	682
1728	Drug targets in severe acute respiratory syndrome (SARS) virus and other coronavirus infections. 2009 , 9, 223-45	34

1727	The identification of a calmodulin-binding domain within the cytoplasmic tail of angiotensin-converting enzyme-2. 2009 , 150, 2376-81	26
1726	Potent human monoclonal antibodies against SARS CoV, Nipah and Hendra viruses. 2009 , 9, 355-68	45
1725	Therapies for coronaviruses. Part I of II -- viral entry inhibitors. 2009 , 19, 357-67	15
1724	Searching immunodominant epitopes prior to epidemic: HLA class II-restricted SARS-CoV spike protein epitopes in unexposed individuals. 2009 , 21, 63-71	24
1723	Ectodomain shedding of angiotensin converting enzyme 2 in human airway epithelia. 2009 , 297, L84-96	222
1722	Host-species transferrin receptor 1 orthologs are cellular receptors for nonpathogenic new world clade B arenaviruses. 2009 , 5, e1000358	85
1721	Selective and specific regulation of ectodomain shedding of angiotensin-converting enzyme 2 by tumor necrosis factor alpha-converting enzyme. 2009 , 297, C1318-29	50
1720	Comparison of vesicular stomatitis virus pseudotyped with the S proteins from a porcine and a human coronavirus. 2009 , 90, 1724-1729	27
1719	Role of lipid rafts in virus infection. 2009 , 4, 487-500	1
1718	Angiotensin-converting enzyme 2 (ACE2) from raccoon dog can serve as an efficient receptor for the spike protein of severe acute respiratory syndrome coronavirus. 2009 , 90, 2695-2703	17
1717	Differential virological and immunological outcome of severe acute respiratory syndrome coronavirus infection in susceptible and resistant transgenic mice expressing human angiotensin-converting enzyme 2. 2009 , 83, 5451-65	38
1716	Identification of major histocompatibility complex class I C molecule as an attachment factor that facilitates coronavirus HKU1 spike-mediated infection. 2009 , 83, 1026-35	26
1715	Protease-mediated entry via the endosome of human coronavirus 229E. 2009 , 83, 712-21	86
1714	Conserved amino acids W423 and N424 in receptor-binding domain of SARS-CoV are potential targets for therapeutic monoclonal antibody. 2009 , 383, 39-46	13
1713	Recombinant receptor-binding domain of SARS-CoV spike protein expressed in mammalian, insect and E. coli cells elicits potent neutralizing antibody and protective immunity. 2009 , 393, 144-50	93
1712	Human monoclonal antibodies to SARS-coronavirus inhibit infection by different mechanisms. 2009 , 394, 39-46	27
1711	SARS-coronavirus spike S2 domain flanked by cysteine residues C822 and C833 is important for activation of membrane fusion. 2009 , 393, 265-71	37
1710	A new mouse-adapted strain of SARS-CoV as a lethal model for evaluating antiviral agents in vitro and in vivo. 2009 , 395, 210-22	116

1709	Mouse models with human immunity and their application in biomedical research. 2009 , 13, 1043-58	38
1708	Identification of a minimal peptide derived from heptad repeat (HR) 2 of spike protein of SARS-CoV and combination of HR1-derived peptides as fusion inhibitors. 2009 , 81, 82-7	33
1707	Procyanidins and butanol extract of Cinnamomi Cortex inhibit SARS-CoV infection. 2009 , 82, 73-81	90
1706	Efficient induction of cytotoxic T lymphocytes specific for severe acute respiratory syndrome (SARS)-associated coronavirus by immunization with surface-linked liposomal peptides derived from a non-structural polyprotein 1a. 2009 , 84, 168-77	25
1705	Characterization of cytotoxic T-lymphocyte epitopes and immune responses to SARS coronavirus spike DNA vaccine expressing the RGD-integrin-binding motif. 2009 , 81, 1131-9	12
1704	Potential enhancement of osteoclastogenesis by severe acute respiratory syndrome coronavirus 3a/X1 protein. 2009 , 154, 1457-64	21
1703	Expression of SARS-coronavirus spike glycoprotein in <i>Pichia pastoris</i> . 2009 , 38, 1-9	9
1702	Neutralizing antibody against severe acute respiratory syndrome (SARS)-coronavirus spike is highly effective for the protection of mice in the murine SARS model. 2009 , 53, 75-82	14
1701	SARS-coronavirus modulation of myocardial ACE2 expression and inflammation in patients with SARS. 2009 , 39, 618-25	576
1700	The spike protein of SARS-CoV--a target for vaccine and therapeutic development. 2009 , 7, 226-36	1007
1699	Coronaviruses post-SARS: update on replication and pathogenesis. 2009 , 7, 439-50	1045
1698	Phylogenetic perspectives on the epidemiology and origins of SARS and SARS-like coronaviruses. 2009 , 9, 1185-96	31
1697	Coronavirus diversity, phylogeny and interspecies jumping. 2009 , 234, 1117-27	415
1696	Antibody-mediated synergy and interference in the neutralization of SARS-CoV at an epitope cluster on the spike protein. 2009 , 390, 1056-60	10
1695	Synthetic peptides coupled to the surface of liposomes effectively induce SARS coronavirus-specific cytotoxic T lymphocytes and viral clearance in HLA-A*0201 transgenic mice. 2009 , 27, 3912-20	43
1694	Monoclonal antibody-based therapies for microbial diseases. 2009 , 27 Suppl 6, G38-46	125
1693	SARS coronavirus spike protein-induced innate immune response occurs via activation of the NF-kappaB pathway in human monocyte macrophages in vitro. 2009 , 142, 19-27	160
1692	Elucidating the molecular physiopathology of acute respiratory distress syndrome in severe acute respiratory syndrome patients. 2009 , 145, 260-9	66

1691	[Human coronaviruses]. 2009 , 57, 149-60	36
1690	The sweeter side of ACE2: physiological evidence for a role in diabetes. 2009 , 302, 193-202	155
1689	Structural insights into immune recognition of the severe acute respiratory syndrome coronavirus S protein receptor binding domain. 2009 , 388, 815-23	53
1688	Identification of a new region of SARS-CoV S protein critical for viral entry. 2009 , 394, 600-5	26
1687	Recently discovered human coronaviruses. 2009 , 29, 715-24	74
1686	Tissue-specific amino acid transporter partners ACE2 and collectrin differentially interact with hartnup mutations. 2009 , 136, 872-82	186
1685	Studies on membrane topology, N-glycosylation and functionality of SARS-CoV membrane protein. 2009 , 6, 79	42
1684	Crystal structure of NL63 respiratory coronavirus receptor-binding domain complexed with its human receptor. 2009 , 106, 19970-4	214
1683	Interaction of a peptide corresponding to the loop domain of the S2 SARS-CoV virus protein with model membranes. 2009 , 26, 236-48	6
1682	SARS-CoV spike proteins expressed by the vaccinia virus Tiantan strain: secreted sq protein induces robust neutralization antibody in mice. 2009 , 22, 57-66	9
1681	Human coronaviruses 229E and NL63: close yet still so far. 2009 , 108, 270-9	38
1680	Novel Aspects of the Cardiac Renin-Angiotensin System. 2009 , 75-89	1
1679	Expression of angiotensin-converting enzyme 2 in CCL4-induced rat liver fibrosis. 2009 , 23, 717-23	20
1678	[Angiotensin-converting enzyme: a protein conserved during evolution]. 2009 , 203, 281-93	6
1677	Angiotensin-(1-7), an alternative metabolite of the renin-angiotensin system, is up-regulated in human liver disease and has antifibrotic activity in the bile-duct-ligated rat. 2009 , 117, 375-86	79
1676	Peptide-based inhibitors of the HIV envelope protein and other class I viral fusion proteins. 2010 , 16, 1143-58	46
1675	Recombinant angiotensin-converting enzyme 2 improves pulmonary blood flow and oxygenation in lipopolysaccharide-induced lung injury in piglets. 2010 , 38, 596-601	84
1674	Subcellular Targeting of Virus-Envelope-Coated Nanoparticles. 2010 , 357-383	

1673	Renin-angiotensin system in human coronavirus pathogenesis. 2010 , 5, 145-161	40
1672	Angiotensin-converting enzyme 2 (ACE2) in disease pathogenesis. 2010 , 74, 405-10	123
1671	Not just angiotensinases: new roles for the angiotensin-converting enzymes. 2010 , 67, 89-98	69
1670	Binding of SARS coronavirus to its receptor damages islets and causes acute diabetes. 2010 , 47, 193-9	589
1669	Enhanced cell fusion activity in porcine epidemic diarrhea virus adapted to suckling mice. 2010 , 155, 1989-95	9
1668	Immunogenicity of the spike glycoprotein of bat SARS-like coronavirus. 2010 , 25, 36-44	4
1667	Trilogy of ACE2: a peptidase in the renin-angiotensin system, a SARS receptor, and a partner for amino acid transporters. 2010 , 128, 119-28	295
1666	TACE antagonists blocking ACE2 shedding caused by the spike protein of SARS-CoV are candidate antiviral compounds. 2010 , 85, 551-5	92
1665	Contribution of the porcine aminopeptidase N (CD13) receptor density to porcine epidemic diarrhea virus infection. 2010 , 144, 41-50	72
1664	Identification of N-linked carbohydrates from severe acute respiratory syndrome (SARS) spike glycoprotein. 2010 , 399, 257-69	76
1663	Structural basis for receptor recognition by New World hemorrhagic fever arenaviruses. 2010 , 17, 438-44	105
1662	Identification of SARS-COV spike protein-derived and HLA-A2-restricted human CTL epitopes by using a new muramyl dipeptidederivative adjuvant. 2010 , 23, 165-77	13
1661	A single asparagine-linked glycosylation site of the severe acute respiratory syndrome coronavirus spike glycoprotein facilitates inhibition by mannose-binding lectin through multiple mechanisms. 2010 , 84, 8753-64	109
1660	Identification of key amino acid residues required for horseshoe bat angiotensin-I converting enzyme 2 to function as a receptor for severe acute respiratory syndrome coronavirus. 2010 , 91, 1708-12	7
1659	Upregulation of the chemokine (C-C motif) ligand 2 via a severe acute respiratory syndrome coronavirus spike-ACE2 signaling pathway. 2010 , 84, 7703-12	81
1658	Differential downregulation of ACE2 by the spike proteins of severe acute respiratory syndrome coronavirus and human coronavirus NL63. 2010 , 84, 1198-205	324
1657	Structural considerations in the fitness landscape of a virus. 2010 , 27, 1782-91	4
1656	Recombinant soluble, multimeric HA and NA exhibit distinctive types of protection against pandemic swine-origin 2009 A(H1N1) influenza virus infection in ferrets. 2010 , 84, 10366-74	80

1655	Preparation and characterization of polyclonal antibody against severe acute respiratory syndrome-associated coronavirus spike protein. 2010 , 29, 511-6	10
1654	Studies of severe acute respiratory syndrome coronavirus pathology in human cases and animal models. 2010 , 47, 881-92	21
1653	Intranasal immunization with plasmid DNA encoding spike protein of SARS-coronavirus/polyethylenimine nanoparticles elicits antigen-specific humoral and cellular immune responses. 2010 , 11, 65	40
1652	The highly cited SARS research literature. 2010 , 36, 299-317	11
1651	Tissue-specific pattern of angiotensin-converting enzyme 2 expression in rat pancreas. 2010 , 38, 558-69	24
1650	Responses of human endothelial cells to pathogenic and non-pathogenic <i>Leptospira</i> species. 2010 , 4, e918	36
1649	Glycoprotein D of bovine herpesvirus 5 (BoHV-5) confers an extended host range to BoHV-1 but does not contribute to invasion of the brain. 2010 , 84, 5583-93	13
1648	Neutralizing epitopes of the SARS-CoV S-protein cluster independent of repertoire, antigen structure or mAb technology. 2010 , 2, 53-66	93
1647	Identification of a severe acute respiratory syndrome coronavirus-like virus in a leaf-nosed bat in Nigeria. 2010 , 1,	114
1646	Severe acute respiratory syndrome and coronavirus. 2010 , 24, 619-38	48
1645	Identification of NCAM that interacts with the PHE-CoV spike protein. 2010 , 7, 254	17
1644	Potent and persistent antibody responses against the receptor-binding domain of SARS-CoV spike protein in recovered patients. 2010 , 7, 299	52
1643	Interactions of SARS coronavirus nucleocapsid protein with the host cell proteasome subunit p42. 2010 , 7, 99	28
1642	Efficient activation of the severe acute respiratory syndrome coronavirus spike protein by the transmembrane protease TMPRSS2. 2010 , 84, 12658-64	511
1641	CD209 (DC-SIGN) -336A>G promoter polymorphism and severe acute respiratory syndrome in Hong Kong Chinese. 2010 , 71, 702-7	31
1640	Analysis of the mechanism by which BALB/c mice having prior immunization with nucleocapsid protein of SARS-CoV develop severe pneumonia after SARS-CoV infection. 2010 , 2, 44-50	
1639	Modulation of the renin-angiotensin-aldosterone system in sepsis: a new therapeutic approach?. 2010 , 14, 11-20	47
1638	Renin Angiotensin System and Cardiovascular Disease. 2010 ,	2

1637	Physiology of kidney renin. 2010 , 90, 607-73	188
1636	Recombination, reservoirs, and the modular spike: mechanisms of coronavirus cross-species transmission. 2010 , 84, 3134-46	441
1635	Longitudinal profiles of immunoglobulin G antibodies against severe acute respiratory syndrome coronavirus components and neutralizing activities in recovered patients. 2011 , 43, 515-21	31
1634	The cell biology of receptor-mediated virus entry. 2011 , 195, 1071-82	305
1633	A transmembrane serine protease is linked to the severe acute respiratory syndrome coronavirus receptor and activates virus entry. 2011 , 85, 873-82	460
1632	Evolution of SARS Coronavirus and the Relevance of Modern Molecular Epidemiology. 2011 , 711-728	3
1631	Coronavirus pathogenesis. 2011 , 81, 85-164	478
1630	The SARS-CoV heptad repeat 2 exhibits pH-induced helix formation. 2011 , 412, 483-6	1
1629	Transferrin receptor 1 in the zoonosis and pathogenesis of New World hemorrhagic fever arenaviruses. 2011 , 14, 476-82	42
1628	Purification and characterization of angiotensin converting enzyme 2 (ACE2) from murine model of mesangial cell in culture. 2011 , 49, 79-84	15
1627	Chimeric severe acute respiratory syndrome coronavirus (SARS-CoV) S glycoprotein and influenza matrix 1 efficiently form virus-like particles (VLPs) that protect mice against challenge with SARS-CoV. 2011 , 29, 6606-13	71
1626	Genetic determinants of pathogenesis by feline infectious peritonitis virus. 2011 , 143, 265-8	13
1625	Characterization of the spike protein of human coronavirus NL63 in receptor binding and pseudotype virus entry. 2011 , 160, 283-93	14
1624	Ectodomain Shedding of ACE and ACE2 as Regulators of Their Protein Functions. 2011 , 7, 42-55	8
1623	Severe Acute Respiratory Syndrome (SARS). 2011 , 392-397	2
1622	Comparative pathogenesis of three human and zoonotic SARS-CoV strains in cynomolgus macaques. 2011 , 6, e18558	22
1621	Machupo virus glycoprotein determinants for human transferrin receptor 1 binding and cell entry. 2011 , 6, e21398	28
1620	Protocol for recombinant RBD-based SARS vaccines: protein preparation, animal vaccination and neutralization detection. 2011 ,	5

1619	Report of the 'mechanisms of lung injury and immunomodulator interventions in influenza' workshop, 21 March 2010, Ventura, California, USA. 2011 , 5, 453-4, e458-75	9
1618	Complement and viral pathogenesis. 2011 , 411, 362-73	173
1617	Different host cell proteases activate the SARS-coronavirus spike-protein for cell-cell and virus-cell fusion. 2011 , 413, 265-74	94
1616	Subcellular location and topology of severe acute respiratory syndrome coronavirus envelope protein. 2011 , 415, 69-82	144
1615	Inhibition of severe acute respiratory syndrome coronavirus replication in a lethal SARS-CoV BALB/c mouse model by stinging nettle lectin, <i>Urtica dioica</i> agglutinin. 2011 , 90, 22-32	52
1614	Emodin inhibits current through SARS-associated coronavirus 3a protein. 2011 , 90, 64-9	118
1613	Structure and infrastructure of infectious agent research literature: SARS. 2011 , 86, 195-209	14
1612	SARS-CoV heptad repeat 2 is a trimer of parallel helices. 2011 , 20, 2125-9	3
1611	Development of anti-viral agents using molecular modeling and virtual screening techniques. 2011 , 11, 64-93	33
1610	Local renin-angiotensin II systems, angiotensin-converting enzyme and its homologue ACE2: their potential role in the pathogenesis of chronic obstructive pulmonary diseases, pulmonary hypertension and acute respiratory distress syndrome. 2011 , 18, 3506-15	63
1609	Crystal structure of mouse coronavirus receptor-binding domain complexed with its murine receptor. 2011 , 108, 10696-701	151
1608	Cleavage and activation of the severe acute respiratory syndrome coronavirus spike protein by human airway trypsin-like protease. 2011 , 85, 13363-72	219
1607	Epithelial cells lining salivary gland ducts are early target cells of severe acute respiratory syndrome coronavirus infection in the upper respiratory tracts of rhesus macaques. 2011 , 85, 4025-30	231
1606	T-cell immunoglobulin and mucin domain 1 (TIM-1) is a receptor for Zaire Ebolavirus and Lake Victoria Marburgvirus. 2011 , 108, 8426-31	270
1605	Ebolavirus delta-peptide immunoadhesins inhibit marburgvirus and ebolavirus cell entry. 2011 , 85, 8502-13	38
1604	Identification of the myelin oligodendrocyte glycoprotein as a cellular receptor for rubella virus. 2011 , 85, 11038-47	48
1603	Anti-severe acute respiratory syndrome coronavirus spike antibodies trigger infection of human immune cells via a pH- and cysteine protease-independent Fc β pathway. 2011 , 85, 10582-97	235
1602	Evidence that TMPRSS2 activates the severe acute respiratory syndrome coronavirus spike protein for membrane fusion and reduces viral control by the humoral immune response. 2011 , 85, 4122-34	711

1601	Fully human monoclonal antibody directed to proteolytic cleavage site in severe acute respiratory syndrome (SARS) coronavirus S protein neutralizes the virus in a rhesus macaque SARS model. 2011 , 203, 1574-81	33
1600	Recombinant Live Vaccines to Protect Against the Severe Acute Respiratory Syndrome Coronavirus. 2011 , 73-97	3
1599	Regulation of alveolar epithelial cell survival by the ACE-2/angiotensin 1-7/Mas axis. 2011 , 301, L269-74	98
1598	Inhibition of SARS pseudovirus cell entry by lactoferrin binding to heparan sulfate proteoglycans. 2011 , 6, e23710	268
1597	Distinct patterns of IFITM-mediated restriction of filoviruses, SARS coronavirus, and influenza A virus. 2011 , 7, e1001258	417
1596	The role of severe acute respiratory syndrome (SARS)-coronavirus accessory proteins in virus pathogenesis. 2012 , 4, 2902-23	89
1595	The murine coronavirus hemagglutinin-esterase receptor-binding site: a major shift in ligand specificity through modest changes in architecture. 2012 , 8, e1002492	38
1594	Structural bases of coronavirus attachment to host aminopeptidase N and its inhibition by neutralizing antibodies. 2012 , 8, e1002859	128
1593	Mechanisms of coronavirus cell entry mediated by the viral spike protein. 2012 , 4, 1011-33	779
1592	Angiotensin-Converting Enzyme 2 (ACE2) Is a Key Modulator of the Renin Angiotensin System in Health and Disease. 2012 , 2012, 256294	350
1591	Human coronaviruses: insights into environmental resistance and its influence on the development of new antiseptic strategies. 2012 , 4, 3044-68	243
1590	Replication-dependent downregulation of cellular angiotensin-converting enzyme 2 protein expression by human coronavirus NL63. 2012 , 93, 1924-1929	110
1589	Recent transmission of a novel alphacoronavirus, bat coronavirus HKU10, from Leschenault's rousettes to pomona leaf-nosed bats: first evidence of interspecies transmission of coronavirus between bats of different suborders. 2012 , 86, 11906-18	69
1588	Human coronavirus EMC does not require the SARS-coronavirus receptor and maintains broad replicative capability in mammalian cell lines. 2012 , 3,	154
1587	Receptor-binding domains of spike proteins of emerging or re-emerging viruses as targets for development of antiviral vaccines. 2012 , 1, e13	33
1586	Severe acute respiratory syndrome coronavirus replication is severely impaired by MG132 due to proteasome-independent inhibition of M-calpain. 2012 , 86, 10112-22	101
1585	An antibody recognizing the apical domain of human transferrin receptor 1 efficiently inhibits the entry of all new world hemorrhagic Fever arenaviruses. 2012 , 86, 4024-8	41
1584	Angiotensin-converting enzyme 2: the first decade. 2012 , 2012, 307315	147

1583	Binding of the 5'-untranslated region of coronavirus RNA to zinc finger CCHC-type and RNA-binding motif 1 enhances viral replication and transcription. 2012 , 40, 5065-77	31
1582	Mechanisms of host receptor adaptation by severe acute respiratory syndrome coronavirus. 2012 , 287, 8904-11	169
1581	Crystal structure of bovine coronavirus spike protein lectin domain. 2012 , 287, 41931-8	100
1580	Comparative evaluation of two hemagglutinating encephalomyelitis coronavirus vaccine candidates in mice. 2012 , 19, 1102-9	3
1579	Monitoring of S protein maturation in the endoplasmic reticulum by calnexin is important for the infectivity of severe acute respiratory syndrome coronavirus. 2012 , 86, 11745-53	51
1578	Inhibition of angiotensin II-induced contraction of human airway smooth muscle cells by angiotensin-(1-7) via downregulation of the RhoA/ROCK2 signaling pathway. 2012 , 30, 811-8	15
1577	Development of novel entry inhibitors targeting emerging viruses. 2012 , 10, 1129-38	36
1576	Recent insights into pulmonary repair following virus-induced inflammation of the respiratory tract. 2012 , 2, 233-41	24
1575	Characterization of cellular furin content as a potential factor determining the susceptibility of cultured human and animal cells to coronavirus infectious bronchitis virus infection. 2012 , 433, 421-30	26
1574	Manipulating angiotensin metabolism with angiotensin converting enzyme 2 (ACE2) in heart failure. 2012 , 9, e141-e148	3
1573	Phosphatidylinositol 4-kinase III α s required for severe acute respiratory syndrome coronavirus spike-mediated cell entry. 2012 , 287, 8457-67	35
1572	Design of Angiotensin-converting Enzyme 2 (ACE2) Inhibitors by Virtual Lead Optimization and Screening. 2012 , 59, 1394-1400	2
1571	Roadmap to developing a recombinant coronavirus S protein receptor-binding domain vaccine for severe acute respiratory syndrome. 2012 , 11, 1405-13	93
1570	SARS coronavirus pathogenesis: host innate immune responses and viral antagonism of interferon. 2012 , 2, 264-75	305
1569	Neutralization interfering antibodies: a "novel" example of humoral immune dysfunction facilitating viral escape?. 2012 , 4, 1731-52	22
1568	Evidence for ACE2-utilizing coronaviruses (CoVs) related to severe acute respiratory syndrome CoV in bats. 2012 , 86, 6350-3	72
1567	Influenza and SARS-coronavirus activating proteases TMPRSS2 and HAT are expressed at multiple sites in human respiratory and gastrointestinal tracts. 2012 , 7, e35876	290
1566	Lack of innate interferon responses during SARS coronavirus infection in a vaccination and reinfection ferret model. 2012 , 7, e45842	51

1565	ACE2/Angiotensin-(1-7)/Mas Axis and Cardiovascular Regeneration. 2012 , 8, 35-46	3
1564	Milk Derived Peptides with Immune Stimulating Antiviral Properties. 2012 ,	2
1563	Coronaviral Ion Channels as Target for Chinese Herbal Medicine. 2012 , 3, 1-13	8
1562	Neutralizing human monoclonal antibodies to severe acute respiratory syndrome coronavirus: target, mechanism of action, and therapeutic potential. 2012 , 22, 2-17	67
1561	Angiotensin converting enzyme 2 abrogates bleomycin-induced lung injury. 2012 , 90, 637-47	82
1560	A hexapeptide of the receptor-binding domain of SARS corona virus spike protein blocks viral entry into host cells via the human receptor ACE2. 2012 , 94, 288-96	61
1559	A novel method for high-throughput screening to quantify antiviral activity against viruses that induce limited CPE. 2012 , 183, 176-9	14
1558	Molecular basis of binding between novel human coronavirus MERS-CoV and its receptor CD26. <i>Nature</i> , 2013 , 500, 227-31	50.4 466
1557	Virus discovery: one step beyond. 2013 , 3, e1-e6	21
1556	The receptor binding domain of the new Middle East respiratory syndrome coronavirus maps to a 231-residue region in the spike protein that efficiently elicits neutralizing antibodies. 2013 , 87, 9379-83	171
1555	The replication of a mouse adapted SARS-CoV in a mouse cell line stably expressing the murine SARS-CoV receptor mACE2 efficiently induces the expression of proinflammatory cytokines. 2013 , 193, 639-46	12
1554	Isolation and characterization of a bat SARS-like coronavirus that uses the ACE2 receptor. <i>Nature</i> , 2013 , 503, 535-8	50.4 1085
1553	A decade after SARS: strategies for controlling emerging coronaviruses. 2013 , 11, 836-48	448
1552	ACE2 - from the renin-angiotensin system to gut microbiota and malnutrition. 2013 , 15, 866-73	135
1551	Phages bearing affinity peptides to severe acute respiratory syndromes-associated coronavirus differentiate this virus from other viruses. 2013 , 57, 305-10	6
1550	A safe and convenient pseudovirus-based inhibition assay to detect neutralizing antibodies and screen for viral entry inhibitors against the novel human coronavirus MERS-CoV. 2013 , 10, 266	102
1549	Bats as animal reservoirs for the SARS coronavirus: hypothesis proved after 10 years of virus hunting. 2013 , 28, 315-7	10
1548	Inhibition of novel Coronavirus replication by a combination of interferon- β and ribavirin. 2013 , 3, 1686	220

1547	Repeated lumbar puncture in adults with pneumococcal meningitis: an observational study. 2013 , 67, 350-3	4
1546	From SARS to MERS: 10 years of research on highly pathogenic human coronaviruses. 2013 , 100, 286-95	226
1545	Receptor recognition and cross-species infections of SARS coronavirus. 2013 , 100, 246-54	166
1544	Genetic characterization of Betacoronavirus lineage C viruses in bats reveals marked sequence divergence in the spike protein of pipistrellus bat coronavirus HKU5 in Japanese pipistrelle: implications for the origin of the novel Middle East respiratory syndrome coronavirus. 2013 , 87, 8638-50	191
1543	Novel polymeric inhibitors of HCoV-NL63. 2013 , 97, 112-21	50
1542	Proteolytic activation of the SARS-coronavirus spike protein: cutting enzymes at the cutting edge of antiviral research. 2013 , 100, 605-14	279
1541	Up-regulation of components of the renin-angiotensin system in liver fibrosis in the rat induced by CCL4 2013 , 95, 54-8	13
1540	Quantitative and sensitive detection of the SARS-CoV spike protein using bispecific monoclonal antibody-based enzyme-linked immunoassay. 2013 , 187, 72-8	20
1539	A predicted receptor-binding and critical neutralizing domain in S protein of the novel human coronavirus HCoV-EMC. 2013 , 66, 464-6	34
1538	Dipeptidyl peptidase 4 is a functional receptor for the emerging human coronavirus-EMC. <i>Nature</i> , 2013 , 495, 251-4	50.4 1362
1537	Ocular tropism of respiratory viruses. 2013 , 77, 144-56	192
1536	Structure of MERS-CoV spike receptor-binding domain complexed with human receptor DPP4. 2013 , 23, 986-93	459
1535	Antibodies induced by receptor-binding domain in spike protein of SARS-CoV do not cross-neutralize the novel human coronavirus hCoV-EMC. 2013 , 67, 348-50	16
1534	Animal models in virus research: their utility and limitations. 2013 , 39, 325-61	12
1533	Viral pathogens and acute lung injury: investigations inspired by the SARS epidemic and the 2009 H1N1 influenza pandemic. 2013 , 34, 475-86	51
1532	TIM-family proteins promote infection of multiple enveloped viruses through virion-associated phosphatidylserine. 2013 , 9, e1003232	223
1531	Emergence of the Middle East respiratory syndrome coronavirus. 2013 , 9, e1003595	31
1530	Cell cycle dependence of ACE-2 explains downregulation in idiopathic pulmonary fibrosis. 2013 , 42, 198-210	52

1529	Identification of a receptor-binding domain in the S protein of the novel human coronavirus Middle East respiratory syndrome coronavirus as an essential target for vaccine development. 2013 , 87, 9939-42	140
1528	The spike protein of the emerging betacoronavirus EMC uses a novel coronavirus receptor for entry, can be activated by TMPRSS2, and is targeted by neutralizing antibodies. 2013 , 87, 5502-11	251
1527	Anti-SARS coronavirus agents: a patent review (2008 - present). 2013 , 23, 1337-48	69
1526	Editorial: an anniversary and a new member of the family. 2013 , 23, 211-2	0
1525	Crystal structure of the receptor-binding domain from newly emerged Middle East respiratory syndrome coronavirus. 2013 , 87, 10777-83	94
1524	Multiple functions of angiotensin-converting enzyme 2 and its relevance in cardiovascular diseases. 2013 , 77, 301-8	123
1523	Apelin is a positive regulator of ACE2 in failing hearts. 2013 , 123, 5203-11	114
1522	Spironolactone attenuates bleomycin-induced pulmonary injury partially via modulating mononuclear phagocyte phenotype switching in circulating and alveolar compartments. 2013 , 8, e81090	24
1521	A truncated receptor-binding domain of MERS-CoV spike protein potently inhibits MERS-CoV infection and induces strong neutralizing antibody responses: implication for developing therapeutics and vaccines. 2013 , 8, e81587	126
1520	Angiotensin-Converting Enzyme-2. 2013 , 499-504	4
1519	Receptor for new coronavirus found. <i>Nature</i> , 2013 , 495, 149-50	50.4 3
1518	Middle East Respiratory Syndrome Coronavirus (MERS CoV): An Emerging Pathogen. 2014 , 14, 156-163	1
1517	Substitution at aspartic acid 1128 in the SARS coronavirus spike glycoprotein mediates escape from a S2 domain-targeting neutralizing monoclonal antibody. 2014 , 9, e102415	25
1516	IFITM3 polymorphism rs12252-C restricts influenza A viruses. 2014 , 9, e110096	35
1515	Pathogenesis of Human Coronaviruses Other than Severe Acute Respiratory Syndrome Coronavirus. 2014 , 313-324	11
1514	Angiotensin-Converting Enzyme 2, the Cellular Receptor for Severe Acute Respiratory Syndrome Coronavirus and Human Coronavirus NL63. 2014 , 147-156	
1513	Viral Pathogenesis. 2014 ,	5
1512	Current advancements and potential strategies in the development of MERS-CoV vaccines. 2014 , 13, 761-74	113

1511	Identification of diverse alphacoronaviruses and genomic characterization of a novel severe acute respiratory syndrome-like coronavirus from bats in China. 2014 , 88, 7070-82	104
1510	IFITM-Family Proteins: The Cell's First Line of Antiviral Defense. 2014 , 1, 261-283	262
1509	Epigenetic regulation of angiotensin-converting enzyme 2 (ACE2) by SIRT1 under conditions of cell energy stress. 2014 , 126, 507-16	107
1508	Mesenchymal stem cell-based angiotensin-converting enzyme 2 in treatment of acute lung injury rat induced by bleomycin. 2014 , 40, 392-403	10
1507	Role of angiotensin-converting enzyme 2 (ACE2) in diabetic cardiovascular complications. 2014 , 126, 471-82	59
1506	Screening of an FDA-approved compound library identifies four small-molecule inhibitors of Middle East respiratory syndrome coronavirus replication in cell culture. 2014 , 58, 4875-84	504
1505	Severe acute respiratory syndrome vs. the Middle East respiratory syndrome. 2014 , 20, 233-41	148
1504	Coronaviruses: severe acute respiratory syndrome coronavirus and Middle East respiratory syndrome coronavirus in travelers. 2014 , 27, 411-7	59
1503	Infectious Diseases and the Kidney in Children. 2014 , 1-53	
1502	ACE for all - a molecular perspective. 2014 , 8, 195-210	20
1501	TMPRSS2 and ADAM17 cleave ACE2 differentially and only proteolysis by TMPRSS2 augments entry driven by the severe acute respiratory syndrome coronavirus spike protein. 2014 , 88, 1293-307	547
1500	Effects of human anti-spike protein receptor binding domain antibodies on severe acute respiratory syndrome coronavirus neutralization escape and fitness. 2014 , 88, 13769-80	60
1499	Productive replication of Middle East respiratory syndrome coronavirus in monocyte-derived dendritic cells modulates innate immune response. 2014 , 454-455, 197-205	122
1498	Membrane ectopeptidases targeted by human coronaviruses. 2014 , 6, 55-60	28
1497	Downregulation of angiotensin-converting enzyme 2 by the neuraminidase protein of influenza A (H1N1) virus. 2014 , 185, 64-71	43
1496	Influence of hydrophobic and electrostatic residues on SARS-coronavirus S2 protein stability: insights into mechanisms of general viral fusion and inhibitor design. 2014 , 23, 603-17	25
1495	A conformation-dependent neutralizing monoclonal antibody specifically targeting receptor-binding domain in Middle East respiratory syndrome coronavirus spike protein. 2014 , 88, 7045-53	112
1494	Protection from SARS coronavirus conferred by live measles vaccine expressing the spike glycoprotein. 2014 , 452-453, 32-41	49

1493	Carboxyterminal protein processing in health and disease: key actors and emerging technologies. 2014 , 13, 4497-504	18
1492	Bat origins of MERS-CoV supported by bat coronavirus HKU4 usage of human receptor CD26. 2014 , 16, 328-37	198
1491	Phosphatidylserine receptors: enhancers of enveloped virus entry and infection. 2014 , 468-470, 565-580	121
1490	Yellow head virus binding to cell surface proteins from <i>Penaeus monodon</i> hemocytes. 2014 , 41, 126-36	7
1489	A recombinant rabies vaccine expressing the trimeric form of the glycoprotein confers enhanced immunogenicity and protection in outbred mice. 2014 , 32, 4644-50	23
1488	Human coronavirus NL63 utilizes heparan sulfate proteoglycans for attachment to target cells. 2014 , 88, 13221-30	189
1487	A structural view of coronavirus-receptor interactions. 2014 , 194, 3-15	41
1486	Antiviral drugs specific for coronaviruses in preclinical development. 2014 , 8, 45-53	64
1485	Host species restriction of Middle East respiratory syndrome coronavirus through its receptor, dipeptidyl peptidase 4. 2014 , 88, 9220-32	167
1484	Influence of HLA gene polymorphisms on susceptibility and outcome post infection with the SARS-CoV virus. 2014 , 29, 128-30	19
1483	Functional analysis of the receptor binding domain of SARS coronavirus S1 region and its monoclonal antibody. 2014 , 36, 387-397	1
1482	Antibody-dependent SARS coronavirus infection is mediated by antibodies against spike proteins. 2014 , 451, 208-14	276
1481	Dromedary MERS-CoV replicates in human respiratory tissues. 2014 , 2, 779-81	1
1480	Association between serum angiotensin-converting enzyme 2 level with postoperative morbidity and mortality after major pulmonary resection in non-small cell lung cancer patients. 2014 , 23, 661-6	4
1479	Intranasal vaccination with recombinant receptor-binding domain of MERS-CoV spike protein induces much stronger local mucosal immune responses than subcutaneous immunization: Implication for designing novel mucosal MERS vaccines. 2014 , 32, 2100-8	107
1478	The pathology and pathogenesis of experimental severe acute respiratory syndrome and influenza in animal models. 2014 , 151, 83-112	113
1477	Cell adhesion as a novel approach to determining the cellular binding motif on the severe acute respiratory syndrome coronavirus spike protein. 2014 , 201, 1-6	10
1476	Controlling Epidemic of Human Respiratory Viral Infections. 2014 , 219-229	

1475	Enterovirus 68 and Human Respiratory Infections. 2014 , 613-628	
1474	Cough Formation in Viral Infections in Children. 2014 , 71-89	
1473	Losartan and enalapril decrease viral absorption and interleukin 1 beta production by macrophages in an experimental dengue virus infection. 2015 , 160, 2861-5	12
1472	Single amino acid substitution (G42E) in the receptor binding domain of mouse mammary tumour virus envelope protein facilitates infection of non-murine cells in a transferrin receptor 1-independent manner. 2015 , 12, 43	14
1471	Bat origin of human coronaviruses. 2015 , 12, 221	232
1470	Bat Coronaviruses. 2015 , 127-155	4
1469	ACE2 and Microbiota: Emerging Targets for Cardiopulmonary Disease Therapy. 2015 , 66, 540-50	67
1468	Mesenchymal Stem Cells Overexpressing Angiotensin-Converting Enzyme 2 Rescue Lipopolysaccharide-Induced Lung Injury. 2015 , 24, 1699-715	71
1467	Renal Complications and Their Prognosis in Korean Patients with Middle East Respiratory Syndrome-Coronavirus from the Central MERS-CoV Designated Hospital. 2015 , 30, 1807-14	58
1466	Nicotianamine is a novel angiotensin-converting enzyme 2 inhibitor in soybean. 2015 , 36, 219-24	44
1465	Middle East Respiratory Syndrome-Coronavirus (MERS-CoV): An Updated Overview and Pharmacotherapeutics. 2015 ,	8
1464	Ferret models of viral pathogenesis. 2015 , 479-480, 259-70	106
1463	Preface. Coronaviruses. 2015 , 1282, v	55
1462	Intranasal and oral vaccination with protein-based antigens: advantages, challenges and formulation strategies. 2015 , 6, 480-503	79
1461	Development of animal models against emerging coronaviruses: From SARS to MERS coronavirus. 2015 , 479-480, 247-58	68
1460	Middle East respiratory syndrome. 2015 , 386, 995-1007	730
1459	Gene Therapy for Respiratory Viral Infections. 2015 , 281-297	4
1458	Pathogenesis of Middle East respiratory syndrome coronavirus. 2015 , 235, 175-84	104

1457	Tryptophan-dependent membrane interaction and heteromerization with the internal fusion peptide by the membrane proximal external region of SARS-CoV spike protein. 2015 , 54, 1819-30	22
1456	Receptor-binding domain-based subunit vaccines against MERS-CoV. 2015 , 202, 151-9	49
1455	Receptor recognition mechanisms of coronaviruses: a decade of structural studies. 2015 , 89, 1954-64	358
1454	A review of genetic methods and models for analysis of coronavirus-induced severe pneumonitis. 2015 , 96, 494-506	1
1453	The structure and functions of coronavirus genomic 3' and 5' ends. 2015 , 206, 120-33	225
1452	Inhibition of endoplasmic reticulum-resident glucosidases impairs severe acute respiratory syndrome coronavirus and human coronavirus NL63 spike protein-mediated entry by altering the glycan processing of angiotensin I-converting enzyme 2. 2015 , 59, 206-16	48
1451	Bat-to-human: spike features determining 'host jump' of coronaviruses SARS-CoV, MERS-CoV, and beyond. 2015 , 23, 468-78	363
1450	Identification of the Receptor-Binding Domain of the Spike Glycoprotein of Human Betacoronavirus HKU1. 2015 , 89, 8816-27	33
1449	Hunting Viral Receptors Using Haploid Cells. 2015 , 2, 219-39	14
1448	Animal models for SARS and MERS coronaviruses. 2015 , 13, 123-9	129
1447	Angiotensin-Converting Enzyme 2/Angiotensin-(1-7)/Mas Receptor Axis: Emerging Pharmacological Target for Pulmonary Diseases. 2015 , 269-274	5
1446	ACE2 Cell Biology, Regulation, and Physiological Functions. 2015 , 185-189	45
1445	Angiotensin-(1-7) and Mas. 2015 , 155-159	3
1444	A small region of porcine hemagglutinating encephalomyelitis virus spike protein interacts with the neural cell adhesion molecule. 2015 , 58, 130-7	14
1443	Middle East respiratory syndrome coronavirus: another zoonotic betacoronavirus causing SARS-like disease. 2015 , 28, 465-522	582
1442	Human Coronavirus HKU1 Spike Protein Uses O-Acetylated Sialic Acid as an Attachment Receptor Determinant and Employs Hemagglutinin-Esterase Protein as a Receptor-Destroying Enzyme. 2015 , 89, 7202-13	166
1441	Respiratory protease/antiprotease balance determines susceptibility to viral infection and can be modified by nutritional antioxidants. 2015 , 308, L1189-201	39
1440	Inhibitor recognition specificity of MERS-CoV papain-like protease may differ from that of SARS-CoV. 2015 , 10, 1456-65	75

1439	Severe acute respiratory syndrome-associated coronavirus vaccines formulated with delta inulin adjuvants provide enhanced protection while ameliorating lung eosinophilic immunopathology. 2015 , 89, 2995-3007	136
1438	Coronavirus and influenza virus proteolytic priming takes place in tetraspanin-enriched membrane microdomains. 2015 , 89, 6093-104	37
1437	Reconstitution of the receptor-binding motif of the SARS coronavirus. 2015 , 28, 567-75	7
1436	Hyperoxia downregulates angiotensin-converting enzyme-2 in human fetal lung fibroblasts. 2015 , 77, 656-62	31
1435	Severe Acute Respiratory Syndrome Coronavirus ORF7a Inhibits Bone Marrow Stromal Antigen 2 Virion Tethering through a Novel Mechanism of Glycosylation Interference. 2015 , 89, 11820-33	91
1434	The ns12.9 Accessory Protein of Human Coronavirus OC43 Is a Viroporin Involved in Virion Morphogenesis and Pathogenesis. 2015 , 89, 11383-95	20
1433	Middle East respiratory syndrome coronavirus: transmission, virology and therapeutic targeting to aid in outbreak control. 2015 , 47, e181	75
1432	Middle East Respiratory Syndrome (MERS). 2016 , 73-104	
1431	Coronaviruses. 2016 , 1243-1265	8
1430	SARS coronavirus infections of the lower respiratory tract and their prevention. 2016 , 45-53	1
1429	Human Coronaviruses: A Review of Virus-Host Interactions. 2016 , 4,	319
1428	Middle East Respiratory Syndrome (MERS). 2016 , 4,	17
1427	Interaction of SARS and MERS Coronaviruses with the Antiviral Interferon Response. 2016 , 96, 219-243	195
1426	Middle East respiratory syndrome coronavirus shows poor replication but significant induction of antiviral responses in human monocyte-derived macrophages and dendritic cells. 2016 , 97, 344-355	63
1425	A Human Lectin Microarray for Sperm Surface Glycosylation Analysis. 2016 , 15, 2839-51	15
1424	Principles of Virus Uncoating: Cues and the Snooker Ball. 2016 , 17, 569-92	71
1423	Angiotensin-converting enzyme 2. 2016 , 147, 120-1	4
1422	SARS-CoV fusion peptides induce membrane surface ordering and curvature. 2016 , 6, 37131	41

1421	Annexing AXL: Endothelial Cell Infection by the Zika Virus. 2016 , 119, 1149-1150	3
1420	Identification of the Fusion Peptide-Containing Region in Betacoronavirus Spike Glycoproteins. 2016 , 90, 5586-5600	50
1419	Pre-fusion structure of a human coronavirus spike protein. <i>Nature</i> , 2016 , 531, 118-21	50-4 474
1418	Development of a SARS Coronavirus Vaccine from Recombinant Spike Protein Plus Delta Inulin Adjuvant. 2016 , 1403, 269-84	16
1417	Role of the ACE2/Angiotensin 1-7 Axis of the Renin-Angiotensin System in Heart Failure. 2016 , 118, 1313-26	478
1416	Glycopeptide Antibiotics Potently Inhibit Cathepsin L in the Late Endosome/Lysosome and Block the Entry of Ebola Virus, Middle East Respiratory Syndrome Coronavirus (MERS-CoV), and Severe Acute Respiratory Syndrome Coronavirus (SARS-CoV). 2016 , 291, 9218-32	188
1415	Structure, Function, and Evolution of Coronavirus Spike Proteins. 2016 , 3, 237-261	1495
1414	Neurotropic Viral Infections. 2016 ,	0
1413	Putative Receptor Binding Domain of Bat-Derived Coronavirus HKU9 Spike Protein: Evolution of Betacoronavirus Receptor Binding Motifs. 2016 , 55, 5977-5988	14
1412	Middle East Respiratory Syndrome Virus Pathogenesis. 2016 , 37, 572-7	40
1411	Carcinoembryonic Antigen-Related Cell Adhesion Molecule 5 Is an Important Surface Attachment Factor That Facilitates Entry of Middle East Respiratory Syndrome Coronavirus. 2016 , 90, 9114-27	56
1410	Antioxidant effect of angiotensin (1-7) in the protection of pancreatic β cell function. 2016 , 14, 1963-9	17
1409	Disease Outbreaks: Critical Biological Factors and Control Strategies. 2016 , 173-204	2
1408	Urban Resilience. 2016 ,	18
1407	Introduction of neutralizing immunogenicity index to the rational design of MERS coronavirus subunit vaccines. 2016 , 7, 13473	77
1406	Neurotropic Coronavirus Infections. 2016 , 115-148	3
1405	Vaccine Development Against Middle East Respiratory Syndrome. 2016 , 3, 80-86	1
1404	Immunodominant SARS Coronavirus Epitopes in Humans Elicited both Enhancing and Neutralizing Effects on Infection in Non-human Primates. 2016 , 2, 361-76	207

1403	Surface vimentin is critical for the cell entry of SARS-CoV. 2016 , 23, 14	87
1402	A molecular arms race between host innate antiviral response and emerging human coronaviruses. 2016 , 31, 12-23	34
1401	Equine Arteritis Virus Uses Equine CXCL16 as an Entry Receptor. 2016 , 90, 3366-84	15
1400	Infectious Diseases and the Kidney in Children. 2016 , 1609-1654	2
1399	Coronaviruses - drug discovery and therapeutic options. 2016 , 15, 327-47	1060
1398	Clinicopathologic, Immunohistochemical, and Ultrastructural Findings of a Fatal Case of Middle East Respiratory Syndrome Coronavirus Infection in the United Arab Emirates, April 2014. 2016 , 186, 652-8	269
1397	Middle East respiratory syndrome and severe acute respiratory syndrome. 2016 , 16, 70-76	47
1396	Proteomic approaches to uncovering virus-host protein interactions during the progression of viral infection. 2016 , 13, 325-40	57
1395	Moving beyond metagenomics to find the next pandemic virus. 2016 , 113, 2812-4	10
1394	A rapid and quantitative assay for measuring neutralizing antibodies of Coxsackievirus B3. 2016 , 232, 1-7	5
1393	Diagnostic Imaging of Emerging Infectious Diseases. 2016 ,	
1392	Decoding protein networks during virus entry by quantitative proteomics. 2016 , 218, 25-39	18
1391	Epidemic and Emerging Coronaviruses (Severe Acute Respiratory Syndrome and Middle East Respiratory Syndrome). 2017 , 38, 71-86	76
1390	Safety and immunogenicity of mammalian cell derived and Modified Vaccinia Ankara vectored African swine fever subunit antigens in swine. 2017 , 185, 20-33	34
1389	Vaccine development for emerging virulent infectious diseases. 2017 , 35, 5437-5443	21
1388	Heat shock protein 70 in lung and kidney of specific-pathogen-free chickens is a receptor-associated protein that interacts with the binding domain of the spike protein of infectious bronchitis virus. 2017 , 162, 1625-1631	10
1387	Global research trends of World Health Organization's top eight emerging pathogens. 2017 , 13, 9	105
1386	Human airway trypsin-like protease, a serine protease involved in respiratory diseases. 2017 , 312, L657-L668	20

1385	Targeting endosomal acidification by chloroquine analogs as a promising strategy for the treatment of emerging viral diseases. 2017 , 5, e00293	233
1384	Cytoplasmic tail of coronavirus spike protein has intracellular targeting signals. 2017 , 42, 231-244	25
1383	A Consensus Definitive Classification of Scavenger Receptors and Their Roles in Health and Disease. 2017 , 198, 3775-3789	165
1382	Development of a pseudovirus based assay for measuring neutralizing antibodies against coxsackievirus B5. 2017 , 246, 21-26	5
1381	Factors determining human-to-human transmissibility of zoonotic pathogens via contact. 2017 , 22, 7-12	10
1380	VirusPlatelet Associations. 2017 , 1085-1102	11
1379	AIDS, Avian flu, SARS, MERS, Ebola, Zika—what next?. 2017 , 35, 4470-4474	68
1378	Future drug discovery in renin-angiotensin-aldosterone system intervention. 2017 , 12, 827-848	21
1377	Aminopeptidase N is not required for porcine epidemic diarrhea virus cell entry. 2017 , 235, 6-13	47
1376	The recombinant N-terminal domain of spike proteins is a potential vaccine against Middle East respiratory syndrome coronavirus (MERS-CoV) infection. 2017 , 35, 10-18	64
1375	Cryo-electron microscopy structures of the SARS-CoV spike glycoprotein reveal a prerequisite conformational state for receptor binding. 2017 , 27, 119-129	410
1374	MERS-CoV spike protein: a key target for antivirals. 2017 , 21, 131-143	176
1373	Are RNA Viruses Candidate Agents for the Next Global Pandemic? A Review. 2017 , 58, 343-358	89
1372	Vaccines for emerging infectious diseases: Lessons from MERS coronavirus and Zika virus. 2017 , 13, 2918-2930	20
1371	The Rho ADP-ribosylating C3 exoenzyme binds cells via an Arg-Gly-Asp motif. 2017 , 292, 17668-17680	8
1370	Novel Alphacoronaviruses and Paramyxoviruses Cocirculate with Type 1 and Severe Acute Respiratory System (SARS)-Related Betacoronaviruses in Synanthropic Bats of Luxembourg. 2017 , 83,	18
1369	Acute Respiratory Distress Syndrome. 2017 , 377, 562-572	742
1368	Lipidation increases antiviral activities of coronavirus fusion-inhibiting peptides. 2017 , 511, 9-18	11

1367	Development of small-molecule viral inhibitors targeting various stages of the life cycle of emerging and re-emerging viruses. 2017 , 11, 449-461	16
1366	Receptor-binding loops in alphacoronavirus adaptation and evolution. 2017 , 8, 1735	60
1365	Cross-neutralization of SARS coronavirus-specific antibodies against bat SARS-like coronaviruses. 2017 , 60, 1399-1402	23
1364	Human monoclonal antibodies as candidate therapeutics against emerging viruses. 2017 , 11, 462-470	33
1363	Host Factors in Coronavirus Replication. 2018 , 419, 1-42	267
1362	Heat shock protein 90 α in the Vero cell membrane binds Japanese encephalitis virus. 2017 , 40, 474-482	10
1361	Quantitative structure-activity relationship and molecular docking revealed a potency of anti-hepatitis C virus drugs against human corona viruses. 2017 , 89, 1040-1047	80
1360	Middle East Respiratory Syndrome: Emergence of a Pathogenic Human Coronavirus. 2017 , 68, 387-399	168
1359	Evolution of SARS Coronavirus and the Relevance of Modern Molecular Epidemiology. 2017 , 601-619	3
1358	Markers and Biomarkers of Endothelium: When Something Is Rotten in the State. 2017 , 2017, 9759735	81
1357	Technologies for Proteome-Wide Discovery of Extracellular Host-Pathogen Interactions. 2017 , 2017, 2197615	19
1356	The tetraspanin CD9 facilitates MERS-coronavirus entry by scaffolding host cell receptors and proteases. 2017 , 13, e1006546	84
1355	Expression and regulation of the neutral amino acid transporter BOAT1 in rat small intestine. 2017 , 12, e0184845	39
1354	Other Positive-Strand RNA Viruses. 2017 , 177-184	
1353	Alterations in Gene Expression of Components of the Renin-Angiotensin System and Its Related Enzymes in Lung Cancer. 2017 , 2017, 6914976	20
1352	Angiotensin Converting Enzyme Inhibitors and Angiotensin Receptor Blockers: A Promising Medication for Chronic Obstructive Pulmonary Disease?. 2018 , 15, 148-156	10
1351	Fatal swine acute diarrhoea syndrome caused by an HKU2-related coronavirus of bat origin. <i>Nature</i> , 2018 , 556, 255-258	50.4 369
1350	Porcine Deltacoronavirus Engages the Transmissible Gastroenteritis Virus Functional Receptor Porcine Aminopeptidase N for Infectious Cellular Entry. 2018 , 92,	56

1349	Contribution of porcine aminopeptidase N to porcine deltacoronavirus infection. 2018 , 7, 65	38
1348	ACE2 and pACE2: A Pair of Aces for Pulmonary Arterial Hypertension Treatment?. 2018 , 198, 422-423	11
1347	Human Coronaviruses. 2018 , 1148-1152.e3	8
1346	Identification of Residues Controlling Restriction versus Enhancing Activities of IFITM Proteins on Entry of Human Coronaviruses. 2018 , 92,	67
1345	Physiological and molecular triggers for SARS-CoV membrane fusion and entry into host cells. 2018 , 517, 3-8	169
1344	MERS, SARS and other coronaviruses as causes of pneumonia. 2018 , 23, 130-137	605
1343	Cryo-Electron Microscopy Structure of Porcine Deltacoronavirus Spike Protein in the Prefusion State. 2018 , 92,	72
1342	Attenuation of pulmonary ACE2 activity impairs inactivation of des-Arg bradykinin/BKB1R axis and facilitates LPS-induced neutrophil infiltration. 2018 , 314, L17-L31	220
1341	Entry of Human Coronavirus NL63 into the Cell. 2018 , 92,	116
1340	Replication of MERS and SARS coronaviruses in bat cells offers insights to their ancestral origins. 2018 , 7, 209	22
1339	Lysosomal Proteases Are a Determinant of Coronavirus Tropism. 2018 , 92,	40
1338	Stabilized coronavirus spikes are resistant to conformational changes induced by receptor recognition or proteolysis. 2018 , 8, 15701	259
1337	Three Main Inducers of Alphacoronavirus Infection of Enterocytes: Sialic Acid, Proteases, and Low pH. 2018 , 61, 53-63	11
1336	Activation of Viruses by Host Proteases. 2018 ,	9
1335	The Antiviral Potential of Host Protease Inhibitors. 2018 , 279-325	16
1334	Characterization of the interaction between recombinant porcine aminopeptidase N and spike glycoprotein of porcine epidemic diarrhea virus. 2018 , 117, 704-712	7
1333	Priming Time: How Cellular Proteases Arm Coronavirus Spike Proteins. 2018 , 71-98	48
1332	Broad receptor engagement of an emerging global coronavirus may potentiate its diverse cross-species transmissibility. 2018 , 115, E5135-E5143	129

1331	The ACE2/Angiotensin-(1-7)/MAS Axis of the Renin-Angiotensin System: Focus on Angiotensin-(1-7). 2018 , 98, 505-553	494
1330	CRISPR-Cas Targeting of Host Genes as an Antiviral Strategy. 2018 , 10,	26
1329	The S2 Subunit of Infectious Bronchitis Virus Beaudette Is a Determinant of Cellular Tropism. 2018 , 92,	28
1328	Early events during human coronavirus OC43 entry to the cell. 2018 , 8, 7124	77
1327	Constructing Smart Protocells with Built-In DNA Computational Core to Eliminate Exogenous Challenge. 2018 , 140, 6912-6920	31
1326	Novel Angiotensin-Converting Enzyme Inhibitory Peptides Derived from <i>Oncorhynchus mykiss</i> Nebulin: Virtual Screening and In Silico Molecular Docking Study. 2018 , 83, 2375-2383	12
1325	Cryo-EM structure of the SARS coronavirus spike glycoprotein in complex with its host cell receptor ACE2. 2018 , 14, e1007236	523
1324	Middle East respiratory syndrome coronavirus and bat coronavirus HKU9 both can utilize GRP78 for attachment onto host cells. 2018 , 293, 11709-11726	114
1323	Angiotensin-(1-7). 2019 ,	2
1322	Molecular Pathogenesis of Middle East Respiratory Syndrome (MERS) Coronavirus. 2019 , 6, 139-147	14
1321	Membrane Protein of Human Coronavirus NL63 Is Responsible for Interaction with the Adhesion Receptor. 2019 , 93,	45
1320	Crystal structure of the S1 subunit N-terminal domain from DcCoV UAE-HKU23 spike protein. 2019 , 535, 74-82	2
1319	MERS Coronavirus: An Emerging Zoonotic Virus. 2019 , 11,	10
1318	Novel Therapeutic Approaches Targeting the Renin-Angiotensin System and Associated Peptides in Hypertension and Heart Failure. 2019 , 71, 539-570	146
1317	Structural insights into coronavirus entry. 2019 , 105, 93-116	479
1316	Antiviral Effect of Lithium Chloride and Diammonium Glycyrrhizinate on Porcine Deltacoronavirus In Vitro. 2019 , 8,	16
1315	Structural Definition of a Neutralization-Sensitive Epitope on the MERS-CoV S1-NTD. 2019 , 28, 3395-3405.e6	53
1314	Broad Cross-Species Infection of Cultured Cells by Bat HKU2-Related Swine Acute Diarrhea Syndrome Coronavirus and Identification of Its Replication in Murine Dendritic Cells Highlight Its Potential for Diverse Interspecies Transmission. 2019 , 93,	42

1313	Unexpected Receptor Functional Mimicry Elucidates Activation of Coronavirus Fusion. 2019 , 176, 1026-1039.e15	16
1312	Human coronaviruses OC43 and HKU1 bind to 9-acetylated sialic acids via a conserved receptor-binding site in spike protein domain A. 2019 , 116, 2681-2690	242
1311	Membrane Composition Modulates Fusion by Altering Membrane Properties and Fusion Peptide Structure. 2019 , 252, 261-272	22
1310	Canine Respiratory Coronavirus, Bovine Coronavirus, and Human Coronavirus OC43: Receptors and Attachment Factors. 2019 , 11,	46
1309	Guinea Fowl Coronavirus Diversity Has Phenotypic Consequences for Glycan and Tissue Binding. 2019 , 93,	12
1308	COVID-19 Outbreak: An Overview. 2019 , 64, 215-223	128
1307	Membrane Cholesterol Modulates Oligomeric Status and Peptide-Membrane Interaction of Severe Acute Respiratory Syndrome Coronavirus Fusion Peptide. 2019 , 123, 10654-10662	67
1306	Severe Acute Respiratory Syndrome: Historical, Epidemiologic, and Clinical Features. 2019 , 33, 869-889	291
1305	Entry of Bat Coronavirus-512 and Severe Acute Respiratory Syndrome Coronavirus in Human and Multiple Animal Cells. 2019 , 8,	7
1304	Tetraspanins: Architects of Viral Entry and Exit Platforms. 2019 , 93,	41
1303	ACE2 in Brain Physiology and Pathophysiology: Evidence from Transgenic Animal Models. 2019 , 44, 1323-1329	82
1302	From SARS to MERS, Thrusting Coronaviruses into the Spotlight. 2019 , 11,	678
1301	Loss of Apelin Augments Angiotensin II-Induced Cardiac Dysfunction and Pathological Remodeling. 2019 , 20,	25
1300	Origin and evolution of pathogenic coronaviruses. 2019 , 17, 181-192	2651
1299	Hypertensive urgencies and emergencies: Misconceptions and pitfalls. 2020 , 71, 15-17	5
1298	Gold nanoparticle-adjuvanted S protein induces a strong antigen-specific IgG response against severe acute respiratory syndrome-related coronavirus infection, but fails to induce protective antibodies and limit eosinophilic infiltration in lungs. 2020 , 64, 33-51	92
1297	The use of cells from ANPEP knockout pigs to evaluate the role of aminopeptidase N (APN) as a receptor for porcine deltacoronavirus (PDCoV). 2020 , 541, 136-140	17
1296	A review of severe acute respiratory syndrome coronavirus 2 infection in the reproductive system. 2020 , 83, 895-897	10

1295	Peritoneal Dialysis Is an Option for Acute Kidney Injury Management in Patients with COVID-19. 2021 , 50, 283-289	2
1294	Severe Acute Respiratory Syndrome Coronavirus 2, COVID-19, and the Renin-Angiotensin System: Pressing Needs and Best Research Practices. 2020 , 76, 1350-1367	36
1293	How COVID-19 induces cytokine storm with high mortality. 2020 , 40, 37	238
1292	Scientific Rationale for a Bottom-Up Approach to Target the Host Response in Order to Try and Reduce the Numbers Presenting With Adult Respiratory Distress Syndrome Associated With COVID-19. Is There a Role for Statins and COX-2 Inhibitors in the Prevention and Early Treatment of the Disease?. 2020 , 11, 2167	7
1291	COVID-19-Related Anosmia: The Olfactory Pathway Hypothesis and Early Intervention. 2020 , 11, 956	20
1290	SARS-CoV-2 pathophysiology and its clinical implications: An integrative overview of the pharmacotherapeutic management of COVID-19. 2020 , 146, 111769	82
1289	Zoonotic and reverse zoonotic events of SARS-CoV-2 and their impact on global health. 2020 , 9, 2222-2235	25
1288	Endothelial Cell Contributions to COVID-19. 2020 , 9,	12
1287	Update of the current knowledge on genetics, evolution, immunopathogenesis, and transmission for coronavirus disease 19 (COVID-19). 2020 , 16, 2906-2923	20
1286	ACE2 enhance viral infection or viral infection aggravate the underlying diseases. 2020 , 18, 2100-2106	4
1285	From SARS to SARS-CoV-2, insights on structure, pathogenicity and immunity aspects of pandemic human coronaviruses. 2020 , 85, 104502	56
1284	The role of dysregulated immune responses in COVID-19 pathogenesis. 2020 , 290, 198197	31
1283	Greener liquid-phase synthesis and the ACE inhibitory structure-activity relationship of an anti-SARS octapeptide. 2020 , 18, 8433-8442	2
1282	Duodenal chemosensory system: enterocytes, enteroendocrine cells, and tuft cells. 2020 , 36, 501-508	3
1281	Immunopathogenesis of Coronavirus-Induced Acute Respiratory Distress Syndrome (ARDS): Potential Infection-Associated Hemophagocytic Lymphohistiocytosis. 2020 , 34,	12
1280	Sex steroids skew ACE2 expression in human airway: a contributing factor to sex differences in COVID-19?. 2020 , 319, L843-L847	23
1279	Syncytia formation by SARS-CoV-2-infected cells. 2020 , 39, e106267	167
1278	Clinical Courses and Outcomes of Patients with Chronic Obstructive Pulmonary Disease During the COVID-19 Epidemic in Hubei, China. 2020 , 15, 2237-2248	13

1277	Strategies for Targeting SARS CoV-2: Small Molecule Inhibitors-The Current Status. 2020 , 11, 552925	24
1276	PI3K Inhibition as a Potential Therapeutic Target in COVID-19. 2020 , 11, 2094	15
1275	Unraveling the Possible Routes of SARS-COV-2 Invasion into the Central Nervous System. 2020 , 22, 37	38
1274	The emergence of COVID-19 as a global pandemic: Understanding the epidemiology, immune response and potential therapeutic targets of SARS-CoV-2. 2020 , 179, 85-100	47
1273	Potential use of polyphenols in the battle against COVID-19. 2020 , 32, 149-155	52
1272	Should ACE2 be given a chance in COVID-19 therapeutics: A semi-systematic review of strategies enhancing ACE2. 2020 , 887, 173545	23
1271	Can pentoxifylline and similar xanthine derivatives find a niche in COVID-19 therapeutic strategies? A ray of hope in the midst of the pandemic. 2020 , 887, 173561	8
1270	Covid-19 pandemic and food: Present knowledge, risks, consumers fears and safety. 2020 , 105, 145-160	38
1269	COVID-19 Infection: Concise Review Based on the Immunological Perspective. 2020 , 1-20	5
1268	Expression of ACE2 in airways: Implication for COVID-19 risk and disease management in patients with chronic inflammatory respiratory diseases. 2020 , 50, 1313-1324	41
1267	Structure-Based Repositioning of Approved Drugs for Spike Glycoprotein S2 Domain Fusion Peptide of SARS-CoV-2: Rationale from Molecular Dynamics and Binding Free Energy Calculations. 2020 , 5,	17
1266	Relative Bradycardia in Patients with Mild-to-Moderate Coronavirus Disease, Japan. 2020 , 26, 2504-2506	15
1265	Unraveling the Epidemiology, Geographical Distribution, and Genomic Evolution of Potentially Lethal Coronaviruses (SARS, MERS, and SARS CoV-2). 2020 , 10, 499	10
1264	ACE2, TMPRSS2 distribution and extrapulmonary organ injury in patients with COVID-19. 2020 , 131, 110678	98
1263	Current approaches for target-specific drug discovery using natural compounds against SARS-CoV-2 infection. 2020 , 290, 198169	23
1262	SARS-CoV-2 another kind of liver aggressor, how does it do that?. 2020 , 19, 592-596	14
1261	COVID-19 and cancer: A guide with suggested COVID-19 rule-out criteria to support clinical decision-making. 2020 , 1874, 188412	3
1260	Mutations in the phosphorylation sites of SARS-CoV-2 encoded nucleocapsid protein and structure model of sequestration by protein 14-3-3. 2020 , 532, 134-138	20

1259	Chloroquine and hydroxychloroquine in the treatment of malaria and repurposing in treating COVID-19. 2020 , 216, 107672	31
1258	Structural and functional modelling of SARS-CoV-2 entry in animal models. 2020 , 10, 15917	37
1257	Toward Understanding Molecular Bases for Biological Diversification of Human Coronaviruses: Present Status and Future Perspectives. 2020 , 11, 2016	10
1256	A Single-Cell RNA Expression Map of Human Coronavirus Entry Factors. 2020 , 32, 108175	118
1255	Predicted therapeutic targets for COVID-19 disease by inhibiting SARS-CoV-2 and its related receptors. 2020 , 20, 100407	40
1254	Clinical management of lung cancer patients during the outbreak of COVID-19 epidemic. 2020 , 15, 56	1
1253	Clostridioides difficile in COVID-19 Patients, Detroit, Michigan, USA, March-April 2020. 2020 , 26,	5
1252	Experimental Models for the Study of Central Nervous System Infection by SARS-CoV-2. 2020 , 11, 2163	17
1251	Interaction of Human ACE2 to Membrane-Bound SARS-CoV-1 and SARS-CoV-2 S Glycoproteins. 2020 , 12,	17
1250	Virus-Receptor Interactions of Glycosylated SARS-CoV-2 Spike and Human ACE2 Receptor. 2020 , 28, 586-601.e6	192
1249	Variability in genes related to SARS-CoV-2 entry into host cells (ACE2, TMPRSS2, TMPRSS11A, ELANE, and CTSL) and its potential use in association studies. 2020 , 260, 118313	27
1248	Identifying pathophysiological bases of disease in COVID-19. 2020 , 5, 15	4
1247	In-silico design of a potential inhibitor of SARS-CoV-2 S protein. 2020 , 15, e0240004	25
1246	Gastrointestinal involvement of COVID-19 and potential faecal transmission of SARS-CoV-2. 2020 , 21, 749-751	3
1245	A high-stringency blueprint of the human proteome. 2020 , 11, 5301	59
1244	Drugs for Multiple Sclerosis Activate Natural Killer Cells: Do They Protect Against COVID-19 Infection?. 2020 , 13, 3243-3254	10
1243	ACE2 mouse models: a toolbox for cardiovascular and pulmonary research. 2020 , 11, 5165	31
1242	Interferons and viruses induce a novel truncated ACE2 isoform and not the full-length SARS-CoV-2 receptor. 2020 , 52, 1283-1293	132

1241	Molecular basis of COVID-19 pathogenesis. 2020 , 89, 858-878	11
1240	Comparison of transgenic and adenovirus hACE2 mouse models for SARS-CoV-2 infection. 2020 , 9, 2433-2445	86
1239	Unraveling the Role of ACE2, the Binding Receptor for SARS-CoV-2, in Inflammatory Bowel Disease. 2020 , 26, 1787-1795	10
1238	A comprehensive review about SARS-CoV-2. 2020 , 15, 625-648	37
1237	The Possible Dual Role of the ACE2 Receptor in Asthma and Coronavirus (SARS-CoV2) Infection. 2020 , 10, 550571	14
1236	Analysis of the Spectrum of Variation Suggests a Possible Influence of Rare and Common Variants on Susceptibility to COVID-19 and Severity of Outcome. 2020 , 11, 551220	12
1235	2020 update on human coronaviruses: One health, one world. 2020 , 8, 100043	12
1234	Molecular docking study of potential phytochemicals and their effects on the complex of SARS-CoV2 spike protein and human ACE2. 2020 , 10, 17699	96
1233	Development of humanized tri-specific nanobodies with potent neutralization for SARS-CoV-2. 2020 , 10, 17806	27
1232	Rapid production of SARS-CoV-2 receptor binding domain (RBD) and spike specific monoclonal antibody CR3022 in <i>Nicotiana benthamiana</i> . 2020 , 10, 17698	58
1231	SARS-CoV-2 infection in the COPD population is associated with increased healthcare utilization: An analysis of Cleveland clinic's COVID-19 registry. 2020 , 26, 100515	28
1230	Antiviral Peptides as Promising Therapeutics against SARS-CoV-2. 2020 , 124, 9785-9792	33
1229	COVID-19-associated Multisystem Inflammatory Syndrome in Children Presenting as Acute Pancreatitis. 2020 , 71, 669-671	22
1228	Recent progress in translational engineered in vitro models of the central nervous system. 2020 , 143, 3181-3213	26
1227	Potential zoonotic sources of SARS-CoV-2 infections. 2021 , 68, 1824-1834	41
1226	Furin Inhibitors Block SARS-CoV-2 Spike Protein Cleavage to Suppress Virus Production and Cytopathic Effects. 2020 , 33, 108254	107
1225	COVID-19 and the kidney: A matter of concern. 2020 , 10, 165-168	6
1224	Heterogeneous expression of the SARS-Coronavirus-2 receptor ACE2 in the human respiratory tract. 2020 , 60, 102976	94

1223	Molecular dynamics analysis predicts ritonavir and naloxegol strongly block the SARS-CoV-2 spike protein-hACE2 binding. 2020 , 1-10	7
1222	Coagulopathy and thromboembolic events in patients with SARS-CoV-2 infection: pathogenesis and management strategies. 2020 , 99, 1953-1965	27
1221	Obesity, Diabetes and COVID-19: An Infectious Disease Spreading From the East Collides With the Consequences of an Unhealthy Western Lifestyle. 2020 , 11, 582870	22
1220	Proteomics Insights Into the Molecular Basis of SARS-CoV-2 Infection: What We Can Learn From the Human Olfactory Axis. 2020 , 11, 2101	7
1219	Projected supportive effects of Pycnogenol in patients suffering from multi-dimensional health impairments after a SARS-CoV2 infection. 2020 , 56, 106191	2
1218	Structures and dynamics of the novel S1/S2 protease cleavage site loop of the SARS-CoV-2 spike glycoprotein. 2020 , 4, 100038	13
1217	Non-synonymous mutations of SARS-CoV-2 leads epitope loss and segregates its variants. 2020 , 22, 598-607	24
1216	New Frontiers for Selective Biosensing with Biomembrane-Based Organic Transistors. 2020 , 14, 12271-12280	14
1215	Swine acute diarrhea syndrome coronavirus replication in primary human cells reveals potential susceptibility to infection. 2020 , 117, 26915-26925	49
1214	GB-2 inhibits ACE2 and TMPRSS2 expression: In vivo and in vitro studies. 2020 , 132, 110816	7
1213	Chloroquine and hydroxychloroquine for combating COVID-19: Investigating efficacy and hypothesizing new formulations using Bio/chemoinformatics tools. 2020 , 21, 100446	11
1212	Coronaviruses: Innate Immunity, Inflammasome Activation, Inflammatory Cell Death, and Cytokines. 2020 , 41, 1083-1099	87
1211	Angiotensin-converting enzyme 2 expression is not induced by the renin-angiotensin system in the lung. 2020 , 6,	2
1210	Host Receptors of Influenza Viruses and Coronaviruses-Molecular Mechanisms of Recognition. 2020 , 8,	6
1209	Biomarkers of COVID-19 and technologies to combat SARS-CoV-2. 2020 , 2, 1-23	45
1208	Clinical characteristics and outcomes among hospitalized adults with severe COVID-19 admitted to a tertiary medical center and receiving antiviral, antimalarials, glucocorticoids, or immunomodulation with tocilizumab or cyclosporine: A retrospective observational study (COQUIMA cohort). 2020 , 28, 100591	47
1207	Mechanisms of SARS-CoV-2 Transmission and Pathogenesis. 2020 , 41, 1100-1115	345
1206	Development of a High-Throughput Homogeneous AlphaLISA Drug Screening Assay for the Detection of SARS-CoV-2 Nucleocapsid. 2020 , 3, 1233-1241	4

1205	Role of angiotensin-converting enzyme 2 and pericytes in cardiac complications of COVID-19 infection. 2020 , 319, H1059-H1068	13
1204	Clinical Features of COVID-19 Patients with Different Outcomes in Wuhan: A Retrospective Observational Study. 2020 , 2020, 2138387	14
1203	Peptides: Prospects for Use in the Treatment of COVID-19. 2020 , 25,	13
1202	[Are renin-angiotensin system inhibitors protective or deleterious in patients with COVID-19?]. 2020 , 2020, 20-24	
1201	The inorganic polymer, polyphosphate, blocks binding of SARS-CoV-2 spike protein to ACE2 receptor at physiological concentrations. 2020 , 182, 114215	28
1200	Insights into antiviral mechanisms of remdesivir, lopinavir/ritonavir and chloroquine/hydroxychloroquine affecting the new SARS-CoV-2. 2020 , 131, 110668	59
1199	Occurrence of backward bifurcation and prediction of disease transmission with imperfect lockdown: A case study on COVID-19. 2020 , 140, 110163	22
1198	Emerging strategies on in silico drug development against COVID-19: challenges and opportunities. 2020 , 155, 105522	17
1197	Molecular biology of coronaviruses: current knowledge. 2020 , 6, e04743	40
1196	Incidence and impact of cardiac arrhythmias in coronavirus disease 2019 (COVID-19): A systematic review and meta-analysis. 2020 , 20, 193-198	29
1195	Amplifying immunogenicity of prospective Covid-19 vaccines by glycoengineering the coronavirus glycan-shield to present T _H 1 epitopes. 2020 , 38, 6487-6499	21
1194	Prospect of SARS-CoV-2 spike protein: Potential role in vaccine and therapeutic development. 2020 , 288, 198141	59
1193	Consensus transcriptional regulatory networks of coronavirus-infected human cells. 2020 , 7, 314	14
1192	SARS-CoV-2 spike protein predicted to form complexes with host receptor protein orthologues from a broad range of mammals. 2020 , 10, 16471	65
1191	The immuno-oncological challenge of COVID-19.. 2020 , 1, 946-964	52
1190	Withaferin A: a potential therapeutic agent against COVID-19 infection. 2020 , 13, 79	24
1189	Could a specific ACE2 activator drug improve the clinical outcome of SARS-CoV-2? A potential pharmacological insight. 2020 , 13, 807-811	4
1188	Potential Fast COVID-19 Containment With Trehalose. 2020 , 11, 1623	9

1187	Recent Advancements in the Diagnosis, Prevention, and Prospective Drug Therapy of COVID-19. 2020 , 8, 384	7
1186	Inhibition of SARS-CoV-2 entry through the ACE2/TMPRSS2 pathway: a promising approach for uncovering early COVID-19 drug therapies. 2020 , 76, 1623-1630	51
1185	Drugs targeting various stages of the SARS-CoV-2 life cycle: Exploring promising drugs for the treatment of Covid-19. 2020 , 74, 109721	63
1184	SARS-CoV-2-host dynamics: Increased risk of adverse outcomes of COVID-19 in obesity. 2020 , 14, 1355-1360	24
1183	Lack of antibody-mediated cross-protection between SARS-CoV-2 and SARS-CoV infections. 2020 , 58, 102890	15
1182	Can COVID 2019 induce a specific cardiovascular damage or it exacerbates pre-existing cardiovascular diseases?. 2020 , 216, 153086	26
1181	SARS-CoV-2 proteome microarray for global profiling of COVID-19 specific IgG and IgM responses. 2020 , 11, 3581	158
1180	The molecular virology of coronaviruses. 2020 , 295, 12910-12934	175
1179	The role of host genetics in the immune response to SARS-CoV-2 and COVID-19 susceptibility and severity. 2020 , 296, 205-219	99
1178	Angiotensin-converting enzyme 2 as a versatile player in the management of coronavirus disease 2019. 2020 , 11, 1120-1122	1
1177	Broad and Differential Animal Angiotensin-Converting Enzyme 2 Receptor Usage by SARS-CoV-2. 2020 , 94,	89
1176	Coagulation Abnormalities and Thrombosis in Patients Infected With SARS-CoV-2 and Other Pandemic Viruses. 2020 , 40, 2033-2044	78
1175	Role of angiotensin-converting enzyme 2 (ACE2) in COVID-19. 2020 , 24, 422	378
1174	Should we use angiotensin II infusion in COVID-19-associated vasoplegic shock?. 2020 , 24, 407	1
1173	Coronavirus infections: Epidemiological, clinical and immunological features and hypotheses. 2020 , 4, 66-75	189
1172	SARS-COV-2 in Ophthalmology: Current Evidence and Standards for Clinical Practice. 2020 , 33, 593-600	5
1171	COVID-19, Renin-Angiotensin System and Endothelial Dysfunction. 2020 , 9,	125
1170	Minireview of progress in the structural study of SARS-CoV-2 proteins. 2020 , 1, 53-61	23

1169	Lactoferrin as Protective Natural Barrier of Respiratory and Intestinal Mucosa against Coronavirus Infection and Inflammation. 2020 , 21,	46
1168	FDA approved drugs with pharmacotherapeutic potential for SARS-CoV-2 (COVID-19) therapy. 2020 , 53, 100719	79
1167	Computer-aided screening for potential TMPRSS2 inhibitors: a combination of pharmacophore modeling, molecular docking and molecular dynamics simulation approaches. 2021 , 39, 5638-5656	26
1166	Comment on: COVID-19 and Older Adults: What We Know. 2020 , 68, 2197	2
1165	Potential Targets for Treatment of Coronavirus Disease 2019 (COVID-19): A Review of Qing-Fei-Pai-Du-Tang and Its Major Herbs. 2020 , 48, 1051-1071	32
1164	Mild and Asymptomatic Covid-19 Infections: Implications for Maternal, Fetal, and Reproductive Health. 2020 , 2,	5
1163	Men and COVID-19: A Biopsychosocial Approach to Understanding Sex Differences in Mortality and Recommendations for Practice and Policy Interventions. 2020 , 17, E63	108
1162	Matrix metalloproteinase 9 as a host protein target of chloroquine and melatonin for immunoregulation in COVID-19: A network-based meta-analysis. 2020 , 257, 118096	24
1161	Comprehensive Review on Current Interventions, Diagnostics, and Nanotechnology Perspectives against SARS-CoV-2. 2020 , 31, 2021-2045	36
1160	Epidemiology, prognosis, and clinical manifestation of cardiovascular disease in COVID-19. 2020 , 18, 531-539	4
1159	Prevalence of Cardiovascular Comorbidities in Coronavirus Disease 2019, Severe Acute Respiratory Syndrome, and Middle East Respiratory Syndrome: Pooled Analysis of Published Data. 2020 , 9, e016812	10
1158	SARS-CoV-2 as a Factor to Disbalance the Renin-Angiotensin System: A Suspect in the Case of Exacerbated IL-6 Production. 2020 , 205, 1198-1206	16
1157	Evidence supporting the use of peptides and peptidomimetics as potential SARS-CoV-2 (COVID-19) therapeutics. 2020 , 12, 1647-1656	33
1156	The diagnostic and prognostic role of myocardial injury biomarkers in hospitalized patients with COVID-19. 2020 , 510, 186-190	19
1155	and expression by clinical, HLA, immune, and microbial correlates across 34 human cancers and matched normal tissues: implications for SARS-CoV-2 COVID-19. 2020 , 8,	26
1154	Gene expression and protein profiling of candidate SARS-CoV-2 receptors in human airway epithelial cells and lung tissue. 2020 , 56,	93
1153	Single-Cell Sequencing of Peripheral Mononuclear Cells Reveals Distinct Immune Response Landscapes of COVID-19 and Influenza Patients. 2020 , 53, 685-696.e3	148
1152	Neuropathogenic human coronaviruses: A review. 2020 , 30, e2118	13

1151	Association Between Renin-Angiotensin-Aldosterone System Inhibitors and COVID-19 Infection in South Korea. 2020 , 76, 742-749	26
1150	Endocrine Significance of SARS-CoV-2's Reliance on ACE2. 2020 , 161,	72
1149	SARS-CoV-2, ACE2, and Hydroxychloroquine: Cardiovascular Complications, Therapeutics, and Clinical Readouts in the Current Settings. 2020 , 9,	23
1148	ACE2, the Receptor that Enables Infection by SARS-CoV-2: Biochemistry, Structure, Allostery and Evaluation of the Potential Development of ACE2 Modulators. 2020 , 15, 1682-1690	17
1147	Dual Substance Use of Electronic Cigarettes and Alcohol. 2020 , 11, 593803	3
1146	Clinical Features and Pathogenic Mechanisms of Gastrointestinal Injury in COVID-19. 2020 , 9,	8
1145	New onset diabetes, type 1 diabetes and COVID-19. 2020 , 14, 2211-2217	45
1144	Bioengineered Tissue Models to Study SARS-CoV-2 Pathogenesis and Therapeutic Validation. 2020 , 6, 6540-6555	13
1143	Cardiovascular Disease and SARS-CoV-2: the Role of Host Immune Response Versus Direct Viral Injury. 2020 , 21,	2
1142	The potential antiviral effect of major royal jelly protein2 and its isoform X1 against severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2): Insight on their sialidase activity and molecular docking. 2020 , 75, 104282	8
1141	Fallacies in medical practice: Renin-angiotensin-aldosterone system inhibition and COVID-19 as a Paradigm. 2021 , 62, 185-189	1
1140	SARS-CoV-2 Targets by the pscRNA Profiling of ACE2, TMPRSS2 and Furin Proteases. 2020 , 23, 101744	29
1139	Physical Exercise as a Multimodal Tool for COVID-19: Could It Be Used as a Preventive Strategy?. 2020 , 17,	19
1138	Investigation on the human coronaviruses origin (bats and pangolins): a review. 2020 , 44, 387-400	1
1137	Selective pressure on SARS-CoV-2 protein coding genes and glycosylation site prediction. 2020 , 6, e05001	22
1136	Pulmonary edema in COVID-19: Explained by bradykinin?. 2020 , 146, 1454-1455	15
1135	Bilirubin Levels as Potential Indicators of Disease Severity in Coronavirus Disease Patients: A Retrospective Cohort Study. 2020 , 7, 598870	15
1134	Gastrointestinal Symptoms Associated With Unfavorable Prognosis of COVID-19 Patients: A Retrospective Study. 2020 , 7, 608259	14

1133	Type I Interferon (IFN)-Regulated Activation of Canonical and Non-Canonical Signaling Pathways. 2020 , 11, 606456	22
1132	Cardiovascular Manifestations of COVID-19 Infection. 2020 , 9,	49
1131	Lifestyle factors in the prevention of COVID-19. 2020 , 4, 146-152	30
1130	SARS-CoV-2: Structure, Biology, and Structure-Based Therapeutics Development. 2020 , 10, 587269	199
1129	Comparative Transcriptome Analysis Reveals the Intensive Early Stage Responses of Host Cells to SARS-CoV-2 Infection. 2020 , 11, 593857	37
1128	SARS-CoV-2 spike-protein D614G mutation increases virion spike density and infectivity. 2020 , 11, 6013	450
1127	HDL-scavenger receptor B type 1 facilitates SARS-CoV-2 entry. 2020 , 2, 1391-1400	95
1126	Insights into the Origin, Transmission and Outbreak of Coronavirus Disease (Covid 19): A Recent Study. 2020 , 32, 2403-2415	
1125	Monoclonal Antibodies B38 and H4 Produced in Neutralize SARS-CoV-2. 2020 , 11, 589995	24
1124	Multiple epitope-based vaccine prediction against SARS-CoV-2 spike glycoprotein. 2020 , 1-12	7
1123	COVID-19, hypertension, and RAAS blockers: the BRACE-CORONA trial. 2020 , 116, e198-e199	10
1122	Assessing COVID-19 susceptibility through analysis of the genetic and epigenetic diversity of ACE2-mediated SARS-CoV-2 entry. 2020 , 21, 1311-1329	16
1121	A comprehensive review of the impact of COVID-19 on human reproductive biology, assisted reproduction care and pregnancy: a Canadian perspective. 2020 , 13, 140	39
1120	COVID-19: Brief check through the pathologist's eye (autopsy archive). 2020 , 216, 153195	24
1119	Risks and Impact of Angiotensin-Converting Enzyme Inhibitors or Angiotensin-Receptor Blockers on SARS-CoV-2 Infection in Adults: A Living Systematic Review. 2020 , 173, 195-203	81
1118	Serodiagnostics for Severe Acute Respiratory Syndrome-Related Coronavirus 2 : A Narrative Review. 2020 , 173, 450-460	81
1117	Receptor binding and priming of the spike protein of SARS-CoV-2 for membrane fusion. <i>Nature</i> , 2020 , 588, 327-330	50.4 339
1116	Human coronavirus dependency on host heat shock protein 90 reveals an antiviral target. 2020 , 9, 2663-2672	17

1115	The SKI complex is a broad-spectrum, host-directed antiviral drug target for coronaviruses, influenza, and filoviruses. 2020 , 117, 30687-30698	7
1114	Computational gene expression profiling in the exploration of biomarkers, non-coding functional RNAs and drug perturbagens for COVID-19. 2020 , 1-16	7
1113	SARS coronavirus 2: from genome to infectome. 2020 , 21, 318	30
1112	COVID-19 and Pulmonary Arterial Hypertension: Early Data and Many Questions. 2020 , 17, 1528-1530	11
1111	Targeting ACE2-RBD Interaction as a Platform for COVID-19 Therapeutics: Development and Drug-Repurposing Screen of an AlphaLISA Proximity Assay. 2020 , 3, 1352-1360	31
1110	. 2020 , 192, E1383-E1386	
1109	Modeling the Molecular Impact of SARS-CoV-2 Infection on the Renin-Angiotensin System. 2020 , 12,	8
1108	CD147-spike protein is a novel route for SARS-CoV-2 infection to host cells. 2020 , 5, 283	399
1107	Prognostic Significance of COVID-19 Receptor ACE2 and Recommendation for Antihypertensive Drug in Renal Cell Carcinoma. 2020 , 2020, 2054376	2
1106	The Human Leukocyte Antigen Class II Immunoepitome of the SARS-CoV-2 Spike Glycoprotein. 2020 , 33, 108454	12
1105	Determinants of soluble angiotensin-converting enzyme 2 concentrations in adult patients with complex congenital heart disease. 2020 , 1	3
1104	Kallikrein 13 serves as a priming protease during infection by the human coronavirus HKU1. 2020 , 13,	4
1103	The Intersection between COVID-19, the Gene Family of ACE2 and Alzheimer's Disease. 2020 , 15, 2633105520975743	7
1102	Renin-angiotensin system blockers and the risk of critical or fatal coronavirus disease 2019 in African Americans. 2020 , 38, 2384-2386	1
1101	Recent advances in therapeutic applications of neutralizing antibodies for virus infections: an overview. 2020 , 68, 325-339	18
1100	Vitamin D high doses supplementation could represent a promising alternative to prevent or treat COVID-19 infection. 2020 , 32, 267-277	4
1099	Ultrasound Imaging Findings of Acute Testicular Infection in Patients With Coronavirus Disease 2019: A Single-Center-Based Study in Wuhan, China. 2021 , 40, 1787-1794	19
1098	Dissecting the Drug Development Strategies Against SARS-CoV-2 Through Diverse Computational Modeling Techniques. 2020 , 329	4

1097	Designing spike protein (S-Protein) based multi-epitope peptide vaccine against SARS COVID-19 by immunoinformatics. 2020 , 6, e05528	4
1096	Asthma in COVID-19 patients: An extra chain fitting around the neck?. 2020 , 175, 106205	9
1095	Human coronaviruses: ophthalmic manifestations. 2020 , 5, e000630	11
1094	The Role of Molecular Chaperones in Virus Infection and Implications for Understanding and Treating COVID-19. 2020 , 9,	12
1093	Spike Glycoprotein-Mediated Entry of SARS Coronaviruses. 2020 , 12,	20
1092	Chinese herbal compounds against SARS-CoV-2: Puerarin and quercetin impair the binding of viral S-protein to ACE2 receptor. 2020 , 18, 3518-3527	30
1091	Characterization of changes in global gene expression in the hearts and kidneys of transgenic mice overexpressing human angiotensin-converting enzyme 2. 2020 , 36, 23	0
1090	Association of angiotensin converting enzyme inhibitors and angiotensin II receptor blockers with risk of COVID-19, inflammation level, severity, and death in patients with COVID-19: A rapid systematic review and meta-analysis. 2020 ,	42
1089	Modeling the viral dynamics of SARS-CoV-2 infection. 2020 , 328, 108438	52
1088	Methylene blue may have a role in the treatment of COVID-19. 2020 , 144, 110163	13
1087	Coronavirus disease 2019-Historical context, virology, pathogenesis, immunotherapy, and vaccine development. 2020 , 16, 2992-3000	6
1086	Deficiency of Tfh Cells and Germinal Center in Deceased COVID-19 Patients. 2020 , 40, 618-624	30
1085	The concern about ACE/ARB and COVID-19: Time to hold your horses!. 2020 , 60, e88-e90	3
1084	SARS-CoV-2 causes a specific dysfunction of the kidney proximal tubule. 2020 , 98, 1296-1307	91
1083	Morphogenesis and cytopathic effect of SARS-CoV-2 infection in human airway epithelial cells. 2020 , 11, 3910	151
1082	Structure-guided covalent stabilization of coronavirus spike glycoprotein trimers in the closed conformation. 2020 , 27, 942-949	89
1081	designing of multi-epitope vaccine construct against human coronavirus infections. 2021 , 39, 6903-6917	8
1080	Characterization of the SARS-CoV-2 S Protein: Biophysical, Biochemical, Structural, and Antigenic Analysis. 2020 ,	15

1079	Heightened ACE Activity and Unfavorable Consequences in COVID-19 Diabetic Subjects. 2020 , 2020, 7847526	8
1078	Overview of Immune Response During SARS-CoV-2 Infection: Lessons From the Past. 2020 , 11, 1949	163
1077	SARS-CoV-2 Infection and Lung Cancer: Potential Therapeutic Modalities. 2020 , 12,	7
1076	Emerging Therapeutic Modalities against COVID-19. 2020 , 13,	11
1075	Anthraquinone Derivatives as an Immune Booster and their Therapeutic Option Against COVID-19. 2020 , 10, 325-335	29
1074	Interdiction of Protein Folding for Therapeutic Drug Development in SARS CoV-2. 2020 , 124, 8201-8208	7
1073	Fractional diffusion on the human proteome as an alternative to the multi-organ damage of SARS-CoV-2. 2020 , 30, 081104	10
1072	COVID-19: pathophysiology, diagnosis, complications and investigational therapeutics. 2020 , 37, 100738	49
1071	Non-neuronal expression of SARS-CoV-2 entry genes in the olfactory system suggests mechanisms underlying COVID-19-associated anosmia. 2020 , 6,	514
1070	Is the Reason of Increased D-Dimer Levels in COVID-19 Because of ACE-2-Induced Apoptosis in Endothelium?. 2020 , 26, 1076029620935526	6
1069	Orthopaedic Considerations Following COVID-19: Lessons from the 2003 SARS Outbreak. 2020 , 8, e2000052	8
1068	Twenty-First Century Viral Pandemics: A Literature Review of Sexual Transmission and Fertility Implications in Men. 2020 , 8, 518-530	12
1067	Molecular Pathogenesis, Immunopathogenesis and Novel Therapeutic Strategy Against COVID-19. 2020 , 7, 196	32
1066	The Plasmatic Aldosterone and C-Reactive Protein Levels, and the Severity of Covid-19: The Dyhor-19 Study. 2020 , 9,	18
1065	Protective Immunity against SARS Subunit Vaccine Candidates Based on Spike Protein: Lessons for Coronavirus Vaccine Development. 2020 , 2020, 7201752	13
1064	Innate Immune Responses to Highly Pathogenic Coronaviruses and Other Significant Respiratory Viral Infections. 2020 , 11, 1979	14
1063	COVID-19: A Review on Diagnosis, Treatment, and Prophylaxis. 2020 , 21,	12
1062	COVID-19: Complement, Coagulation, and Collateral Damage. 2020 , 205, 1488-1495	79

1061	A SARS-CoV-2 surrogate virus neutralization test based on antibody-mediated blockage of ACE2-spike protein-protein interaction. 2020 , 38, 1073-1078	528
1060	Pharmacotherapy in COVID-19 patients: a review of ACE2-raising drugs and their clinical safety. 2020 , 28, 683-699	17
1059	Evolutionary Arms Race between Virus and Host Drives Genetic Diversity in Bat Severe Acute Respiratory Syndrome-Related Coronavirus Spike Genes. 2020 , 94,	36
1058	Hydroxychloroquine in COVID-19 Therapy: Protection Versus Proarrhythmia. 2020 , 25, 497-502	2
1057	Mesenchymal stem cells: current clinical progress in ARDS and COVID-19. 2020 , 11, 305	37
1056	While We Wait for a Vaccine Against SARS-CoV-2, Why Not Think About Available Drugs?. 2020 , 11, 820	12
1055	Genetic gateways to COVID-19 infection: Implications for risk, severity, and outcomes. 2020 , 34, 8787-8795	61
1054	A comparative overview of COVID-19, MERS and SARS: Review article. 2020 , 81, 1-8	45
1053	Contribution of acute-phase reaction proteins to the diagnosis and treatment of 2019 novel coronavirus disease (COVID-19). 2020 , 148, e164	16
1052	An overview of key potential therapeutic strategies for combat in the COVID-19 battle. 2020 , 10, 28243-28266	25
1051	Evolving Consensus Experience of the IUSG-IOIS-FOIS with Uveitis in the Time of COVID-19 Infection. 2020 , 28, 709-713	10
1050	COVID-19: The Influence of ACE Genotype and ACE-I and ARBs on the Course of SARS-CoV-2 Infection in Elderly Patients. 2020 , 15, 1231-1240	18
1049	Nanomedicine as a promising approach for diagnosis, treatment and prophylaxis against COVID-19. 2020 , 15, 2085-2102	36
1048	COVID-19 and the Kidneys: An Update. 2020 , 7, 423	48
1047	The four horsemen of a viral Apocalypse: The pathogenesis of SARS-CoV-2 infection (COVID-19). 2020 , 58, 102887	78
1046	Flavonoids Activation of the Transcription Factor Nrf2 as a Hypothesis Approach for the Prevention and Modulation of SARS-CoV-2 Infection Severity. 2020 , 9,	37
1045	Plasmapheresis, Anti-ACE2 and Anti-Fc β II Monoclonal Antibodies: A Possible Treatment for Severe Cases of COVID-19. 2020 , 14, 2607-2611	5
1044	Differences and similarities between SARS-CoV and SARS-CoV-2: spike receptor-binding domain recognition and host cell infection with support of cellular serine proteases. 2020 , 48, 665-669	35

1043	Targeting SARS-CoV2 Spike Protein Receptor Binding Domain by Therapeutic Antibodies. 2020 , 130, 110559	29
1042	The Effects of Chloroquine and Hydroxychloroquine on ACE2-Related Coronavirus Pathology and the Cardiovascular System: An Evidence-Based Review. 2020 , 1,	10
1041	Computational Prediction of Mutational Effects on SARS-CoV-2 Binding by Relative Free Energy Calculations. 2020 , 60, 5794-5802	36
1040	Does SARS-CoV-2 Bind to Human ACE2 More Strongly Than Does SARS-CoV?. 2020 , 124, 7336-7347	54
1039	COVAN is the new HIVAN: the re-emergence of collapsing glomerulopathy with COVID-19. 2020 , 16, 565-567	59
1038	Endothelial dysfunction in COVID-19: a position paper of the ESC Working Group for Atherosclerosis and Vascular Biology, and the ESC Council of Basic Cardiovascular Science. 2020 , 116, 2177-2184	184
1037	Engineering human ACE2 to optimize binding to the spike protein of SARS coronavirus 2. 2020 , 369, 1261-1265	269
1036	Potential Role of ACE2 in Coronavirus Disease 2019 (COVID-19) Prevention and Management. 2020 , 8, 9-19	69
1035	Approaches and advances in the development of potential therapeutic targets and antiviral agents for the management of SARS-CoV-2 infection. 2020 , 885, 173450	9
1034	Acute respiratory distress syndrome: a life threatening associated complication of SARS-CoV-2 infection inducing COVID-19. 2021 , 39, 6842-6851	21
1033	COVID-19 and diabetes mellitus: how one pandemic worsens the other. 2020 , 21, 451-463	41
1032	In silico molecular docking analysis for repurposing therapeutics against multiple proteins from SARS-CoV-2. 2020 , 886, 173430	35
1031	A novel receptor-binding domain (RBD)-based mRNA vaccine against SARS-CoV-2. 2020 , 30, 932-935	73
1030	Molecular docking, molecular dynamics simulations and reactivity, studies on approved drugs library targeting ACE2 and SARS-CoV-2 binding with ACE2. 2021 , 39, 7246-7262	20
1029	Is pregnancy an immunological contributor to severe or controlled COVID-19 disease?. 2020 , 84, e13317	20
1028	Recent discovery and development of inhibitors targeting coronaviruses. 2020 , 25, 668-688	211
1027	Presentation of Severe Acute Respiratory Syndrome-Coronavirus 2 Infection as Cholestatic Jaundice in Two Healthy Adolescents. 2020 , 226, 278-280	10
1026	Studying the Effects of ACE2 Mutations on the Stability, Dynamics, and Dissociation Process of SARS-CoV-2 S1/hACE2 Complexes. 2020 , 19, 4609-4623	12

1025	COVID-19: a novel menace for the practice of nephrology and how to manage it with minor devastation?. 2020 , 42, 710-725	7
1024	Association Between Nonsteroidal Antiinflammatory Drug Use and Adverse Clinical Outcomes Among Adults Hospitalized With Coronavirus 2019 in South Korea: A Nationwide Study. 2021 , 73, e4179-e4188 ¹⁶	
1023	Cardio-Oncology in the Era of the COVID-19 Pandemic and Beyond. 2020 , 9, e017787	15
1022	Genomic variance of Open Reading Frames (ORFs) and Spike protein in severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2). 2020 , 83, 725-732	7
1021	Potential effects of SARS-CoV-2 infection during pregnancy on fetuses and newborns are worthy of attention. 2020 , 46, 1951-1957	17
1020	Investigating Virological, Immunological, and Pathological Avenues to Identify Potential Targets for Developing COVID-19 Treatment and Prevention Strategies. 2020 , 8,	12
1019	High affinity interaction of Solanum tuberosum and Brassica juncea residue smoke water compounds with proteins involved in coronavirus infection. 2020 , 34, 3400-3410	4
1018	In Silico Identification of Potential Inhibitors of ADP-Ribose Phosphatase of SARS-CoV-2 nsP3 by Combining E-Pharmacophore- and Receptor-Based Virtual Screening of Database. 2020 , 5, 9388-9398	9
1017	Deep Mutational Scanning of SARS-CoV-2 Receptor Binding Domain Reveals Constraints on Folding and ACE2 Binding. 2020 , 182, 1295-1310.e20	935
1016	Derivatization and combination therapy of current COVID-19 therapeutic agents: a review of mechanistic pathways, adverse effects, and binding sites. 2020 , 25, 1822-1838	5
1015	Potential mechanisms of Chinese Herbal Medicine that implicated in the treatment of COVID-19 related renal injury. 2020 , 28, 1138-1148	10
1014	Obesity and COVID-19: A Perspective from the European Association for the Study of Obesity on Immunological Perturbations, Therapeutic Challenges, and Opportunities in Obesity. 2020 , 13, 439-452	26
1013	Immunosuppressive Drugs and COVID-19: A Review. 2020 , 11, 1333	48
1012	Immune Response and COVID-19: A mirror image of Sepsis. 2020 , 16, 2479-2489	32
1011	Antimalarials as Antivirals for COVID-19: Believe it or Not!. 2020 , 360, 618-630	14
1010	Cardiovascular involvement during COVID-19 and clinical implications in elderly patients. A review. 2020 , 57, 236-243	23
1009	ACE deletion allele is associated with susceptibility to SARS-CoV-2 infection and mortality rate: An epidemiological study in the Asian population. 2020 , 510, 455-458	35
1008	Global multi-omics and systems pharmacological strategy unravel the multi-targeted therapeutic potential of natural bioactive molecules against COVID-19: An in silico approach. 2020 , 112, 4486-4504	17

1007	Potently neutralizing and protective human antibodies against SARS-CoV-2. <i>Nature</i> , 2020 , 584, 443-449	50.4	609
1006	COVID-19 and COPD. 2020 , 56,		124
1005	Severe acute respiratory syndrome coronavirus-2 (SARS-CoV-2) and coronavirus disease 19 (COVID-19) - anatomic pathology perspective on current knowledge. 2020 , 15, 103		60
1004	Targeting Macrophages as a Therapeutic Option in Coronavirus Disease 2019. 2020 , 11, 577571		24
1003	ACE2, COVID-19 Infection, Inflammation, and Coagulopathy: Missing Pieces in the Puzzle. 2020 , 11, 574753		26
1002	Renin-Angiotensin System: An Important Player in the Pathogenesis of Acute Respiratory Distress Syndrome. 2020 , 21,		20
1001	Transcriptomic analysis reveals novel mechanisms of SARS-CoV-2 infection in human lung cells. 2020 , 8, 753-762		8
1000	COVID-19 and Cardiovascular Health Among Patients with Cancer. 2020 , 22, 171		5
999	S1-Leitlinie: Neurologische Manifestationen bei COVID-19. 2020 , 3, 495-519		3
998	Evaluation of mechanisms of action of re-purposed drugs for treatment of COVID-19. 2020 , 358, 104240		4
997	Current Evidence of 2019 Novel Coronavirus Disease (COVID-19) Ocular Transmission: A Systematic Review and Meta-Analysis. 2020 , 2020, 7605453		8
996	Identification of a repurposed drug as an inhibitor of Spike protein of human coronavirus SARS-CoV-2 by computational methods. 2020 , 45, 1		24
995	Potential neuroinvasive and neurotrophic properties of SARS-CoV-2 in pediatric patients: comparison of SARS-CoV-2 with non-segmented RNA viruses. 2020 , 26, 929-940		1
994	The effects of aging on host resistance and disease tolerance to SARS-CoV-2 infection. 2021 , 288, 5055-5070		2
993	Possible affective cognitive cerebellar syndrome in a young patient with COVID-19 CNS vasculopathy and stroke. 2020 , 13,		7
992	Role of Renin-Angiotensin System in Acute Lung Injury Caused by Viral Infection. 2020 , 13, 3715-3725		19
991	Cytokine Response in SARS-CoV-2 Infection in the Elderly. 2020 , 13, 737-747		11
990	A Testimony of the Surgent SARS-CoV-2 in the Immunological Panorama of the Human Host. 2020 , 10, 575404		3

989	Physical Exercise and the Renin Angiotensin System: Prospects in the COVID-19. 2020 , 11, 561403	4
988	Animal Models for COVID-19: More to the Picture Than ACE2, Rodents, Ferrets, and Non-human Primates. A Case for Porcine Respiratory Coronavirus and the Obese Ossabaw Pig. 2020 , 11, 573756	10
987	ACE2 in the Era of SARS-CoV-2: Controversies and Novel Perspectives. 2020 , 7, 588618	49
986	Prevention of SARS-CoV-2 cell entry: insight from interaction of drug-like alkaloids with spike glycoprotein, human ACE2, and TMPRSS2. 2020 , 1-25	17
985	SARS-CoV-2-triggered neutrophil extracellular traps mediate COVID-19 pathology. 2020 , 217,	325
984	Measuring SARS-CoV-2 neutralizing antibody activity using pseudotyped and chimeric viruses. 2020 , 217,	289
983	Implications of COVID-19 Pandemic on Evolution of Diabetes in Malaria-Endemic African Region. 2020 , 2020, 8205261	0
982	Understanding Gender-Bias in Critically Ill Patients With COVID-19. 2020 , 7, 564117	3
981	SAMHD1 as the Potential Link Between SARS-CoV-2 Infection and Neurological Complications. 2020 , 11, 562913	5
980	Applying computer simulations in battling with COVID-19,. 2020 , 21, 100458	8
979	Computational Identification of Human Biological Processes and Protein Sequence Motifs Putatively Targeted by SARS-CoV-2 Proteins Using Protein-Protein Interaction Networks. 2020 , 19, 4553-4566	6
978	The global population of SARS-CoV-2 is composed of six major subtypes. 2020 , 10, 18289	29
977	The Current Status of COVID-19 Vaccines. 2020 , 2, 579297	13
976	Heteromeric Solute Carriers: Function, Structure, Pathology and Pharmacology. 2021 , 21, 13-127	16
975	A graph-based approach identifies dynamic H-bond communication networks in spike protein S of SARS-CoV-2. 2020 , 212, 107617	19
974	Targeting Crucial Host Factors of SARS-CoV-2. 2020 , 6, 2844-2865	13
973	Clinical manifestations and factors associated with mortality from COVID-19 in older adults: Retrospective population-based study with 9807 older Brazilian COVID-19 patients. 2020 , 20, 1177-1181	13
972	COVID-19: An overview for dermatologists. 2020 , 59, 1437-1449	12

971	Molecular Basis of SARS-CoV-2 Infection and Rational Design of Potential Antiviral Agents: Modeling and Simulation Approaches. 2020 , 19, 4291-4315	36
970	Global scenario, public health concerns and mitigation strategies to counter current ongoing SARS-CoV-2 / COVID-19 pandemic. 2020 , 16, 3023-3033	4
969	ACE2 and TMPRSS2 Potential Involvement in Genetic Susceptibility to SARS-COV-2 in Cancer Patients. 2020 , 29, 963689720968749	14
968	Lung Secretoglobin Scgb1a1 Influences Alveolar Macrophage-Mediated Inflammation and Immunity. 2020 , 11, 584310	9
967	The influence of ACE inhibitors and ARBs on hospital length of stay and survival in people with COVID-19. 2020 , 31, 100660	14
966	High affinity binding of SARS-CoV-2 spike protein enhances ACE2 carboxypeptidase activity. 2020 , 295, 18579-18588	47
965	analysis of the interactions of certain flavonoids with the receptor-binding domain of 2019 novel coronavirus and cellular proteases and their pharmacokinetic properties. 2020 , 1-15	14
964	Exploring Host Genetic Polymorphisms Involved in SARS-CoV Infection Outcomes: Implications for Personalized Medicine in COVID-19. 2020 , 2020, 6901217	6
963	Covid-19: Fat, Obesity, Inflammation, Ethnicity, and Sex Differences. 2020 , 9,	10
962	Intricate interplay between Covid-19 and cardiovascular diseases. 2021 , 31, e2188	3
961	Severe acute respiratory syndrome coronavirus 2 and renin-angiotensin system blockers: A review and pooled analysis. 2020 , 113, 797-810	1
960	Elicitation of Potent Neutralizing Antibody Responses by Designed Protein Nanoparticle Vaccines for SARS-CoV-2. 2020 , 183, 1367-1382.e17	217
959	Genome based evolutionary lineage of SARS-CoV-2 towards the development of novel chimeric vaccine. 2020 , 85, 104517	9
958	Sunitinib reduces the infection of SARS-CoV, MERS-CoV and SARS-CoV-2 partially by inhibiting AP2M1 phosphorylation. 2020 , 6, 71	14
957	Ultrastructural analysis of SARS-CoV-2 interactions with the host cell via high resolution scanning electron microscopy. 2020 , 10, 16099	37
956	Animal models for SARS-CoV-2 research: A comprehensive literature review. 2021 , 68, 1868-1885	28
955	Targeting Lipid Rafts-A Potential Therapy for COVID-19. 2020 , 11, 574508	19
954	Expression Pattern of the SARS-CoV-2 Entry Genes and in the Respiratory Tract. 2020 , 12,	12

953	Defensin 5 for prevention of SARS-CoV-2 invasion and Covid-19 disease. 2020 , 143, 110244	7
952	A role of glycation and methylation for SARS-CoV-2 infection in diabetes?. 2020 , 144, 110247	7
951	Neurotropism of SARS-CoV-2 and its neuropathological alterations: Similarities with other coronaviruses. 2020 , 119, 184-193	25
950	Utility of Proteomics in Emerging and Re-Emerging Infectious Diseases Caused by RNA Viruses. 2020 , 19, 4259-4274	14
949	Deep mutagenesis in the study of COVID-19: a technical overview for the proteomics community. 2020 , 17, 633-638	5
948	Design and Evaluation of Anti-SARS-Coronavirus Agents Based on Molecular Interactions with the Viral Protease. 2020 , 25,	11
947	EGlutamyltransferase Elevations Are Frequent in Patients With COVID-19: A Clinical Epidemiologic Study. 2020 , 4, 1744	11
946	Neurological injuries in COVID-19 patients: direct viral invasion or a bystander injury after infection of epithelial/endothelial cells. 2020 , 26, 631-641	18
945	Managing the COVID-19 Pandemic: Research Strategies Based on the Evolutionary and Molecular Characteristics of Coronaviruses. 2020 , 2, 1-10	1
944	SARS-CoV-2 Assays To Detect Functional Antibody Responses That Block ACE2 Recognition in Vaccinated Animals and Infected Patients. 2020 , 58,	31
943	Clinical and imaging findings of discharged patients with SARS-CoV-2 positive anal swab samples: a descriptive study. 2020 , 20, 644	3
942	Severe Acute Respiratory Syndrome Coronavirus 2 Impact on the Central Nervous System: Are Astrocytes and Microglia Main Players or Merely Bystanders?. 2020 , 12, 1759091420954960	32
941	Reduced development of COVID-19 in children reveals molecular checkpoints gating pathogenesis illuminating potential therapeutics. 2020 , 117, 24620-24626	59
940	Ocular Symptoms of SARS-CoV-2: Indication of Possible Ocular Transmission or Viral Shedding. 2020 , 28, 1269-1279	5
939	SARS-CoV-2/COVID-19 and advances in developing potential therapeutics and vaccines to counter this emerging pandemic. 2020 , 19, 40	62
938	Neurological Aspects of SARS-CoV-2 Infection: Mechanisms and Manifestations. 2020 , 11, 1039	35
937	SARS-CoV-2 in children: spectrum of disease, transmission and immunopathological underpinnings. 2020 , 52, 801-808	40
936	Genetic Association of rs2285666 Polymorphism With COVID-19 Spatial Distribution in India. 2020 , 11, 564741	36

935	Computational and Transcriptome Analyses Revealed Preferential Induction of Chemotaxis and Lipid Synthesis by SARS-CoV-2. 2020 , 9,	7
934	The potential role of procyanidin as a therapeutic agent against SARS-CoV-2: a text mining, molecular docking and molecular dynamics simulation approach. 2020 , 1-16	17
933	The use of mesenchymal stromal cells in the treatment of coronavirus disease 2019. 2020 , 18, 359	15
932	Prognostic and Immunological Value of Angiotensin-Converting Enzyme 2 in Pan-Cancer. 2020 , 7, 189	6
931	Quinazoline-Schiff base conjugates: study and ADMET predictions as multi-target inhibitors of coronavirus (SARS-CoV-2) proteins.. 2020 , 10, 34033-34045	13
930	Laboratory abnormalities in children with novel Coronavirus Disease 2019. 2020 , 14, 1179556520955177	9
929	Diffuse necrotising leukoencephalopathy with microhaemorrhages in a patient with severe COVID-19 disease. 2020 , 33, 528-531	2
928	SARS-CoV-2 Infection Depends on Cellular Heparan Sulfate and ACE2. 2020 , 183, 1043-1057.e15	454
927	COVID19: an announced pandemic. 2020 , 11, 799	23
926	STAT3 isoforms differentially affect ACE2 expression: A potential target for COVID-19 therapy. 2020 , 24, 12864-12868	5
925	Double-Barreled CRISPR Technology as a Novel Treatment Strategy For COVID-19. 2020 , 3, 790-800	14
924	[Evolving Consensus of International Uveitis Study Group, Intraocular Inflammation Society, and Foster Ocular Inflammation Society with Uveitis in the Time of COVID-19 Infection]. 2020 , 237, 1124-1128	
923	COVID-19 in Children: Present and Future Perspective, An Interim Review. 2020 , 10, e53-e62	3
922	Sex differences in severity and mortality from COVID-19: are males more vulnerable?. 2020 , 11, 53	109
921	Environmental Nanoparticles, SARS-CoV-2 Brain Involvement, and Potential Acceleration of Alzheimer's and Parkinson's Diseases in Young Urbanites Exposed to Air Pollution. 2020 , 78, 479-503	15
920	An overview of Middle East respiratory syndrome coronavirus vaccines in preclinical studies. 2020 , 19, 817-829	2
919	Zika Virus Infection, Philippines, 2012. 2020 , 26, 2300-2301	2
918	Lifting the mask on neurological manifestations of COVID-19. 2020 , 16, 636-644	190

917	Renin-Angiotensin System and Coronavirus Disease 2019: A Narrative Review. 2020 , 7, 143	23
916	Sex differences underlying preexisting cardiovascular disease and cardiovascular injury in COVID-19. 2020 , 148, 25-33	15
915	COVID-19 and renin-angiotensin system modulators: what do we know so far?. 2020 , 18, 743-748	3
914	Recent advances in therapeutic modalities and vaccines to counter COVID-19/SARS-CoV-2. 2020 , 16, 3034-3042	4
913	Origin and cross-species transmission of bat coronaviruses in China. 2020 , 11, 4235	144
912	SARS-CoV-2 and Three Related Coronaviruses Utilize Multiple ACE2 Orthologs and Are Potently Blocked by an Improved ACE2-Ig. 2020 , 94,	48
911	Advances in Viral Diagnostic Technologies for Combating COVID-19 and Future Pandemics. 2020 , 25, 513-521	8
910	Difference in Biomarkers Between COVID-19 Patients and Other Pulmonary Infection Patients. 2020 , 13, 2609-2615	3
909	ACE2 Protein Landscape in the Head and Neck Region: The Conundrum of SARS-CoV-2 Infection. 2020 , 9,	25
908	Immune responses during COVID-19 infection. 2020 , 9, 1807836	49
907	Interaction of SARS-CoV-2 and Other Coronavirus With ACE (Angiotensin-Converting Enzyme)-2 as Their Main Receptor: Therapeutic Implications. 2020 , 76, 1339-1349	86
906	The Immune Response and Immunopathology of COVID-19. 2020 , 11, 2037	61
905	Identify the Risk Factors of COVID-19-Related Acute Kidney Injury: A Single-Center, Retrospective Cohort Study. 2020 , 7, 436	10
904	Neurological manifestations of coronavirus infections - a systematic review. 2020 , 7, 2057-2071	40
903	From SARS and MERS to COVID-19: a brief summary and comparison of severe acute respiratory infections caused by three highly pathogenic human coronaviruses. 2020 , 21, 224	223
902	The Potential Role of Renin Angiotensin System (RAS) and Dipeptidyl Peptidase-4 (DPP-4) in COVID-19: Navigating the Uncharted. 2020 ,	3
901	Vimentin as a target for the treatment of COVID-19. 2020 , 7,	13
900	COVID-19 Outbreak: Pathogenesis, Current Therapies, and Potentials for Future Management. 2020 , 11, 563478	30

899	Renin-Angiotensin System Inhibitors and COVID-19: a Systematic Review and Meta-Analysis. Evidence for Significant Geographical Disparities. 2020 , 22, 90	22
898	Prospects for mucosal vaccine: shutting the door on SARS-CoV-2. 2020 , 16, 2921-2931	37
897	Repurposing Fragile X Drugs to Inhibit SARS-CoV-2 Viral Reproduction. 2020 , 8, 856	1
896	Nanotechnology-Based Approaches for the Detection of SARS-CoV-2. 2020 , 2,	13
895	Smoking and COVID-19: Adding Fuel to the Flame. 2020 , 21,	31
894	Immune Response to COVID-19: Can We Benefit from the SARS-CoV and MERS-CoV Pandemic Experience?. 2020 , 9,	0
893	Characterisation of SARS-CoV-2 Lentiviral Pseudotypes and Correlation between Pseudotype-Based Neutralisation Assays and Live Virus-Based Micro Neutralisation Assays. 2020 , 12,	28
892	Low Baseline Pulmonary Levels of Cytotoxic Lymphocytes as a Predisposing Risk Factor for Severe COVID-19. 2020 , 5,	3
891	Available Compounds With Therapeutic Potential Against COVID-19: Antimicrobial Therapies, Supportive Care, and Probable Vaccines. 2020 , 11, 582025	11
890	Hijacking SARS-CoV-2/ACE2 Receptor Interaction by Natural and Semi-synthetic Steroidal Agents Acting on Functional Pockets on the Receptor Binding Domain. 2020 , 8, 572885	32
889	Identification of potential inhibitors of SARS-CoV-2 main protease and spike receptor from 10 important spices through structure-based virtual screening and molecular dynamic study. 2020 , 1-22	23
888	Severity of Coronavirus Disease 2019 (COVID-19): Does Surfactant Matter?. 2020 , 11, 1905	7
887	Implications of COVID-19 for an ageing population. 2020 , 213, 342-344.e1	14
886	Development of a Minimal Physiologically-Based Pharmacokinetic Model to Simulate Lung Exposure in Humans Following Oral Administration of Ivermectin for COVID-19 Drug Repurposing. 2020 , 109, 3574-3578	23
885	COVID-19 in Human, Animal, and Environment: A Review. 2020 , 7, 578	31
884	Efficacy and safety of ACEI/ARB drugs in patients with COVID-19 combined with diabetes mellitus: A protocol for systematic review and meta-analysis of randomized controlled trials. 2020 , 99, e21723	
883	Research Progress on Coronavirus Prevention and Control in Animal-Source Foods. 2020 , 13, 743-751	
882	Polyphenols vs. Coronaviruses: How Far Has Research Moved Forward?. 2020 , 25,	10

881	Genetic and pathogenic characterization of SARS-CoV-2: a review. 2020 , 15, 533-549	7
880	The Role of Adaptogens in Prophylaxis and Treatment of Viral Respiratory Infections. 2020 , 13,	17
879	[Renin-Angiotensin-System (RAS) and COVID-19 - On The Prescription of RAS Blockers]. 2020 , 74, 611-614	
878	Dendritic Cells and SARS-CoV-2 Infection: Still an Unclassified Connection. 2020 , 9,	29
877	Molecular interaction and inhibition of SARS-CoV-2 binding to the ACE2 receptor. 2020 , 11, 4541	246
876	Therapeutic Strategies in the Development of Anti-viral Drugs and Vaccines Against SARS-CoV-2 Infection. 2020 , 57, 4856-4877	20
875	COVID-19 Therapeutic Options Under Investigation. 2020 , 11, 1196	49
874	Repurposing Drugs, Ongoing Vaccine, and New Therapeutic Development Initiatives Against COVID-19. 2020 , 11, 1258	61
873	Animal and translational models of SARS-CoV-2 infection and COVID-19. 2020 , 13, 877-891	106
872	Broad Anti-coronavirus Activity of Food and Drug Administration-Approved Drugs against SARS-CoV-2 and SARS-CoV. 2020 , 94,	113
871	ACE2 (Angiotensin-Converting Enzyme 2) in Cardiopulmonary Diseases: Ramifications for the Control of SARS-CoV-2. 2020 , 76, 651-661	38
870	DPP4 and ACE2 in Diabetes and COVID-19: Therapeutic Targets for Cardiovascular Complications?. 2020 , 11, 1161	44
869	Pharmacological treatments of COVID-19. 2020 , 72, 1446-1478	16
868	Conformational transition of SARS-CoV-2 spike glycoprotein between its closed and open states. 2020 , 153, 075101	64
867	Broad host range of SARS-CoV-2 predicted by comparative and structural analysis of ACE2 in vertebrates. 2020 , 117, 22311-22322	267
866	COVID-19 pandemic: Insights into structure, function, and hACE2 receptor recognition by SARS-CoV-2. 2020 , 16, e1008762	96
865	A cross-reactive human IgA monoclonal antibody blocks SARS-CoV-2 spike-ACE2 interaction. 2020 , 11, 4198	69
864	Computational Alanine Scanning and Structural Analysis of the SARS-CoV-2 Spike Protein/Angiotensin-Converting Enzyme 2 Complex. 2020 , 14, 11821-11830	33

863	The Genetic Dissection of Expression Variation in the Heart of Murine Genetic Reference Population. 2020 , 7, 582949	4
862	A methodology for predicting tissue-specific metabolic roles of receptors applied to subcutaneous adipose. 2020 , 10, 19535	
861	Differences in RAAS/vitamin D linked to genetics and socioeconomic factors could explain the higher mortality rate in African Americans with COVID-19. 2020 , 14, 1753944720977715	4
860	A potential hypothesis for 2019-nCoV infection therapy through delivery of recombinant ACE2 by red blood cell-hitchhiking. 2020 , 27,	0
859	Molecular Mechanisms Lead to Sex-Specific COVID-19 Prognosis and Targeted Therapies. 2020 , 7, 589060	4
858	Impact of COVID-19 Pandemic on Pediatrics and Pediatric Transplantation Programs. 2020 , 8, 612627	5
857	Viral Pandemics of the Last Four Decades: Pathophysiology, Health Impacts and Perspectives. 2020 , 17,	24
856	Integrative medicine considerations for convalescence from mild-to-moderate COVID-19 disease. 2020 , 18, 140-140	11
855	High affinity nanobodies block SARS-CoV-2 spike receptor binding domain interaction with human angiotensin converting enzyme. 2020 , 10, 22370	46
854	Will SARS-CoV-2 Infection Elicit Long-Lasting Protective or Sterilising Immunity? Implications for Vaccine Strategies (2020). 2020 , 11, 571481	28
853	COVID-19 and Pulmonary Hypertension in Children: What Do We Know So Far?. 2020 , 56,	3
852	Monitoring Viral Entry in Real-Time Using a Luciferase Recombinant Vesicular Stomatitis Virus Producing SARS-CoV-2, EBOV, LASV, CHIKV, and VSV Glycoproteins. 2020 , 12,	9
851	Immunohistochemical Study of SARS-CoV-2 Viral Entry Factors in the Cornea and Ocular Surface. 2020 , 39, 1556-1562	32
850	An ACE2 Microbody Containing a Single Immunoglobulin Fc Domain Is a Potent Inhibitor of SARS-CoV-2. 2020 , 33, 108528	39
849	Multitarget studies of , family against SARS-CoV-2 supported by molecular dynamics simulation. 2020 , 1-11	6
848	Pathophysiology and potential future therapeutic targets using preclinical models of COVID-19. 2020 , 6,	6
847	A Potent SARS-CoV-2 Neutralizing Human Monoclonal Antibody That Reduces Viral Burden and Disease Severity in Syrian Hamsters. 2020 , 11, 614256	25
846	Functional Complexes of Angiotensin-Converting Enzyme 2 and Renin-Angiotensin System Receptors: Expression in Adult but Not Fetal Lung Tissue. 2020 , 21,	5

845	The Role of Host Genetic Factors in Coronavirus Susceptibility: Review of Animal and Systematic Review of Human Literature. 2020 , 107, 381-402	36
844	Don't sugar coat the COVID (only the vasculature). 2020 , 43, 393-398	
843	Plausible mechanisms explaining the role of cucurbitacins as potential therapeutic drugs against coronavirus 2019. 2020 , 21, 100484	6
842	Reply. 2020 , 146, 1455-1456	1
841	Association of Renin-Angiotensin System Blockers With Outcomes in Patients with COVID-19. 2020 , 95, 2559-2561	4
840	Intrinsic disorder perspective of an interplay between the renin-angiotensin-aldosterone system and SARS-CoV-2. 2020 , 85, 104510	6
839	COVID-19 and the renin-angiotensin system (RAS): A spark that sets the forest alight?. 2020 , 144, 110231	27
838	Covid-19 cytokine storm in pulmonary tissue: Anatomopathological and immunohistochemical findings. 2020 , 31, 101292	9
837	The immunology of SARS-CoV-2 infection, the potential antibody based treatments and vaccination strategies. 2021 , 19, 899-910	2
836	SARS-CoV-2, Early Entry Events. 2020 , 2020, 9238696	10
835	Body Localization of ACE-2: On the Trail of the Keyhole of SARS-CoV-2. 2020 , 7, 594495	63
834	Spike Proteins of SARS-CoV and SARS-CoV-2 Utilize Different Mechanisms to Bind With Human ACE2. 2020 , 7, 591873	30
833	Pathophysiology of SARS-CoV-2 in Lung of Diabetic Patients. 2020 , 11, 587013	7
832	Lectin Protein as a Promising Component to Functionalize Micelles, Liposomes and Lipid NPs against Coronavirus. 2020 , 8,	11
831	An Updated Understanding of the Current Emerging Respiratory Infection: COVID-19. 2020 , 2020, 6870512	2
830	SARS-CoV-2: ACE inhibitors, disastrous or desirable?. 2020 , 7, 40-46	6
829	Covid-19 and Diabetes: A Complex Bidirectional Relationship. 2020 , 11, 582936	36
828	Osmotic Adaptation by Na-Dependent Transporters and ACE2: Correlation with Hemostatic Crisis in COVID-19. 2020 , 8,	6

827	Coronavirus pandemic: treatment and future prevention. 2020 , 15, 1507-1521	1
826	Clinical value of procalcitonin in critically ill patients infected by SARS-CoV-2. 2021 , 46, 525-531	3
825	Nasal lavage containing Angiotensin-Converting Enzyme-2 agonist can prevent and reduce viral load in COVID-19. 2020 , 144, 110207	2
824	Threading the Pieces Together: Integrative Perspective on SARS-CoV-2. 2020 , 9,	3
823	Small Resistance Artery Disease and ACE2 in Hypertension: A New Paradigm in the Context of COVID-19. 2020 , 7, 588692	5
822	Natural Infection by SARS-CoV-2 in Companion Animals: A Review of Case Reports and Current Evidence of Their Role in the Epidemiology of COVID-19. 2020 , 7, 591216	30
821	The outcomes of the postulated interaction between SARS-CoV-2 and the renin-angiotensin system on the clinician's attitudes toward hypertension treatment. 2021 , 35, 828-836	1
820	Highlights in the fight against COVID-19: does autophagy play a role in SARS-CoV-2 infection?. 2020 , 16, 2123-2127	16
819	COVID-19 and Cerebrovascular Diseases: A Systematic Review and Perspectives for Stroke Management. 2020 , 11, 574694	28
818	Frailty as an integrative marker of physiological vulnerability in the era of COVID-19. 2020 , 18, 333	5
817	Application of Humanized Zebrafish Model in the Suppression of SARS-CoV-2 Spike Protein Induced Pathology by Tri-Herbal Medicine Coronil via Cytokine Modulation. 2020 , 25,	17
816	The Origin, Transmission, and Clinical Therapies in the Management of Coronavirus Diseases. 2020 , 25	0
815	Dermatological aspects of SARS-CoV-2 infection: mechanisms and manifestations. 2021 , 313, 611-622	9
814	Markers of Endothelial Cells in Normal and Pathological Conditions. 2020 , 14, 167-183	5
813	Obesity and COVID-19. 2020 , 11, 581356	7
812	Revisiting the Immune Balance Theory: A Neurological Insight Into the Epidemic of COVID-19 and Its Alike. 2020 , 11, 566680	4
811	Coronavirus in human diseases: Mechanisms and advances in clinical treatment. 2020 , 1, 270	11
810	Massive dissemination of a SARS-CoV-2 Spike Y839 variant in Portugal. 2020 , 9, 2488-2496	12

809	Molecular Insights into Human Transmembrane Protease Serine-2 (TMPS2) Inhibitors against SARS-CoV2: Homology Modelling, Molecular Dynamics, and Docking Studies. 2020 , 25,	8
808	Persistence of viral RNA, pneumocyte syncytia and thrombosis are hallmarks of advanced COVID-19 pathology. 2020 , 61, 103104	155
807	A rational roadmap for SARS-CoV-2/COVID-19 pharmacotherapeutic research and development: IUPHAR Review 29. 2020 , 177, 4942-4966	51
806	Multifaceted Functions of Host Cell Caveolae/Caveolin-1 in Virus Infections. 2020 , 12,	20
805	A human monoclonal antibody blocking SARS-CoV-2 infection. 2020 , 11, 2251	685
804	Immunomodulatory therapy for the management of severe COVID-19. Beyond the anti-viral therapy: A comprehensive review. 2020 , 19, 102569	121
803	Seven recommendations to rescue the patients and reduce the mortality from COVID-19 infection: An immunological point of view. 2020 , 19, 102570	22
802	Efficient functional screening of a cellular cDNA library to identify severe fever with thrombocytopenia syndrome virus entry factors. 2020 , 10, 5996	3
801	Repurposing of clinically approved drugs for treatment of coronavirus disease 2019 in a 2019-novel coronavirus-related coronavirus model. 2020 , 133, 1051-1056	159
800	SARS-CoV-2 infection in a 76-year-old man with initially negative nasopharyngeal swabs. 2020 , 192, E546-E549 8	
799	Association of Use of Angiotensin-Converting Enzyme Inhibitors and Angiotensin II Receptor Blockers With Testing Positive for Coronavirus Disease 2019 (COVID-19). 2020 , 5, 1020-1026	267
798	What could be the better choice between ACE inhibitors and AT1R antagonists in coronavirus disease 2019 (COVID-19) patients?. 2020 , 92, 2302-2303	4
797	The Indian perspective of COVID-19 outbreak. 2020 , 31, 1-8	32
796	Structural Basis for Potent Neutralization of Betacoronaviruses by Single-Domain Camelid Antibodies. 2020 , 181, 1004-1015.e15	319
795	The pathogenesis and alternative treatment of SARS-CoV2. 2020 , 9, 100421	1
794	The lysosome: A potential juncture between SARS-CoV-2 infectivity and Niemann-Pick disease type C, with therapeutic implications. 2020 , 34, 7253-7264	51
793	Potential therapeutic targets and promising drugs for combating SARS-CoV-2. 2020 , 177, 3147-3161	46
792	ACE2 (Angiotensin-Converting Enzyme 2), COVID-19, and ACE Inhibitor and Ang II (Angiotensin II) Receptor Blocker Use During the Pandemic: The Pediatric Perspective. 2020 , 76, 16-22	65

791	Angiotensin-converting enzyme 2 (ACE2), SARS-CoV-2 and the pathophysiology of coronavirus disease 2019 (COVID-19). 2020 , 251, 228-248	473
790	Cigarette Smoke Exposure and Inflammatory Signaling Increase the Expression of the SARS-CoV-2 Receptor ACE2 in the Respiratory Tract. 2020 , 53, 514-529.e3	228
789	Coronavirus disease 2019 (SARS-CoV-2) and colonization of ocular tissues and secretions: a systematic review. 2020 , 34, 1206-1211	63
788	Severe Acute Respiratory Syndrome Coronavirus 2 from Patient with Coronavirus Disease, United States. 2020 , 26, 1266-1273	359
787	COVID-19 as an Acute Inflammatory Disease. 2020 , 205, 12-19	74
786	Cross-reactive Antibody Response between SARS-CoV-2 and SARS-CoV Infections. 2020 , 31, 107725	263
785	Type 2 inflammation modulates ACE2 and TMPRSS2 in airway epithelial cells. 2020 , 146, 80-88.e8	150
784	Molnupiravir: A new candidate for COVID-19 treatment.. 2022 , 10, e00909	18
783	Single cell atlas for 11 non-model mammals, reptiles and birds. 2021 , 12, 7083	5
782	Differential expression in humans of the viral entry receptor ACE2 compared with the short deltaACE2 isoform lacking SARS-CoV-2 binding sites.. 2021 , 11, 24336	2
781	A serum-stable RNA aptamer specific for SARS-CoV-2 neutralizes viral entry. 2021 , 118,	4
780	Rapid discovery of diverse neutralizing SARS-CoV-2 antibodies from large-scale synthetic phage libraries.. 2022 , 14, 2002236	2
779	European Society of Cardiology guidance for the diagnosis and management of cardiovascular disease during the COVID-19 pandemic: part 1-epidemiology, pathophysiology, and diagnosis. 2021 ,	3
778	The effect of Covid-19 mRNA vaccine on serum anti-Müllerian hormone levels.. 2021 ,	4
777	Pathophysiology of coronavirus-19 disease acute lung injury.. 2022 , 28, 9-16	7
776	SARS-CoV-2 Spike triggers barrier dysfunction and vascular leak via integrins and TGF- β signaling.. 2021 ,	2
775	SARS-CoV-2 Omicron spike mediated immune escape and tropism shift.	23
774	Structural analysis of the Spike of the Omicron SARS-COV-2 variant by cryo-EM and implications for immune evasion.	5

773	A genome-wide CRISPR screen identifies interactors of the autophagy pathway as conserved coronavirus targets.. 2021 , 19, e3001490	3
772	Genome-scale CRISPR screen identifies TMEM41B as a multi-function host factor required for coronavirus replication. 2021 , 17, e1010113	6
771	Cholesterol-Rich Lipid Rafts as Platforms for SARS-CoV-2 Entry.. 2021 , 12, 796855	5
770	Transcriptomic Profiles Reveal Downregulation of Low-Density Lipoprotein Particle Receptor Pathway Activity in Patients Surviving Severe COVID-19.. 2021 , 10,	0
769	Erectile dysfunction and testosterone levels prior to COVID-19 disease: What is the relationship?. 2021 , 93, 460-464	4
768	SARS-CoV-2 spike protein induces inflammation via TLR2-dependent activation of the NF-kB pathway. 2021 , 10,	41
767	Highly synergistic combinations of nanobodies that target SARS-CoV-2 and are resistant to escape. 2021 , 10,	3
766	SARS-CoV-2 Entry Genes Are Most Highly Expressed in Nasal Goblet and Ciliated Cells within Human Airways. 2020 ,	1
765	Prediction of repurposed drugs for treating lung injury in COVID-19. 2020 ,	
764	Pathogenesis, Symptomatology, and Transmission of SARS-CoV-2 through analysis of Viral Genomics and Structure. 2021 ,	
763	Regulation of early growth response-1 (Egr-1) gene expression by Stat1-independent type I interferon signaling and respiratory viruses. 2021 , 9, 289-303	0
762	Risk Factors for COVID-19: Diabetes, Hypertension, and Obesity.. 2021 , 1353, 115-129	2
761	Production of a Highly Immunogenic Antigen from SARS-CoV-2 by Covalent Coupling of the Receptor Binding Domain of Spike Protein to a Multimeric Carrier.	0
760	Blood Pressure, Proteases and Inhibitors. 2022 ,	
759	Egyptian perspectives on potential risk of paracetamol/acetaminophen-induced toxicities: Lessons learnt during COVID-19 pandemic.. 2022 , 9, 541-548	3
758	Renin-angiotensin system: Basic and clinical aspects-A general perspective.. 2022 , 69, 52-62	0
757	Findings in COVID-19 cases and protocols to be followed in dental operatories. 2022 , 15, 313	
756	Insights from computational analysis: how does the SARS-CoV-2 Delta (B.1.617.2) variant hijack ACE2 more effectively?. 2022 ,	0

- 755 Identifying factors contributing to increased susceptibility to COVID-19 risk: a systematic review of Mendelian randomization studies.. **2022**, 2
- 754 [Role of ACE2 in COVID-19].. **2022**, 157, 115-118
- 753 Analysis of clinical sign and symptoms and biochemical parameters of post-COVID patients.. **2022**, 39, 214-215
- 752 Diagnostic Tests for COVID-19: How Should Their Results Be Interpreted? A Practical Approach. **2022**, 23-32
- 751 Evaluation of Peppermint Leaf Flavonoids as SARS-CoV-2 Spike Receptor-Binding Domain Attachment Inhibitors to the Human ACE2 Receptor: A Molecular Docking Study. **2022**, 12, 132-152 0
- 750 Infectious Neuropathies. **2022**, 249-280
- 749 COVID-19 and Male Reproduction: A Thorny Problem.. **2022**, 16, 15579883221074816 1
- 748 Microbiome in SARS-CoV-2 (Covid-19). **2022**, 281-294
- 747 Origin of the tight binding mode to ACE2 triggered by multi-point mutations in the omicron variant: a dynamic insight.. **2022**, 1
- 746 COVID-19 and lung involvement. **2022**, 189-211
- 745 SARS-CoV-2???ACE2????????/?????. **2022**,
- 744 Relaci3n entre el sistema renina angiotensina aldosterona y las complicaciones cardiovasculares por SARS-CoV-2. **2022**, 67, 34-43
- 743 Immune Response to Viruses. **2022**, 429-444 0
- 742 Molecular dynamics simulations of the delta and omicron SARS-CoV-2 spike - ACE2 complexes reveal distinct changes between both variants.. **2022**, 3
- 741 Altera3es Hep3icas Causadas pelo Sars-CoV-2. **2022**, 25,
- 740 Multisystem inflammatory syndrome in children associated with COVID-19 in 101 cases from Turkey (Turk-MISC study).. **2022**, 1
- 739 [Valproic Acid Could Help in the Fight Against COVID-19: a case-control study].. **2022**,
- 738 The ACE2 Receptor for Coronavirus Entry Is Localized at Apical Cell-Cell Junctions of Epithelial Cells.. **2022**, 11, 2

- 737 Targeting Angiotensin-Converting Enzyme 2 (ACE2) for the Discovery of Anticoronaviral Drugs. **2022**, 03,
- 736 Molecular and Physiological Aspects of SARS-CoV-2 Infection in Women and Pregnancy.. **2022**, 3, 756362
- 735 Liver Changes Caused by Sars-CoV-2. **2022**, 25,
- 734 Advances in the Prophylaxis of Respiratory Infections by the Nasal and the Oromucosal Route: Relevance to the Fight with the SARS-CoV-2 Pandemic.. **2022**, 14, 0
- 733 The Severe Acute Respiratory Syndrome Coronavirus-2 (SARS-CoV-2) Pandemic: Are Africa's Prevalence and Mortality Rates Relatively Low?. **2022**, 2022, 3387784 3
- 732 Organoid Studies in COVID-19 Research.. **2022**, 15, 3-13 1
- 731 Vaccine Candidate Against COVID-19 Based on Structurally Modified Plant Virus as an Adjuvant.. **2022**, 13, 845316 0
- 730 ACE2 Protein Expression During Childhood, Adolescence, and Early Adulthood.. **2022**, 10935266221075312 1
- 729 COVID-19 and Seizures.
- 728 Baseline haemoglobin A1c and the risk of COVID-19 hospitalization among patients with diabetes in the INSIGHT Clinical Research Network.. **2022**, e14815 1
- 727 Alteraciones Hepáticas Causadas por el Sars-CoV-2. **2022**, 25,
- 726 The relevant information about the severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) using the five-question approach (when, where, what, why, and how) and its impact on the environment.. **2022**, 1 2
- 725 Mechanism of Action of Small-Molecule Agents in Ongoing Clinical Trials for SARS-CoV-2: A Review.. **2022**, 13, 840639 1
- 724 The collectrin-like part of the SARS-CoV-1 and -2 receptor ACE2 is shed by the metalloproteinases ADAM10 and ADAM17.. **2022**, 36, e22234 1
- 723 Drugs Modulating Renin-Angiotensin System in COVID-19 Treatment.. **2022**, 10, 2
- 722 Spectrum of Kidney Injury Following COVID-19 Disease: Renal Biopsy Findings in a Single Italian Pathology Service.. **2022**, 12, 0
- 721 Fatal Neurodissemination and SARS-CoV-2 Tropism in K18-hACE2 Mice Is Only Partially Dependent on hACE2 Expression.. **2022**, 14, 7
- 720 Identification of cell type specific ACE2 modifiers by CRISPR screening.. **2022**, 18, e1010377 1

719	Construction of SARS-CoV-2 spike-pseudotyped retroviral vector inducing syncytia formation.. 2022 , 1	0
718	COVID-19-Related Rhino-Orbito-Cerebral Mucormycosis Complicated by the Optic Nerve and Optic Tract Ischemia With Ischemic Neuropathy.. 2022 , 14, e23068	
717	mRNA vaccine-a desirable therapeutic strategy for surmounting COVID-19 pandemic.. 2022 , 18, 2040330	1
716	Does the Covid-19 pandemic have an effect on wound culture in patients undergoing appendectomy? A Case Control Study.	
715	Oral Lisinopril Raises Tissue Levels of ACE2, the SARS-CoV-2 Receptor, in Healthy Male and Female Mice.. 2022 , 13, 798349	0
714	Mechanistic insights from the review and evaluation of ayurvedic herbal medicines for the prevention and management of COVID-19 patients.. 2022 , 32, 100554	1
713	Therapeutic and prophylactic effect of flavonoids in post-COVID-19 therapy.. 2022 ,	3
712	Safety and Pharmacokinetics of Intranasally Administered Heparin.. 2022 , 39, 541	0
711	COVID-19-Associated Myocarditis: An Evolving Concern in Cardiology and Beyond.. 2022 , 11,	3
710	Cytoplasmic domain and enzymatic activity of ACE2 are not required for PI4KB dependent endocytosis entry of SARS-CoV-2 into host cells.. 2022 ,	0
709	Virtual Screening of Natural Chemical Databases to Search for Potential ACE2 Inhibitors.. 2022 , 27,	
708	Multiple SARS-CoV-2 Variants Exhibit Variable Target Cell Infectivity and Ability to Evade Antibody Neutralization.. 2022 , 13, 836232	0
707	Increased risk for thromboembolic events from combination of a gynecologic malignancy with severe acute respiratory syndrome coronavirus 2 infection: a case report.. 2022 , 16, 119	0
706	Theoretical Investigation of the Coronavirus SARS-CoV-2 (COVID-19) Infection Mechanism and Selectivity.. 2022 , 27,	
705	Cardiovascular Dysfunction in COVID-19: Association Between Endothelial Cell Injury and Lactate.. 2022 , 13, 868679	1
704	Bebtelovimab, alone or together with bamlanivimab and etesevimab, as a broadly neutralizing monoclonal antibody treatment for mild to moderate, ambulatory COVID-19.	6
703	Thrombosis and coagulopathy in COVID-19 patients receiving ECMO: A narrative review of current literature.. 2022 ,	2
702	A tethered ligand assay to probe SARS-CoV-2:ACE2 interactions.. 2022 , 119, e2114397119	0

701	The impact of COVID-19 on the male genital tract: a qualitative literature review of sexual transmission and fertility implications.. 2022 , 49, 9-15	2
700	Targeting the Interaction Between Spike Protein and Nucleocapsid Protein for Suppression and Detection of Human Coronavirus OC43.. 2022 , 13, 835333	1
699	Insights into the immune responses of SARS-CoV-2 in relation to COVID-19 vaccines.. 2022 , 60, 308-320	0
698	Structures of a deltacoronavirus spike protein bound to porcine and human receptors.. 2022 , 13, 1467	2
697	Crosstalk between SARS-CoV-2 Infection and Type II Diabetes.. 2022 ,	0
696	When to operate after SARS-CoV-2 infection? A review on the recent consensus recommendation of the DGC/BDC and the DGAI/BDA.. 2022 , 1	0
695	Dissecting the Role of the Human Microbiome in COVID-19 via Metagenome-assembled Genomes.	
694	Diagnostic, Prognostic, and Therapeutic Roles of Gut Microbiota in COVID-19: A Comprehensive Systematic Review.. 2022 , 12, 804644	6
693	Experience With the Use of Baricitinib and Tocilizumab Monotherapy or Combined, in Patients With Interstitial Pneumonia Secondary to Coronavirus COVID19: A Real-World Study.. 2022 , 18, 150-156	0
692	Erythro-VLPs: Anchoring SARS-CoV-2 spike proteins in erythrocyte liposomes.. 2022 , 17, e0263671	0
691	Host Cell Glycocalyx Remodeling Reveals SARS-CoV-2 Spike Protein Glycomic Binding Sites.. 2022 , 9, 799703	1
690	SARS-CoV-2 Spike Glycoprotein and ACE2 Interaction Reveals Modulation of Viral Entry in Wild and Domestic Animals.. 2021 , 8, 775572	0
689	Exploring SARS-CoV-2 Delta variant spike protein receptor-binding domain (RBD) as a target for tanshinones and antimalarials.. 2022 , 1-6	1
688	Variable susceptibility of intestinal organoid-derived monolayers to SARS-CoV-2 infection.. 2022 , 20, e3001592	2
687	Review of non-invasive detection of SARS-CoV-2 and other respiratory pathogens in exhaled breath condensate.. 2022 ,	0
686	SARS-CoV-2: vaccinology and emerging therapeutics; challenges and future developments.. 2022 , 13, 187-203	3
685	Effects of vitamin C and D on the mRNA expression of angiotensin converting enzyme 2 receptor, cathepsin L, and transmembrane serine protease in the mouse lungs.. 2022 , 17, 2054111	1
684	Advancement of deep learning in pneumonia/Covid-19 classification and localization: A systematic review with qualitative and quantitative analysis.. 2022 ,	0

683	A Novel Soluble ACE2 Protein Provides Lung and Kidney Protection in Mice Susceptible to Lethal SARS-CoV-2 Infection.. 2022,	4
682	Relative bradycardia in patients with moderate-to-severe COVID-19: a retrospective cohort study.. 2022, 4, 65	0
681	Secondary Adrenal Insufficiency After COVID-19 Diagnosed by Insulin Tolerance Test and Corticotropin-Releasing Hormone Test.. 2022, 14, e23021	
680	The SARS-CoV-2 Spike Glycoprotein Directly Binds Exogeneous Sialic Acids: A NMR View.	
679	The growing need to monitor the liver function after SARS-CoV-2 infection in the Mexican population with obesity.. 2022, 100698	
678	Demystifying mRNA vaccines: an emerging platform at the forefront of cryptic diseases.. 2022, 19, 386-410	4
677	Autophagy Modulators in Coronavirus Diseases: A Double Strike in Viral Burden and Inflammation.. 2022, 12, 845368	1
676	Identification and Quantification of Bioactive Compounds Suppressing SARS-CoV-2 Signals in Wastewater-based Epidemiology Surveillance.	0
675	Molecular docking between human TMPRSS2 and the serine protease Kunitz-type inhibitor rBmTI-A.	
674	Metal-based complexes against SARS-CoV-2.. 2022, 1	1
673	An insight into the mechanisms of COVID-19, SARS-CoV2 infection severity concerning Ecell survival and cardiovascular conditions in diabetic patients.. 2022, 1	2
672	ACE2 engagement exposes the fusion peptide to pan-coronavirus neutralizing antibodies.	3
671	An Overview of Systematic Reviews of the Role of Vitamin D on Inflammation in Patients with Diabetes and the Potentiality of Its Application on Diabetic Patients with COVID-19.. 2022, 23,	0
670	COVID-19, Oxidative Stress, and Neuroinflammation in the Depression Route.. 2022,	0
669	SARS-CoV-2 pathogenesis.. 2022,	30
668	Early reduction of SARS-CoV-2-replication in bronchial epithelium by kinin B receptor antagonism.. 2022, 100, 613	1
667	Development of a hybrid alphavirus-SARS-CoV-2 pseudovirion for rapid quantification of neutralization antibodies and antiviral drugs.. 2022, 100181	2
666	A Review: The Manifestations, Mechanisms, and Treatments of Musculoskeletal Pain in Patients With COVID-19.. 2022, 3, 826160	1

665	The SARS-CoV-2 Spike Glycoprotein Directly Binds Exogeneous Sialic Acids: A NMR View.. 2022,	3
664	The role of microRNAs in COVID-19 with a focus on miR-200c.. 2022, 11, 14-23	0
663	Unwinding Link Between Coronavirus and Diabetes Patient.. 2022,	
662	Acute right-sided ischemic colitis in a COVID-19 patient: a case report and review of the literature.. 2022, 16, 135	1
661	Clinical Significance of COVID-19 and Diabetes: In the Pandemic Situation of SARS-CoV-2 Variants including Omicron (B.1.1.529).. 2022, 11,	1
660	New AKT-dependent mechanisms of anti-COVID-19 action of high-CBD Cannabis sativa extracts.. 2022, 8, 110	2
659	Corneal Cellular and Neuroinflammatory Changes After SARS-CoV-2 Infection.. 2022,	1
658	Detection of SARS-CoV-2 using dielectric modulated TFET-based biosensor. 1	1
657	ACE2-independent infection of T lymphocytes by SARS-CoV-2.. 2022, 7, 83	11
656	In silico design of ACE2 mutants for competitive binding of SARS-CoV-2 receptor binding domain with hACE2. 2022,	
655	COVID-19 and myocarditis: a review of literature.. 2022, 74, 23	4
654	Low Dose Radiation Therapy Attenuates ACE2 Depression and Inflammatory Cytokines Induction by COVID-19 Viral Spike Protein in Human Bronchial Epithelial Cells.. 2022, 1-27	
653	Mutational scanning of spike RBD protein for enhanced ACE2 affinity emerging Southeast Asia in the late transmission phase.. 2022, 12, 5896	0
652	SMYD2 Inhibition Downregulates TMPRSS2 and Decreases SARS-CoV-2 Infection in Human Intestinal and Airway Epithelial Cells.. 2022, 11,	0
651	Prefusion Spike Protein Conformational Changes Are Slower in SARS-CoV-2 than in SARS-CoV-1.. 2022, 101814	3
650	Swine Enteric Coronavirus: Diverse Pathogen-Host Interactions.. 2022, 23,	1
649	Thymoquinone's Antiviral Effects: It is Time to be Proven in the Covid-19 Pandemic Era and its Omicron Variant Surge.. 2022, 13, 848676	1
648	SARS-CoV-2 impairs the disassembly of stress granules and promotes ALS-associated amyloid aggregation.. 2022, 1	1

647	Reviewing findings on the polypeptide sequence of the SARS-CoV-2 S-protein to discuss the origins of the virus.. 2022,	0
646	Potential Pathophysiological Mechanisms Underlying Multiple Organ Dysfunction in Cytokine Release Syndrome.. 2022, 2022, 7137900	0
645	Understanding on the possible routes for SARS CoV-2 invasion via ACE2 in the host linked with multiple organs damage.. 2022, 99, 105254	2
644	SARS-CoV-2 Spike Protein Binding of Glycated Serum Albumin-Its Potential Role in the Pathogenesis of the COVID-19 Clinical Syndromes and Bias towards Individuals with Pre-Diabetes/Type 2 Diabetes and Metabolic Diseases.. 2022, 23,	2
643	The innate immune response, microenvironment proteinases, and the COVID-19 pandemic: pathophysiologic mechanisms and emerging therapeutic targets.. 2022, 12, 48-62	5
642	Characterisation and natural progression of SARS-CoV-2 infection in ferrets.. 2022, 12, 5680	0
641	Targeted protein S-nitrosylation of ACE2 as potential treatment to prevent spread of SARS-CoV-2 infection.. 2022,	1
640	Diabetic kidney disease, a potentially serious issue resulting from collision of the Covid-19 and diabetes global pandemics. 2022,	
639	David versus goliath: ACE2-Fc receptor traps as potential SARS-CoV-2 inhibitors.. 2022, 14, 2057832	2
638	Interaction of surface glycoprotein of SARS-CoV-2 variants of concern with potential drug candidates: A molecular docking study. 11, 400	
637	Severe acute respiratory syndrome and thyroid: A molecular point of view.. 2022, 48, 1-4	1
636	Exploring the inhibitory potential of and phytoconstituents against the Spike glycoprotein receptor binding domain of SARS-CoV-2 Delta (B.1.617.2) variant and the main protease (M) as therapeutic candidates, using Molecular docking, DFT, and ADME/Tox studies.. 2022, 133032	2
635	Mechanistic Origin of Different Binding Affinities of SARS-CoV and SARS-CoV-2 Spike RBDs to Human ACE2.. 2022, 11,	1
634	Identification of host transcriptome-guided repurposable drugs for SARS-CoV-1 infections and their validation with SARS-CoV-2 infections by using the integrated bioinformatics approaches.. 2022, 17, e0266124	1
633	PK/PD Modelling Links Accelerated Resolution of COVID-19-Related Clinical Symptoms to SARS-CoV-2 Viral Load Reduction in Patients Following Treatment with Bamlanivimab Alone or Bamlanivimab and Etesevimab Together.. 2022,	
632	Potential benefits of ginseng against COVID-19 by targeting inflammasomes.. 2022,	0
631	Traditional Chinese medicine against COVID-19: Role of the gut microbiota.. 2022, 149, 112787	3
630	Harnessing coronavirus spike proteins' binding affinity to ACE2 receptor through a novel baculovirus surface display system.. 2022, 606, 23-28	1

629	Functional reconstitution of the MERS CoV receptor binding Motif.. 2022 , 145, 3-16	0
628	The accessible promoter-mediated supplementary effect of host factors provides new insight into the tropism of SARS-CoV-2.. 2022 ,	0
627	Bibliometric Analysis Of Research on Coronavirus Infection and Patient Safety in Health Care. 2021 , 15, 373-379	
626	Post-Translational Modifications Optimize the Ability of SARS-CoV-2 Spike for Effective Interaction with Host Cell Receptors.	2
625	Impact of RAAS Inhibitors on Clinical Outcome and Mortality in Patients With STEMI During the COVID-19 Era: A Multicenter Observational Study.. 2021 , 8, 792804	0
624	Naringenin as a Possible Candidate Against SARS-CoV-2 Infection and in the Pathogenesis of COVID-19. 2021 , 16, 1934578X2110667	3
623	Nonmuscle myosin heavy chain IIA facilitates SARS-CoV-2 infection in human pulmonary cells. 2021 , 118,	7
622	Soluble Human Angiotensin- Converting Enzyme 2 as a Potential Therapeutic Tool for COVID-19 is Produced at High Levels In Plant With Potent Anti-SARS-CoV-2 Activity.. 2021 , 12, 742875	2
621	The adverse impact of COVID-19 on men's health.. 2021 , 32,	1
620	A deep learning method for repurposing antiviral drugs against new viruses via multi-view nonnegative matrix factorization and its application to SARS-CoV-2.. 2021 ,	5
619	Computational Saturation Mutagenesis of SARS-CoV-1 Spike Glycoprotein: Stability, Binding Affinity, and Comparison With SARS-CoV-2.. 2021 , 8, 784303	2
618	Heat shock protein 70, glutamate dehydrogenase, and angiotensin-converting enzyme of mediate the cell attachment of .. 2021 , 102,	
617	Occurrence of Spike Antigen Specific SARS-CoV-2 Antibodies in Pre-Pandemic Samples of Domestic Cats Raises New Questions. 2021 , 48, S75-S81	
616	Molecular Evolution of Severe Acute Respiratory Syndrome Coronavirus 2: Hazardous and More Hazardous Strains Behind the Coronavirus Disease 2019 Pandemic and Their Targeting by Drugs and Vaccines.. 2021 , 11, 763687	1
615	Antigenic characterization of influenza and SARS-CoV-2 viruses.. 2021 ,	1
614	Editorial: A Compendium of Recent Research on Stem Cell-Based Therapy for Covid-19.. 2021 , 9, 813384	
613	EVALUATION OF THE ORAL SYMPTOMS IN COVID 19 PATIENTS IN KAMRUP METRO- A CROSS-SECTIONAL STUDY. 2021 , 58-61	
612	Use of exogenic phosphocreatine in ICU rehabilitation of patients with COVID-19 (pilot study). 2022 , 18, 22-29	

611	COVID-19 Transcriptomic Atlas: A Comprehensive Analysis of COVID-19 Related Transcriptomics Datasets.. 2021 , 12, 755222	5
610	Glycoprotein Targeted CAR-NK Cells for the Treatment of SARS-CoV-2 Infection.. 2021 , 12, 763460	4
609	Potential of Quinine Sulfate for COVID-19 Treatment and Its Safety Profile: Review.. 2021 , 13, 225-234	0
608	COVID-19 pandemisinin ilk yılında ḃendiklerimiz.	
607	Angiotensin-Converting Enzyme 2 (ACE2) As a Novel Biorecognition Element in A Cell-Based Biosensor for the Ultra-Rapid, Ultra-Sensitive Detection of the SARS-CoV-2 S1 Spike Protein Antigen. 2021 , 9, 341	0
606	Elevated temperature inhibits SARS-CoV-2 replication in respiratory epithelium independently of IFN-mediated innate immune defenses.. 2021 , 19, e3001065	2
605	The Betacoronavirus PHEV Replicates and Disrupts the Respiratory Epithelia and Upregulates Key Pattern Recognition Receptor Genes and Downstream Mediators, Including IL-8 and IFN- γ 2021 , 6, e0082021	2
604	Insights into the Binding of Receptor-Binding Domain (RBD) of SARS-CoV-2 Wild Type and B.1.620 Variant with hACE2 Using Molecular Docking and Simulation Approaches.. 2021 , 10,	2
603	Lead Identification for Severe Acute Respiratory Syndrome Coronavirus-2 Spike D614G Variant of COVID-19: A virtual Screening Process. 2021 , 14, 1929-1939	
602	SARS-CoV-2 spike engagement of ACE2 primes S2' site cleavage and fusion initiation.. 2022 , 119,	7
601	Changes in Receptor Binding Domain of the Covid-19 during Pandemic; a Review Study. 2021 , 7, 75-86	
600	Angiotensin-converting enzyme 2 as a potential therapeutic target for COVID-19: A review.. 2021 ,	2
599	Machine learning guided design of high affinity ACE2 decoys for SARS-CoV-2 neutralization.. 2021 ,	1
598	Expanded ACE2 dependencies of diverse SARS-like coronavirus receptor binding domains.	1
597	Middle East Respiratory Syndrome Coronavirus.. 2021 , 42, 828-838	0
596	The Role of the Complement System in the Pathogenesis of SARS-CoV-2 Viral Infection in Mental Illness. 2021 , 19, 76-89	
595	Evolutionary pathways to SARS-CoV-2 resistance are opened and closed by epistasis acting on ACE2.. 2021 , 19, e3001510	0
594	COVID-19: The question of genetic diversity and therapeutic intervention approaches.. 2021 , 44, e20200452	0

593	Peptide-Based Dual HIV and Coronavirus Entry Inhibitors.. 2022 , 1366, 87-100	
592	Future Directions of 6G Architecture With Integration of Sensing, Communication, and Security. 2022 , 158-176	
591	Graphene-based nanocomposite using new modeling molecular dynamic simulations for proposed neutralizing mechanism and real-time sensing of COVID-19. 2022 , 11, 1555-1569	1
590	Does mass management of chronic hepatitis C protect the Egyptian population against fulminant coronavirus disease-2019? Postulating a hypothesis[] 2022 , 16,	0
589	Do compromised mitochondria aggravate severity and fatality by SARS-CoV-2?. 2022 , 1-10	1
588	Benchmarking the Widely Used Structure-based Binding Affinity Predictors on the Spike-ACE2 Deep Mutational Interaction Set.	
587	COVID-19 and One-Carbon Metabolism.. 2022 , 23,	1
586	Ischemic colitis after receiving the second dose of a COVID-19 inactivated vaccine: A case report. 2022 , 10, 3866-3871	0
585	[Transparent Depiction of Case Reports Linked to COVID-19 and its Vaccination - a Temporal Coincidence].. 2022 ,	
584	Independent acquisition of short insertions at the R1R1 site in the spike N-terminal domain of the SARS-CoV-2 BA.2 lineage.	
583	ACE2, BAT1, and SARS-CoV-2 spike protein: Structural and functional implications.. 2022 , 74, 102388	0
582	Structural definition of a pan-sarbecovirus neutralizing epitope on the spike S2 subunit.. 2022 , 5, 342	4
581	Effect of common maintenance drugs on the risk and severity of COVID-19 in elderly patients.. 2022 , 17, e0266922	0
580	COVID-19 and kidney disease: insights from epidemiology to inform clinical practice.. 2022 ,	4
579	Design, Synthesis, and Development of 4-[(7-Chloroquinoline-4-yl)amino]phenol as a Potential SARS-CoV-2 Mpro Inhibitor. 2022 , 7,	0
578	Differential effects of macrophage subtypes on SARS-CoV-2 infection in a human pluripotent stem cell-derived model.. 2022 , 13, 2028	3
577	Protease inhibitor Camostat Mesylate blocks wild type SARS-CoV-2 and D614G viral entry in human engineered miniature lungs.. 2022 , 285, 121509	0
576	Development of a Novel Human CD147 Knock-in NSG Mouse Model to Test SARS-CoV-2 Viral Infection.. 2022 ,	0

575 Table_1.DOCX. 2020,

574 Image_1.pdf. 2020,

573 Data_Sheet_1.PDF. 2020,

572 Data_Sheet_1.pdf. 2020,

571 Data_Sheet_1.PDF. 2020,

570 Data_Sheet_2.xlsx. 2020,

569 Image_1.JPEG. 2020,

568 Data_Sheet_1.PDF. 2020,

567 Table_1.xlsx. 2021,

566 Table_2.xlsx. 2021,

565 Data_Sheet_1.PDF. 2020,

564 Data_Sheet_1.ZIP. 2020,

563 Table_1.docx. 2020,

562 Table_2.DOCX. 2020,

561 Table_3.DOCX. 2020,

560 Presentation_1.pdf. 2020,

559 Video_1.mp4. 2020,

558 Video_2.mp4. 2020,

557 Video_3.mp4. **2020**,

556 Video_4.mp4. **2020**,

555 Video_5.mp4. **2020**,

554 DataSheet_1.pdf. **2020**,

553 Table_1.xlsx. **2020**,

552 Table_1.DOC. **2020**,

551 Table_1.XLSX. **2020**,

550 Table_2.XLSX. **2020**,

549 Data_Sheet_1.pdf. **2020**,

548 Genome-wide CRISPR screens identify GATA6 as a proviral host factor for SARS-CoV-2 via modulation of ACE2.. **2022**, 13, 2237 0

547 Structure of a Vaccine-Induced, Germline-Encoded Human Antibody Defines a Neutralizing Epitope on the SARS-CoV-2 Spike N-Terminal Domain.. **2022**, e0358021 2

546 Potential relationships between COVID-19 and the thyroid gland: an update.. **2022**, 50, 3000605221082898 2

545 ACE2 and COVID-19 Susceptibility and Severity.. **2022**, 13, 360-372 0

544 A Modified Fibronectin Type III Domain-Conjugated, Long-Acting Pan-Coronavirus Fusion Inhibitor with Extended Half-Life.. **2022**, 14, 1

543 Evaluation of Hematological Parameters of Children Diagnosed with COVID-19: Single-Center Experience.. **2021**, 56, 463-468

542 Potential effects of COVID-19 on reproductive health: a mini review.. **2021**, 13, 13321-13327

541 Role of SARS-CoV-2 in Modifying Neurodegenerative Processes in Parkinson's Disease: A Narrative Review. **2022**, 12, 536 1

540 Immune Signature of COVID-19: In-Depth Reasons and Consequences of the Cytokine Storm.. **2022**, 23, 2

539	SARS-CoV-2 Infection, Sex-Related Differences, and a Possible Personalized Treatment Approach with Valproic Acid: A Review. 2022 , 10, 962	0
538	Morbidity and mortality in men: Role of androgens.. 2022 , 101662	0
537	Glycopeptide Antibiotic Teicoplanin Inhibits Cell Entry of SARS-CoV-2 by Suppressing the Proteolytic Activity of Cathepsin L.. 2022 , 13, 884034	1
536	Intestinal Ischemia: Unusual but Fearsome Complication of COVID-19 Infection. 2022 , 10, 1010	0
535	Chronic Exposure to the Food Additive tBHQ Modulates Expression of Genes Related to SARS-CoV-2 and Influenza Viruses. 2022 , 12, 642	
534	SARS-CoV-2 Infection of Human Ovarian Cells: A Potential Negative Impact on Female Fertility.. 2022 , 11,	0
533	Potential of sphingosine-1-phosphate in preventing SARS-CoV-2 infection by stabilizing and protecting endothelial cells: Narrative review.. 2022 , 101, e29164	0
532	Serine Protease Inhibitors Restrict Host Susceptibility to SARS-CoV-2 Infections.. 2022 , e0089222	0
531	Recombinant Protein Technology in the Challenging Era of Coronaviruses. 2022 , 10, 946	0
530	Drug Repositioning with GraphSAGE and Clustering Constraints Based on Drug and Disease Networks. 2022 , 13,	0
529	The effects of SARS-CoV-2 infection on modulating innate immunity and strategies of combating inflammatory response for COVID-19 therapy.. 2022 , 29, 27	1
528	Promising Role of Emodin as Therapeutics to Against Viral Infections. 2022 , 13,	0
527	Nsp1 proteins of human coronaviruses HCoV-OC43 and SARS-CoV2 inhibit stress granule formation.	
526	Neuropathological Aspects of SARS-CoV-2 Infection: Significance for Both Alzheimer's and Parkinson's Disease.. 2022 , 16, 867825	1
525	A microfluidic cell chip for virus isolation via rapid screening for permissive cells.. 2022 ,	1
524	Antiviral Drug Discovery for the Treatment of COVID-19 Infections. 2022 , 14, 961	3
523	Frequently Used Allopathic and Traditional Medicine for COVID-19 Treatment and Feasibility of Their Integration.. 2022 , 1	
522	Mucosal immune responses to infection and vaccination in the respiratory tract.. 2022 , 55, 749-780	4

521	Emerging Viral Infections and the Potential Impact on Hypertension, Cardiovascular Disease, and Kidney Disease.. 2022 , 130, 1618-1641	0
520	The effect of the Delta SARS-CoV-2 variant in maternal infection and pregnancy.. 2022 , 104295	0
519	Evaluation of the Effect of Anti-COVID-19 Mouthwashes on Shear Bond Strength of Composite Resin Restorations to Dentin and Enamel: An "In Vitro Study".. 2022 , 2022, 3824796	
518	The Pathophysiology of Long COVID throughout the Renin-Angiotensin System.. 2022 , 27,	3
517	The effect of various compounds on the COVID mechanisms, from chemical to molecular aspects. 2022 , 106824	0
516	SARS-CoV-2 induces barrier damage and inflammatory responses in the human iPSC-derived intestinal epithelium. 2022 ,	2
515	Immunological defense of CNS barriers against infections.. 2022 , 55, 781-799	0
514	Drug repurposing for the treatment of COVID-19. 2022 , 149, 108-114	1
513	Role of curcumin in ameliorating hypertension and associated conditions: a mechanistic insight.. 2022 , 1	0
512	Synthetic Peptides outside the Spike Protein Heptad Repeat Regions as Potent Inhibitors of Sars-Associated Coronavirus. 2005 , 10, 393-403	33
511	Severe Acute Respiratory Syndrome Coronavirus Entry as a Target of Antiviral Therapies. 2007 , 12, 639-650	12
510	A Human Neutralizing Antibody against a Conformational Epitope Shared by Oligomeric Sars S1 Protein. 2006 , 11, 117-123	4
509	Dysregulated Interferon Response and Immune Hyperactivation in Severe COVID-19: Targeting STATs as a Novel Therapeutic Strategy. 2022 , 13,	4
508	Why do some coronaviruses become pandemic threats when others do not?. 2022 , 20, e3001652	
507	Endomembrane remodeling in SARS-CoV-2 infection. 2022 , 100031	0
506	An electrostatically-steered conformational selection mechanism promotes SARS-CoV-2 Spike protein variation. 2022 , 167637	0
505	ACE2-enriched extracellular vesicles enhance infectivity of live SARS-CoV-2 virus.. 2022 , 11, e12231	4
504	Inhibition of IRAK4 dysregulates SARS-CoV-2 spike protein-induced macrophage inflammatory and glycolytic reprogramming.. 2022 , 79, 301	1

503	ACE2 Decoy Receptor Generated by High-throughput Saturation Mutagenesis Efficiently Neutralizes SARS-CoV-2 and Its Prevalent Variants.. 2022 , 1-0	0
502	The assembled and annotated genome of the masked palm civet (<i>Paguma larvata</i>).. 2022 , 11,	1
501	Effect of ArtemiC in patients with COVID-19: A Phase II prospective study.. 2022 ,	2
500	Antiviral activity of chitosan nanoparticles encapsulating silymarin (SiNPs) against SARS-CoV-2 (in silico and in vitro study). 2022 , 12, 15775-15786	2
499	Treatment of Novel Coronavirus (2019-nCoV) Using Hinokitiol (Ehujaplicin) Copper Chelate. 2022 , 147-164	
498	The chimera of S1 and N proteins of SARS-CoV-2: can it be a potential vaccine candidate for COVID-19?.	
497	Discovery of Natural Lead Compound from <i>Dendrobium</i> sp. against SARS-CoV-2 Infection. 2022 , 15, 620	1
496	Post-Proline Cleaving Enzymes (PPCEs): Classification, Structure, Molecular Properties, and Applications. 2022 , 11, 1330	0
495	Severe acute respiratory syndrome coronavirus 2 infection: Role of interleukin-6 and the inflammatory cascade. 2022 , 11, 113-128	3
494	Monoclonal antibody designed for SARS-nCoV-2 spike protein of receptor binding domain on antigenic targeted epitopes for inhibition to prevent viral entry.	1
493	Impact of Entrepreneurial Orientation on Performance of Quoted Breweries in Nigeria: Mediating Role of Organizational Embeddedness. 2022 , 18, 604-616	
492	Tale of Viruses in Male Infertility. 2022 , 275-323	0
491	Brain Biomarkers in Patients with COVID-19 and Neurological Manifestations: A Narrative Review. 2022 , 09, 010-015	
490	Myocardial Injury in COVID-19 and Its Implications in Short- and Long-Term Outcomes. 2022 , 9,	0
489	Antimalarial phytochemicals as potential inhibitors of SARS-CoV-2 guanine N7-methyltransferase (nsp 14): an integrated computational approach. 1-23	
488	The SARS-CoV-2 Spike Protein Activates the Epidermal Growth Factor Receptor-Mediated Signaling.	
487	Antigenic structure of the human coronavirus OC43 spike reveals exposed and occluded neutralizing epitopes. 2022 , 13,	0
486	Gastrointestinal Involvement in SARS-CoV-2 Infection. 2022 , 14, 1188	2

485	Evaluation of Antibody-Dependent Fc-Mediated Viral Entry, as Compared With Neutralization, in SARS-CoV-2 Infection. 13,	0
484	TMPRSS2 Expression and Activity Modulation by Sex-Related Hormones in Lung Calu-3 Cells: Impact on Gender-Specific SARS-CoV-2 Infection. 2022 , 13,	1
483	Increased Risk of COVID-19 in Patients with Diabetes Mellitus Current Challenges in Pathophysiology, Treatment and Prevention. 2022 , 19, 6555	2
482	An Insight Based on Computational Analysis of the Interaction between the Receptor-Binding Domain of the Omicron Variants and Human Angiotensin-Converting Enzyme 2. 2022 , 11, 797	1
481	Protective neutralizing epitopes in SARS-CoV-2.	3
480	COVID-19 therapies: do we see substantial progress?. 2022 , 27,	0
479	The key role of Calpain in COVID-19 as a therapeutic strategy.	1
478	Genomic determinants of Furin cleavage in diverse European SARS-related bat coronaviruses. 2022 , 5,	2
477	Principles of SARS-CoV-2 Glycosylation. 2022 , 102402	0
476	Coronaviruses in Wild Animals Sampled in and Around Wuhan in the Beginning of COVID-19 Emergence.	0
475	Rise of the SARS-CoV-2 Variants: Can proteomics be the silver bullet?.	0
474	Analgesics Induce Alterations in the Expression of SARS-CoV-2 Entry and Arachidonic-Acid-Metabolizing Genes in the Mouse Lungs. 2022 , 15, 696	1
473	Preclinical Assessment of IgY Antibodies Against Recombinant SARS-CoV-2 RBD Protein for Prophylaxis and Post-Infection Treatment of COVID-19. 13,	2
472	Coronavirus pandemic. 2022 , 3-16	0
471	Pathogenesis and mutagenesis of SARS-CoV-2. 2022 , 81-99	
470	Drug repurposing for SARS-CoV-2 (COVID-19) treatment. 2022 , 205-226	
469	Surface Plasmon Resonance Biosensors Based on Kretschmann Configuration: Basic Instrumentation and Applications. 2022 , 191-222	
468	Editorial: Ecology and Evolution of Coronaviruses: Implications for Human Health. 10,	

467	In vitro study on efficacy of PHELA, an African traditional drug against SARS-CoV-2. 2022 , 12,	1
466	The Role of Soluble ACE2 as a Prognostic Marker in Severe COVID-19: A Brief Meta-Analysis. 2022 , 22,	0
465	Association of Statins for Primary Prevention of Cardiovascular Diseases With Hospitalization for COVID-19: A Nationwide Matched Population-Based Cohort Study. 2022 , 11,	0
464	Intronic regulation of SARS-CoV-2 receptor (ACE2) expression mediated by immune signaling and oxidative stress pathways. 2022 , 104614	0
463	Potential therapeutic effects of Ivermectin in COVID-19. 153537022210995	1
462	Porcine ANTXR1, Heparan Sulfate and Neu5Gc act as entry factors for Seneca Valley virus invasion.	0
461	Serotype I and II Feline Coronavirus Replication and Gene Expression Patterns of Feline Cells Building a Better Understanding of Serotype I FIPV Biology. 2022 , 14, 1356	0
460	Identification of critical genes and molecular pathways in COVID-19 myocarditis and constructing gene regulatory networks by bioinformatic analysis. 2022 , 17, e0269386	1
459	Development of an efficient reproducible cell-cell transmission assay for rapid quantification of SARS-CoV-2 Spike interaction with hACE2. 2022 , 100252	1
458	Posttranslational modifications optimize the ability of SARS-CoV-2 spike for effective interaction with host cell receptors. 2022 , 119,	2
457	Detection of SARS-CoV-2 infection in thyroid follicular cells from a COVID-19 autopsy series. 2022 ,	0
456	Computational Investigations of Traditional Chinese Medicinal Compounds against the Omicron Variant of SARS-CoV-2 to Rescue the Host Immune System. 2022 , 15, 741	0
455	A Bioinformatics Approach to Investigate Structural and Non-Structural Proteins in Human Coronaviruses. 13,	0
454	A map of bat virus receptors derived from single-cell multiomics. 2022 , 9,	0
453	SARS-CoV-2 infects an in vitro model of the human developing pancreas through endocytosis. 2022 , 104594	2
452	Covid-19 Delta Variant Resulting in Multi System Thromboembolic Disease. 2022 , 100101	0
451	Natural selection plays a significant role in governing the codon usage bias in the novel SARS-CoV-2 variants of concern (VOC). 10, e13562	0
450	Pathogen-sugar interactions revealed by universal saturation transfer analysis.	1

- 449 Methods of Protein Detection in Cancer for Diagnosis, Prognosis and Therapy.
- 448 Significant role of host sialylated glycans in the infection and spread of severe acute respiratory syndrome coronavirus 2. **2022**, 18, e1010590 2
- 447 MicroRNAs in the development of potential therapeutic targets against COVID-19: A narrative review. **2022**, 15, 788-799 2
- 446 Elevated serum midkine levels in severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) infected patients. **2022**, 110, 108939 0
- 445 A case of COVID-19 STEMI complicated by second: Degree heart block without pulmonary involvement. **2022**, 4, 33
- 444 Nanoparticle-based immunoassays for early and rapid detection of HIV and other viral infections. **2022**, 173-193
- 443 COVID-19 and the hidden threat of diabetic microvascular complications. **2022**, 13, 204201882211107 0
- 442 Natural products as a therapy to combat against SARS-CoV-2 virus infection. **2022**, 115-145
- 441 The Evolution of SARS-CoV-2. **2022**, 55-78
- 440 Thyroid Function During and After COVID-19 Infection: A Review. **2022**, 18, 58 2
- 439 Correlation between ABO blood group and coronavirus disease in 2019 (COVID-19) vulnerability. **2022**,
- 438 Mathematical Analysis of a COVID-19 Epidemic Model by Using Data Driven Epidemiological Parameters of Diseases Spread in India. **2022**, 67, 231-244 0
- 437 Landscape determinants of infectivity and insights into vaccine development and effectiveness □ Novel Coronavirus. **2022**, 19,
- 436 The spike glycoprotein of highly pathogenic human coronaviruses: structural insights for understanding infection, evolution and inhibition. 1
- 435 Antiparasitic Drugs against SARS-CoV-2: A Comprehensive Literature Survey. **2022**, 10, 1284 1
- 434 Development of a novel human CD147 knock-in NSG mouse model to test SARS-CoV-2 viral infection. **2022**, 12, 0
- 433 The Advances of Broad-Spectrum and Hot Anti-Coronavirus Drugs. **2022**, 10, 1294
- 432 SARS-CoV-2 cell entry beyond the ACE2 receptor. 1

431	Enzymes in the time of COVID-19: An overview about the effects in the human body, enzyme market, and perspectives for new drugs.	0
430	Immune Escape Mechanisms of SARS-CoV-2 Delta and Omicron Variants against Two Monoclonal Antibodies That Received Emergency Use Authorization. 2022 , 13, 6064-6073	2
429	Human ACE2 Polymorphisms from Different Human Populations Modulate SARS-CoV-2 Infection. 2022 , 14, 1451	0
428	Cytopathic SARS-CoV-2 screening on VERO-E6 cells in a large-scale repurposing effort. 2022 , 9,	2
427	Will Peptides Help to Stop COVID-19?. 2022 , 87, 590-604	1
426	Spike-mediated ACE2 down-regulation was involved in the pathogenesis of SARS-CoV-2 infection. 2022 ,	4
425	Human Air-Liquid-Interface Organotypic Airway Cultures Express Significantly More ACE2 Receptor Protein and Are More Susceptible to HCoV-NL63 Infection than Monolayer Cultures of Primary Respiratory Epithelial Cells.	1
424	Selection of Bis-Indolyl Pyridines and Triphenylamines as New Inhibitors of SARS-CoV-2 Cellular Entry by Modulating the Spike Protein/ACE2 Interfaces.	0
423	Creation of transgenic mice susceptible to coronaviruses: a platform for studying viral pathogenesis and testing vaccines. 2022 , 26, 402-408	
422	Multifaceted Computational Modeling in Glycoscience.	7
421	The Complexity in the Diagnosis and Treatment of Symptoms in Electronic Cigarette Users during the COVID-19 Pandemic. 2022 , 1, 49-63	
420	Manipulation of Spray-Drying Conditions to Develop an Inhalable Ivermectin Dry Powder. 2022 , 14, 1432	0
419	Animal models for COVID-19: advances, gaps and perspectives. 2022 , 7,	4
418	Goblet Cell Hyperplasia Increases SARS-CoV-2 Infection in Chronic Obstructive Pulmonary Disease.	1
417	Cryo-EM reveals mechanisms of angiotensin I-converting enzyme allostery and dimerization.	
416	Amino acid sensor GCN2 promotes SARS-CoV-2 receptor ACE2 expression in response to amino acid deprivation. 2022 , 5,	0
415	Identification of Cyanobacteria-Based Natural Inhibitors Against SARS-CoV-2 Druggable Target ACE2 Using Molecular Docking Study, ADME and Toxicity Analysis.	0
414	Painless Subacute Thyroiditis in a Patient With Acute COVID-19 Infection: A Transient Event. 2022 ,	0

413	Vitamin D and interferon- γ co-operate to increase the ACE-2 receptor expression in primary cultures of human thyroid cells.	1
412	All-Atom Simulations of Human ACE2-Spike Protein RBD Complexes for SARS-CoV-2 and Some of its Variants: Nature of Interactions and Free Energy Diagrams for Dissociation of the Protein Complexes.	2
411	Mechanisms of COVID-19 Pathogenesis in Diabetes.	3
410	Parametric Mapping Cardiac Magnetic Resonance Imaging for the Diagnosis of Myocarditis in Children in the Era of COVID-19 and MIS-C. 2022 , 9, 1061	0
409	Lineage-specific positive selection on ACE2 contributes to the genetic susceptibility of COVID-19.	
408	Sonographic findings of COVID-19 related acute scrotal infection and associations with clinical-laboratory data.	
407	Evaluation of the Effect of Biochemistry Parameters on the Clinical Course in COVID-19 Patients Who Received Tocilizumab Treatment. 2022 , 115, 435-440	
406	ACE2-binding exposes the SARS-CoV-2 fusion peptide to broadly neutralizing coronavirus antibodies.	4
405	The COVID-19 pandemic [How many times were we warned before?]. 2022 ,	1
404	Identification and quantification of bioactive compounds suppressing SARS-CoV-2 signals in wastewater-based epidemiology surveillance. 2022 , 221, 118824	0
403	Synthesis and structure-activity relationship study of saponin-based membrane fusion inhibitors against SARS-CoV-2. 2022 , 127, 105985	0
402	SARS-CoV-2 infection: Pathogenesis, Immune Responses, Diagnosis.	
401	Oral antiviral treatments for COVID-19: opportunities and challenges.	4
400	The First Geographic Identification by Country of Sustainable Mutations of SARS-COV2 Sequence Samples: Worldwide Natural Selection Trends.	0
399	Evaluation of SARS-CoV-2-Neutralizing Nanobody Using Virus Receptor Binding Domain-Administered Model Mice. 2022 , 2022, 1-14	1
398	The relationship between physical activity and severity of COVID-19 symptoms in non-hospitalized individuals.	
397	Kathryn V. Holmes: A Career of Contributions to the Coronavirus Field. 2022 , 14, 1573	
396	SARS-CoV -2 spike protein enhances MAP4K3 / GLK -induced ACE2 stability in COVID -19.	1

- 395 Expanded ACE2 dependencies of diverse SARS-like coronavirus receptor binding domains. **2022**, 20, e3001738 1
- 394 Bidirectional genome-wide CRISPR screens reveal host factors regulating SARS-CoV-2, MERS-CoV and seasonal HCoVs. 1
- 393 DNA-Vaccine-Induced Immune Response Correlates with Lower Viral SARS-CoV-2 Titers in a Ferret Model. **2022**, 10, 1178 1
- 392 Human coronaviruses: origin, host and receptor. **2022**, 105246 2
- 391 Inhaled therapy for COVID-19: Considerations of drugs, formulations and devices. **2022**, 624, 122042 1
- 390 Study on the potential of Sanghuangporus sanghuang and its components as COVID-19 spike protein receptor binding domain inhibitors. **2022**, 153, 113434 1
- 389 Insight into coronaviruses and natural products-based approach for COVID-19 treatment. **2022**, 443-469
- 388 Coronaviruses: Troubling Crown of the Animal Kingdom. **2022**, 0
- 387 Inflammatory Bowel Disease Management during the COVID-19 Pandemic: A Literature Review. **2022**, 14, 155-166 1
- 386 SMRI: A New Method for siRNA Design for COVID-19 Therapy. **2022**, 37, 991-1002
- 385 Peimine inhibits variants of SARS-CoV -2 cell entry via blocking the interaction between viral spike protein and ACE2. 0
- 384 MicroRNAs as Potential Tools for Predicting Cancer Patients' Susceptibility to SARS-CoV-2 Infection and Vaccination Response. **2022**, 11, 2279 0
- 383 The effect of ACE inhibitors and ARBs on outcomes in hospitalized patients with COVID-19.
- 382 Effectiveness of SARS-CoV-2 Vaccines for Short- and Long-Term Immunity: A General Overview for the Pandemic Contrast. **2022**, 23, 8485 1
- 381 Two point mutations in protocadherin-1 disrupt Andes hantavirus recognition and afford protection against lethal infection.
- 380 SARS-CoV-2 infection threatening intestinal health: A review of potential mechanisms and treatment strategies. 1-19 1
- 379 Structural and Dynamic Insights into SARS-CoV-2 Spike-Protein/Montmorillonite Interactions. **2022**, 38, 9186-9194
- 378 Exercise-induced myokines downregulates the ACE2 level in bronchial epithelial cells: Implications for SARS-CoV-2 prevention. **2022**, 17, e0271303 0

- 377 An Update on Promising Agents against COVID-19: Secondary Metabolites and Mechanistic Aspects. **2022**, 28, 1
- 376 ACE2-like enzyme B38-CAP suppresses abdominal sepsis and severe acute lung injury. **2022**, 17, e0270920
- 375 IS COVID 19 PANDEMIC ADDING MORE OF DIABETIC POPULATION: A STUDY IN CENTRAL INDIA. **2022**, 63-65
- 374 Predictive Value of Systemic Immune-inflammation Index in Determining Mortality in COVID-19 Patients. **2022**, 8, 156-164 0
- 373 Inflammatory pathways in COVID-19: Mechanism and therapeutic interventions. **2022**, 3, 2
- 372 COVID-19 and inflammatory bowel disease crosstalk: From emerging association to clinical proposal. 0
- 371 Risk factors of kidney injury in patients with COVID-19. **2022**, 94, 743-747 1
- 370 An evaluation of the 2019 novel coronavirus (COVID-19) disease. **2022**, 4, 90-97
- 369 Elevated Levels of Soluble CD147 are Associated with Hyperinflammation and Disease Severity in COVID-19: A Proof-of-Concept Clinical Study. **2022**, 70, 1
- 368 COVID-19 and Pregnancy: Clinical outcomes; Mechanisms, and Vaccine Efficacy. **2022**, 1
- 367 Coenzyme Q10 + alpha lipoic acid for chronic COVID syndrome. 1
- 366 A Bispecific Antibody Targeting RBD and S2 Potently Neutralizes SARS-CoV-2 Omicron and Other Variants of Concern. **2022**, 96, 2
- 365 Subversion of autophagy machinery and organelle-specific autophagy by SARS-CoV-2 and coronaviruses. 0
- 364 Human anti-ACE2 monoclonal antibodies as pan-sarbecovirus prophylactic agents. 1
- 363 CRISPR-Cas system: from diagnostic tool to potential antiviral treatment. 0
- 362 We looked at gut from both sides now: Gastrointestinal tract involvement in the pathogenesis of SARS-CoV-2 and HIV/SIV infections. 13, 0
- 361 Lessons from SARS-CoV, MERS-CoV, and SARS-CoV-2 Infections: What We Know So Far. **2022**, 2022, 1-13 1
- 360 Recombinant Decoy Exhibits Broad Protection against Omicron and Resistance Potential to Future Variants. **2022**, 15, 1002 0

- 359 Genomics and pathogenesis of the avian coronavirus infectious bronchitis virus. 0
- 358 IDentif.AI-Omicron: Harnessing an AI-Derived and Disease-Agnostic Platform to Pinpoint Combinatorial Therapies for Clinically Actionable Anti-SARS-CoV-2 Intervention. 1
- 357 In vitro high-content tissue models to address precision medicine challenges. **2022**, 101108
- 356 COVID-19 Ğ Tanıř-Olan Ğocuk Hastaların Klinik Ğzellikleri ile Tedavi SonuĞlarını DeĞerlendirilmesi. 0
- 355 Blockade of TMPRSS2-mediated priming of SARS-CoV-2 by lactoferricin. 13, 2
- 354 Screening of cell-virus, cell-cell, gene-gene crosstalk among animal kingdom at single cell resolution. **2022**, 12, 0
- 353 Extensive Nonsegmental Pulmonary Perfusion Defects on SPECT/CT as an Early Sign of COVID-19 Infection. 0
- 352 A humanized nanobody phage display library yields potent binders of SARS CoV-2 spike. **2022**, 17, e0272364 0
- 351 Independent acquisition of short insertions at the R1R1 site in the spike N-terminal domain of the SARS-CoV-2 BA.2 lineage. 0
- 350 Modeling SARS-CoV-2 and influenza infections and antiviral treatments in human lung epithelial tissue equivalents. **2022**, 5, 0
- 349 Are Ambulatory ACE Inhibitors/Angiotensin Receptor Blockers Associated with Reduced SARS-CoV-2 Infections and Improved Outcomes, and Does Race Matter?. 0
- 348 Two Years into the COVID-19 Pandemic: Lessons Learned. 4
- 347 Development of a novel peptide to prevent entry of SARS-CoV-2 into lung and olfactory bulb cells of hACE2 expressing mice. **2022**, 15, 0
- 346 Sialic Acid and Fucose Residues on the SARS-CoV-2 Receptor-Binding Domain Modulate IgG Antibody Reactivity. 0
- 345 CD98 is critical for a conserved inflammatory response to diverse injury stimuli relevant to IPF exacerbations and COVID pneumonitis. 0
- 344 Small Molecules Targeting SARS-CoV-2 Spike Glycoprotein Receptor-Binding Domain. **2022**, 7, 28779-28789 1
- 343 A systematic review assessing the effectiveness of COVID-19 mRNA vaccines in chronic kidney disease (CKD) individuals. 11, 909 0
- 342 Increased TRIM31 gene expression is positively correlated with SARS-CoV-2 associated genes TMPRSS2 and TMPRSS4 in gastrointestinal cancers. **2022**, 12, 1

341	Vaccine-associated enhanced disease in humans and animal models: Lessons and challenges for vaccine development. 13,	2
340	Multivalent ACE2 engineering: A promising pathway for advanced coronavirus nanomedicine development. 2022 , 46, 101580	1
339	Consequences of COVID-19 on the cardiovascular and renal systems. 2022 , 100, 31-38	0
338	Research progress of biosensors for detection of SARS-CoV-2 variants based on ACE2. 2023 , 251, 123813	0
337	SARS-CoV-2 hijacks macropinocytosis to facilitate its entry and promote viral spike-mediated cell-to-cell fusion. 2022 , 102511	1
336	Kinase-independent activity of DYRK1A promotes viral entry of highly pathogenic human coronaviruses.	0
335	ACE2 in SARS-CoV-2-Mediated COVID-19: A Brief Review. 2022 , 2,	0
334	Photochemical Identification of Auxiliary Severe Acute Respiratory Syndrome Coronavirus 2 Host Entry Factors Using Map. 2022 , 144, 16604-16611	0
333	Quantum chemical studies on the binding domain of SARS-CoV-2 S-protein: human ACE2 interface complex. 1-11	0
332	Plasma Angiotensin Converting Enzyme 2 (ACE2) Activity in Healthy Controls and Patients with Cardiovascular Risk Factors and/or Disease. 2022 , 12, 1495	0
331	Analysis of transcriptomic responses to SARS-CoV-2 reveals plausible defective pathways responsible for increased susceptibility to infection and complications and helps to develop fast-track repositioning of drugs against COVID-19. 2022 , 149, 106029	1
330	Global distribution of ACE1 (rs4646994) and ACE2 (rs2285666) polymorphisms associated with COVID-19: A systematic review and meta-analysis. 2022 , 172, 105781	1
329	Integrating in silico and in vivo approach for investigating the role of polyherbal oil in prevention and treatment of COVID-19 infection. 2022 , 367, 110179	1
328	Pulmonary drug delivery applications of natural polysaccharide polymer derived nano/micro-carrier systems: A review. 2022 , 220, 1464-1479	1
327	Single domain antibodies derived from ancient animals as broadly neutralizing agents for SARS-CoV-2 and other coronaviruses. 2022 , 4, 100054	0
326	Mechanism of action of drugs used in hypertension. 2023 , 349-367	0
325	COVID-19 in Bangladesh: An Exploratory Data Analysis and Prediction of Neurological Syndrome Using Machine Learning Algorithms Based on Comorbidity. 2022 , 595-608	0
324	Current clinical testing approach of COVID. 2022 , 231-274	0

323	Signaling pathways implicated in SARS-CoV-2 infection. 2022 , 23-49	0
322	Research progress on etiology and pathogenesis of MERS-CoV and SARS-CoV. 2022 ,	0
321	Central serous chorioretinopathy in coronavirus disease-19 patient. 2022 , 10, 85	0
320	Viral Infections and the Kidney. 2022 , 707-733	0
319	A study to identify severe acute respiratory syndrome coronavirus 2 in erythrocytes of patients suffering from coronavirus disease-19 at an Apex tertiary care institute in Andhra Pradesh, South India. 2022 , 0	0
318	Serum Angiotensin II as a Biomarker in COVID-19. 2022 , 1-24	0
317	Brief Pathophysiology. 2022 , 177-189	0
316	SARS-CoV-2 genome sequencing and promising druggable targets. 2022 , 3-22	1
315	Gut Microbiome, COVID-19, and Neurological Impairment. 2022 , 235-251	0
314	Will New Variants Emerge after Delta and Omicron?. 2022 , 13, 1317	0
313	Analytical performances of different diagnostic methods for SARS-CoV-2 virus - A review. 2022 , 3, 100197	1
312	SARS-CoV-2 Invasion and Pathogenesis of COVID-19: A Perspective of Viral Receptors, Bradykinin, and Purinergic System. 2022 , 31-48	0
311	Difficulties in diagnosis of SARS-CoV-2 myocarditis in an adolescent. 2022 , 152,	0
310	Mechanisms of the Traditional Chinese Herb <i>Atractylodes lancea</i> against COVID-19 Based on Network Pharmacology and Molecular Docking. 2022 , 27, 349-360	0
309	Human ACE-2, MCP1 and micro-RNA 146 as Novel Markers for COVID- 19 Affection and Severity. 2022 , 22,	0
308	SARS-CoV-2 and HIV: Impact on Pulmonary Epithelial Cells. 2022 , 12, 1317	0
307	Succint review on biological and clinical aspects of Coronavirus disease 2019 (COVID-19). 2022 , 125, 356-365	0
306	New insights into human immune memory from SARS-CoV -2 infection and vaccination.	1

- 305 Dissecting the role of the human microbiome in COVID-19 via metagenome-assembled genomes. **2022**, 13, 3
- 304 The Management of Myocardial Injury Related to SARS-CoV-2 Pneumonia. **2022**, 9, 307 0
- 303 Acquired agitation in acute respiratory distress syndrome with COVID-19 compared to influenza patients: a propensity score matching observational study. **2022**, 19, 0
- 302 Written Briefing and Oral Counseling Increase the Willingness to Receive the SARS-CoV-2 Vaccination among Women in Puerperium: A Qualitative Prospective Cohort Study. **2022**, 10, 1505 0
- 301 Molecular Mechanism of the Non-Covalent Orally Targeted SARS-CoV-2 Mpro Inhibitor S-217622 and Computational Assessment of Its Effectiveness against Mainstream Variants. **2022**, 13, 8893-8901 1
- 300 Therapeutic Approaches in COVID-19 Patients: The Role of the Renin-Angiotensin System. **2022**, 2022, 1-10 1
- 299 Is Diminazene an Angiotensin-Converting Enzyme 2 (ACE2) Activator? Experimental Evidence and Implications. **2022**, 383, 149-156 0
- 298 Intravenous Ascorbic Acid and Lung Function in Severely Ill COVID-19 Patients. **2022**, 12, 865 0
- 297 Zinc and COVID-19: Immunity, Susceptibility, Severity and Intervention. 1-19 0
- 296 Evidence for multiple binding modes in the initial contact between SARS-CoV-2 spike S1 protein and cell surface glycans. 0
- 295 Determinants restricting ACE2 recognition of MERS-related coronaviruses in bats. 0
- 294 A linear SARS-CoV-2 DNA vaccine candidate reduces virus shedding in ferrets. 0
- 293 Clomipramine inhibits dynamin GTPase activity by L- α -phosphatidyl-L-serine stimulation. 0
- 292 Isolation of a human SARS-CoV-2 neutralizing antibody from a synthetic phage library and its conversion to fluorescent biosensors. **2022**, 12, 1 1
- 291 A comparative study of receptor interactions between SARS-CoV and SARS-CoV-2 from molecular modeling. **2022**, 28, 0
- 290 Microbiological and Clinical Findings of SARS-CoV-2 Infection after 2 Years of Pandemic: From Lung to Gut Microbiota. **2022**, 12, 2143 2
- 289 Immune responses to SARS-CoV-2 infection and COVID-19 vaccines. **2022**, 2, 648-664 0
- 288 Structural perspective of the interactions of ACE2 and SARS CoV-2 Spike protein RBD. 0

287	Immunomolecular assay based on selective virion capture by spike antibody and viral nucleic acid amplification for detecting intact SARS-CoV-2 particles. 2022 , 20,	0
286	Acute kidney injury and electrolyte disorders in COVID-19. 11, 283-292	0
285	Discovery of the Cryptic Sites of SARS-CoV-2 Papain-like Protease and Analysis of Its Druggability. 2022 , 23, 11265	0
284	OX40 agonist stimulation increases and sustains humoral and cell-mediated responses to SARS-CoV-2 protein and saRNA vaccines. 13,	0
283	Targeted protein S-nitrosylation of ACE2 inhibits SARS-CoV-2 infection.	1
282	Hydroxychloroquine blocks SARS-CoV-2 entry into the endocytic pathway in mammalian cell culture. 2022 , 5,	0
281	Predictive Factors of Renal Failure in Covid 19 Patients at the Anti-covid Center in Lome, Togo.	0
280	Suppression of ACE2 SUMOylation protects against SARS-CoV-2 infection through TOLLIP-mediated selective autophagy. 2022 , 13,	2
279	The COVID-19 pandemic and Alzheimer's disease: mutual risks and mechanisms. 2022 , 11,	2
278	Identification of immunomodulatory drugs that inhibit multiple inflammasomes and impair SARS-CoV-2 infection. 2022 , 8,	1
277	Immunology to Immunotherapeutics of SARS-CoV-2: Identification of Immunogenic Epitopes for Vaccine Development. 2022 , 79,	0
276	Host cell membrane proteins located near SARS-CoV-2 spike protein attachment sites are identified using proximity labeling and proteomic analysis. 2022 , 102500	0
275	Anti-SARS-CoV-2 immunoadhesin remains effective against Omicron and other emerging variants of concern. 2022 , 105193	1
274	Evaluation of Serum Electrolyte Balance in Pediatric Patients Diagnosed with COVID-19. 2022 , 10, 49-53	0
273	Sequence difference of angiotensin-converting enzyme 2 between nonhuman primates affects its binding-affinity with SARS-CoV-2 S receptor binding domain. 2022 ,	0
272	Tetraspanin-enriched Microdomain Containing CD151, CD9, and TSPAN 8 [Potential Mediators of Entry and Exit Mechanisms in Respiratory Viruses Including SARS-CoV-2. 2022 , 28,	0
271	Development of variant-proof severe acute respiratory syndrome coronavirus 2, pan-sarbecovirus, and pan- β coronavirus vaccines.	1
270	ACE2 and LOX Enzyme Inhibitions of Different Lavender Essential Oils and Major Components Linalool and Camphor.	3

- 269 Biparatopic nanobodies targeting the receptor binding domain efficiently neutralise SARS-CoV-2. **2022**, 105259 0
- 268 Chemoreactome analysis of natural and synthetic statins indicates a more favorable safety profile of monacolin K. **2022**, 74-85 0
- 267 The human disease gene LYSET is essential for lysosomal enzyme transport and viral infection. **2022**, 378, 4
- 266 Diarrheal syndrome in SARS CoV2 infection. **2021**, 70, 87-90 0
- 265 Identification of SARS-CoV-2 spike protein inhibitors from urtica dioica to develop herbal-based therapeutics against COVID-19. **2022**, 0 0
- 264 Comorbidity between lung cancer and COVID-19 pneumonia: role of immunoregulatory gene transcripts in high ACE2-expressing normal lung. **2022**, 14, 175883592211338 0
- 263 Regulation of Lysosomal Associated Membrane Protein 3 (LAMP3) in Lung Epithelial Cells by Coronaviruses (SARS-CoV-1/2) and Type I Interferon Signaling. **2022**, 10, 167-183 0
- 262 Covid-19'un neden olduđı duyuşal kayıpların yađım kalitesi üzerine ilişileri. 0
- 261 SARS-CoV-2 cellular tropism and direct multiorgan failure in COVID-19 patients: Bioinformatic predictions, experimental observations, and open questions. 0
- 260 Does Prophylactic Oral Zinc Reduce the Risk of Contracting COVID-19?. **2022**, 0
- 259 Cell Entry and Unusual Replication of SARS-CoV2. **2022**, 24, 0
- 258 Discovery of putative inhibitors against main drivers of SARS-CoV-2 infection: Insight from quantum mechanical evaluation and molecular modeling. 10, 0
- 257 Variants of Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2) and Vaccine Effectiveness. **2022**, 10, 1751 0
- 256 Molecular Mechanisms Underlying Twin-to-Twin Transfusion Syndrome. **2022**, 11, 3268 0
- 255 Exploring the targets of novel corona virus and docking-based screening of potential natural inhibitors to combat COVID-19. **2022**, 23, 1
- 254 SARS-CoV-2 tetrameric RBD protein blocks viral infection and induces potent neutralizing antibody response. 13, 0
- 253 Association of Clinical Features with Spike Glycoprotein Mutations in Iranian COVID-19 Patients. **2022**, 11, 6315 0
- 252 SARS-CoV-2 downregulates ACE2 through lysosomal degradation. 1

251	The potential of heparin-induced extracorporeal LDL/fibrinogen precipitation (H.E.L.P.)-apheresis for patients with severe acute or chronic COVID-19. 9,	0
250	Comprehensive Review of Pulmonary Hypertension and Treatment Options in the Paediatric Population. 2022,	0
249	Evidence of a Sjögren disease-like phenotype following COVID-19.	0
248	Study of HLA class II loci reveals DQB1*03:03:02 as a risk factor for asthma in a Pakistani population.	0
247	Pharmacologic therapies of ARDS: From natural herb to nanomedicine. 13,	0
246	After the Storm: Regeneration, Repair, and Reestablishment of Homeostasis Between the Alveolar Epithelium and Innate Immune System Following Viral Lung Injury. 2023, 18,	0
245	The impact of COVID-19 monoclonal antibodies on clinical outcomes: A retrospective cohort study.	1
244	Acute Myocardial Infarction Complicating Coronavirus Infection (Case Report). 2022, 18, 18-23	0
243	COVID-19 and the Kidney: Recent Advances and Controversies. 2022,	0
242	Structural basis for mouse receptor recognition by SARS-CoV-2 omicron variant. 2022, 119,	2
241	LRRC15 inhibits SARS-CoV-2 cellular entry in trans. 2022, 20, e3001805	1
240	The Challenge of Long COVID-19 Management: From Disease Molecular Hallmarks to the Proposal of Exercise as Therapy. 2022, 23, 12311	1
239	An IgM-like Inhalable ACE2 fusion protein broadly neutralizes SARS-CoV-2.	0
238	On the essentiality of the angiotensin converting enzyme 2 receptor for SARS-CoV-2 infection and the potential of soluble angiotensin converting enzyme 2 proteins as universal approach for variants causing COVID-19. 2022, 12,	1
237	Vimentin is an important ACE2 co-receptor for SARS-CoV-2 in epithelial cells. 2022, 105463	1
236	New-Onset Diabetes Mellitus, Hypertension, Dyslipidaemia as Sequelae of COVID-19 Infection Systematic Review. 2022, 19, 13280	1
235	A Bitter Experience That Enlightens the Future: COVID-19 Neurological Affection and Perspectives on the Orexigenic System. 2022,	0
234	Pharmacological therapies and drug development targeting SARS-CoV-2 infection. 2022,	0

233	Prevalence and associated factors of COVID-19 among Moroccan physicians: A cross-sectional study. 2022 , 17, e0277157	0
232	Impact of TMPRSS2 Expression, Mutation Prognostics, and Small Molecule (CD, AD, TQ, and TQFL12) Inhibition on Pan-Cancer Tumors and Susceptibility to SARS-CoV-2. 2022 , 27, 7413	1
231	Identification and differential usage of a host metalloproteinase entry pathway by SARS-CoV-2 Delta and Omicron. 2022 , 25, 105316	2
230	Porcine Epidemic Diarrhea Virus: An Updated Overview of Virus Epidemiology, Virulence Variation Patterns and Virus-Host Interactions. 2022 , 14, 2434	4
229	A peptide array pipeline for the development of Spike-ACE2 interaction inhibitors. 2022 , 158, 170898	1
228	Integrated computational approach towards identification of HSPG and ACE2 mimicking moieties for SARS-CoV-2 inhibition. 2022 , 367, 120566	0
227	Polyenes and SARS-CoV-2. 2023 , 445-462	0
226	Severe acute respiratory syndrome (SARS). 2023 , 53-124	0
225	Antiviral biomaterials. 2023 , 519-536	0
224	Mutations in SARS-CoV-2: Insights on structure, variants, vaccines, and biomedical interventions. 2023 , 157, 113977	2
223	Molecular Docking and Dynamics Simulation Studies of Ginsenosides with SARS-CoV-2 Host and Viral Entry Protein Targets. 2022 , 17, 1934578X2211343	0
222	Multimeric ACE2-IgM fusions as broadly active antivirals that potently neutralize SARS-CoV-2 variants. 2022 , 5,	0
221	Mechanistic studies of MALAT1 in respiratory diseases. 9,	1
220	Neurotropic SARS-CoV-2: Causalities and Realities.	0
219	Efficient SARS-CoV-2 detection utilizing chitin-immobilized nanobodies synthesized in <i>Ustilago maydis</i> .	0
218	Biosensors based detection of novel biomarkers associated with COVID-19: Current progress and future promise. 2022 , 100281	1
217	Correlation between structural heart disease and cardiac SARS-CoV-2 manifestations. 2022 , 2,	1
216	High Plasma Levels of Activated Factor VII-Antithrombin Complex Point to Increased Tissue Factor Expression in Patients with SARS-CoV-2 Pneumonia: A Potential Link with COVID-19 Prothrombotic Diathesis. 2022 , 12, 2792	1

215	Vascular dysfunction in COVID-19 patients: update on SARS-CoV-2 infection of endothelial cells and the role of long non-coding RNAs. 2022 , 136, 1571-1590	○
214	Primary hypertension, anti-hypertensive medications and the risk of severe COVID-19 in UK Biobank. 2022 , 17, e0276781	○
213	The Increased Amyloidogenicity of Spike RBD and pH-Dependent Binding to ACE2 May Contribute to the Transmissibility and Pathogenic Properties of SARS-CoV-2 Omicron as Suggested by In Silico Study. 2022 , 23, 13502	○
212	Novel CYP11A1-Derived Vitamin D and Lumisterol Biometabolites for the Management of COVID-19. 2022 , 14, 4779	1
211	Micro-second Time-resolved X-ray Single-molecule Internal Motions of SARS-CoV-2 Spike Variants.	○
210	Lung Fibrosis: Post-COVID-19 Complications and Evidences. 2022 , 109418	○
209	Whole exome sequencing identifies a rare variant in MAS1 gene in a subject with lethal COVID-19. 2022 , 29, 101705	○
208	A receptor-binding domain-based nanoparticle vaccine elicits durable neutralizing antibody responses against SARS-CoV-2 and variants of concern. 1-45	○
207	Is the prognosis of non-hypertensive, COVID-19 patients treated with renin-angiotensin-aldosterone system inhibitors more uncertain?. 2022 , 10,	○
206	Green and Regioselective Approach for the Synthesis of 3-Substituted Indole Based 1,2-Dihydropyridine and Azaxanthone Derivatives as a Potential Lead for SARS-CoV-2 and Delta Plus Mutant Virus: DFT and Docking Studies.	○
205	Molecular dynamics study on the strengthening behavior of Delta and Omicron SARS-CoV-2 spike RBD improved receptor-binding affinity. 2022 , 17, e0277745	○
204	Running ahead of evolution - AI based simulation for predicting future high-risk SARS-CoV-2 variants.	○
203	Human Coronaviruses. 2023 , 1167-1175.e6	○
202	Rapid discovery and classification of inhibitors of coronavirus infection by pseudovirus screen and amplified luminescence proximity homogeneous assay. 2023 , 209, 105473	○
201	Immunity and Therapeutic Approaches against Coronavirus Disease 2019. 2022 , 13, 105-111	○
200	Omicron, a New Variant of Severe Acute Respiratory Syndrome Coronavirus-2 Virus: Global Upsurge, Devastation, and Future Prospect. 2022 , 6, 594	○
199	Identification of an immunogenic epitope and protective antibody against the furin cleavage site of SARS-CoV-2. 2023 , 87, 104401	○
198	Can the triumph of mRNA vaccines against COVID-19 be extended to other viral infections of humans and domesticated animals?. 2023 , 25, 105078	○

- 197 Phenothiazines inhibit SARS-CoV-2 cell entry via a blockade of spike protein binding to neuropilin-1. **2023**, 209, 105481 1
- 196 Counter-regulatory renin-angiotensin system in hypertension: Review and update in the era of COVID-19 pandemic. **2023**, 208, 115370 0
- 195 Peptide-based direct electrochemical detection of receptor binding domains of SARS-CoV-2 spike protein in pristine samples. **2023**, 377, 133052 0
- 194 COVID-19 and Acute Kidney Injury [Direct and Indirect Pathophysiological Mechanisms Underlying Lesion Development. **2022**, 94, 0
- 193 Different drug approaches to COVID-19 treatment worldwide: an update of new drugs and drugs repositioning to fight against the novel coronavirus. **2022**, 10, 251513552211448 0
- 192 Molecular Modeling Targeting the ACE2 Receptor with Cannabis sativa's Active Ingredients for Antiviral Drug Discovery against SARS-CoV-2 Infections. **2022**, 16, 117793222211453 1
- 191 Role of mRAGEs and ACE2 in SARS-CoV-2-Related Inflammation. **2022**, 16, 2-4 0
- 190 Correlation between Corona Viruses Disease (Covid-19) and C-Reactive Protein (CRP) in Patients at Haji Hospital Surabaya. **2022**, 5, 11-16 0
- 189 The expression profile of 79 genes from 107 viruses revealed new insights into disease susceptibility in rats, mice and muskrats. 0
- 188 An update on angiotensin-converting enzyme 2 structure/functions, polymorphism, and duplicitous nature in the pathophysiology of coronavirus disease 2019: Implications for vascular and coagulation disease associated with severe acute respiratory syndrome coronavirus infection. 13, 0
- 187 An overview of viral mutagenesis and the impact on pathogenesis of SARS-CoV-2 variants. 13, 1
- 186 Airway Epithelial Cell Junctions as Targets for Pathogens and Antimicrobial Therapy. **2022**, 14, 2619 0
- 185 A multi-reference poly-conformational method for in silico design, optimization, and repositioning of pharmaceutical compounds illustrated for selected SARS-CoV-2 ligands. 10, e14252 0
- 184 The Role of Host Cell Glycans on Virus Infectivity: The SARS-CoV-2 Case. 2201853 0
- 183 130th anniversary of virology. **2022**, 67, 357-384 0
- 182 Assessment of SARS-CoV-2 entry in gingival epithelial cells expressing CD147. 0
- 181 COVID-19-induced liver injury in adult patients: A brief overview. 11, 443-452 0
- 180 Targeted photodynamic neutralization of SARS-CoV-2 mediated by singlet oxygen. 0

- 179 A systematic review assessing the effectiveness of COVID-19 mRNA vaccines in chronic kidney disease (CKD) individuals. 11, 909 ○
- 178 Illness Risk Perceptions and Efficacy Beliefs Among Indonesian in the Course of COVID-19 Pandemic. **2022**, 5, 396-405 ○
- 177 Behavioral and Dietary Habits That Could Influence Both COVID-19 and Non-Communicable Civilization Disease Prevention What Have We Learned Up to Now?. **2022**, 58, 1686 1
- 176 Potential core genes associated with COVID-19 identified via weighted gene co-expression network analysis. **2022**, 152, 40033 ○
- 175 Nanomaterials to combat SARS-CoV-2: Strategies to prevent, diagnose and treat COVID-19. 10, ○
- 174 SARS-CoV-2 Spike triggers barrier dysfunction and vascular leak via integrins and TGF- β signaling. **2022**, 13, ○
- 173 Label-Free Analysis of Binding and Inhibition of SARS-Cov-19 Spike Proteins to ACE2 Receptor with ACE2-Derived Peptides by Surface Plasmon Resonance. ○
- 172 Liver injury in COVID-19: Holds ferritinophagy-mediated ferroptosis accountable. 10, 13148-13156 ○
- 171 Thermophilic Filamentous Fungus C1-Cell-Cloned SARS-CoV-2-Spike-RBD-Subunit-Vaccine Adjuvanted with Aldhydrogelfi 85 Protects K18-hACE2 Mice against Lethal Virus Challenge. **2022**, 10, 2119 ○
- 170 Development of a robust and convenient dual-reporter high-throughput screening assay for SARS-CoV-2 antiviral drug discovery. **2022**, 105506 ○
- 169 Perspective on the Application of Erythrocyte Liposome-Based Drug Delivery for Infectious Diseases. **2022**, 12, 1226 ○
- 168 The Significance of COVID-19 Diseases in Lipid Metabolism Pregnancy Women and Newborns. **2022**, 23, 15098 ○
- 167 Hydroxychloroquine Mitigates Dilated Cardiomyopathy Phenotype in Transgenic D94A Mice. **2022**, 23, 15589 ○
- 166 Structure of the divergent human astrovirus MLB capsid spike. **2022**, 30, 1573-1581.e3 ○
- 165 Genome-Wide CRISPR/Cas9 Screen Reveals a Role for SLC35A1 in the Adsorption of Porcine Deltacoronavirus. **2022**, 96, ○
- 164 The alternative renin-angiotensin-system (RAS) signalling pathway in prostate cancer and its link to the current COVID-19 pandemic. ○
- 163 Investigating the relationship between arterial blood gases, acid-base disorders, and outcomes in patients with covid-19. ○
- 162 Host-Cell Surface Binding Targets in SARS-CoV-2 for Drug Design. **2022**, 28, 3583-3591 1

161	Interactions of angiotensin-converting enzyme-2 (ACE2) and SARS-CoV-2 spike receptor-binding domain (RBD): a structural perspective.	0
160	COVID-19 Associated Autoimmunity: Are Autoantibodies Neglected?	0
159	Discovery of novel spike/ACE2 inhibitory macrocycles using in silico reinforcement learning. 2,	0
158	Nsp1 proteins of human coronaviruses HCoV-OC43 and SARS-CoV2 inhibit stress granule formation. 2022 , 18, e1011041	0
157	ACE2 polymorphisms impact COVID-19 severity in obese patients. 2022 , 12,	2
156	Strategies to capitalize on cell spheroid therapeutic potential for tissue repair and disease modeling. 2022 , 7,	2
155	SARS-CoV-2 spike protein variant binding affinity to an angiotensin-converting enzyme 2 fusion glycoproteins. 2022 , 17, e0278294	0
154	What do we know about the renin angiotensin system and inflammatory bowel disease?. 1-13	0
153	Close relatives of MERS-CoV in bats use ACE2 as their functional receptors. 2022 , 612, 748-757	3
152	An Escherichia coli Expressed Multi-Disulfide Bonded SARS-CoV-2 RBD Shows Native-like Biophysical Properties and Elicits Neutralizing Antisera in a Mouse Model. 2022 , 23, 15744	0
151	COVID-19 and pathology of cerebral circulation. 2022 , 17-22	0
150	An oral vaccine for SARS-CoV-2 RBD mRNA-bovine milk-derived exosomes induces a neutralizing antibody response in vivo.	0
149	In Vitro Screening and MD Simulations of Thiourea Derivatives against SARS-CoV-2 in Association with Multidrug Resistance ABCB1 Transporter. 2022 , 7, 47671-47679	0
148	Angiotensin-converting enzyme 2 in human plasma and lung tissue. 2023 , 32, 6-15	0
147	Thermodynamic analysis of the interactions between human ACE2 and spike RBD of Betacoronaviruses (SARS-CoV -1 and SARS-CoV -2).	0
146	Intestinal Fatty Acid Binding Protein (I-FABP) as a Prognostic Marker in Critically Ill COVID-19 Patients. 2022 , 11, 1526	0
145	Molecular mechanisms implicated in SARS-CoV-2 liver tropism. 28, 6875-6887	0
144	Targeting SARS-CoV-2 and host cell receptor interactions. 2022 , 105514	0

- 143 The Renin Angiotensin System at the Time of COVID-19. **2023**, 145-156 0
- 142 Angiotensin-Converting Enzyme (ACE) Inhibitors May Moderate COVID-19 Hyperinflammatory Response: An Observational Study with Deep Immunophenotyping. **2022**, 2022, 1
- 141 COVID-19: Has the Liver Been Spared?. **2023**, 24, 1091 1
- 140 Mutational analysis of the spike protein of SARS-COV-2 isolates revealed atomistic features responsible for higher binding and infectivity. 10, 0
- 139 GuillainBarré syndrome associated with COVID-19: A systematic review. **2023**, 100578 0
- 138 Does SARS-CoV-2 Affect Human Semen? A Systematic Review and Meta-Analysis. 0
- 137 Emerging Role of ACE-2 in Cerebrovascular and Neurological Disorders: Lessons Learnt from COVID-19. **2023**, 431-447 0
- 136 Endothelial dysfunction in patients with COVID-19 is a key mechanism for the development of complications. **2023**, 19, 37-44 0
- 135 6-Shogaol Exhibits Anti-viral and Anti-inflammatory Activity in COVID-19-Associated Inflammation by Regulating NLRP3 Inflammasomes. **2023**, 8, 2618-2628 1
- 134 Urtica dioica agglutinin (UDA) as a potential candidate for inhibition of SARS-CoV-2 Omicron variants: In silico prediction and experimental validation. **2023**, 154648 0
- 133 In Vitro Antiviral Evaluations of Coldmixfi : An Essential Oil Blend against SARS-CoV-2. **2023**, 45, 677-684 0
- 132 Toxicity and therapeutic applications of citrus essential oils (CEOs): a review. **2023**, 26, 301-326 2
- 131 The oral manifestations and related mechanisms of COVID-19 caused by SARS-CoV-2 infection. 16, 0
- 130 Advancement in COVID-19 detection using nanomaterial-based biosensors. 20210232 0
- 129 Bionics design of affinity peptide inhibitors for SARS-CoV-2 RBD to block SARS-CoV-2 RBD-ACE2 interactions. **2023**, e12890 0
- 128 SUDDEN SENSORINEURAL HEARING LOSS FOLLOWING mRNA COVID-19 VACCINATION AND SAFETY SIGNAL GENERATION: NATIONAL CROSS-SECTIONAL AUDIOGRAM-BASED STUDY (Preprint). 0
- 127 Pharmacologic Therapeutics for COVID-19. **2023**, 290-318 0
- 126 Immunomodulation in COVID-19. **2023**, 7, 151-153 0

- 125 Omicron: Mystery, history, and impact on existence. **2023**, 323-326 0
- 124 Non-pulmonary involvement in COVID-19: A systemic disease rather than a pure respiratory infection. **11**, 493-505 1
- 123 Transmissible Gastroenteritis Virus: An Update Review and Perspective. **2023**, 15, 359 2
- 122 A retrospective study on prevalence and profile of reverse transcriptase polymerase chain reaction positive severe acute respiratory syndrome corona virus 2 samples tested in a tertiary care hospital, South India. **2023**, 0 0
- 121 Is N-acetylcysteine effective in treating patients with coronavirus disease 2019? A meta-analysis. Publish Ahead of Print, 0
- 120 COVID-19: The Ethno-Geographic Perspective of Differential Immunity. **2023**, 11, 319 0
- 119 Virtual Screening-Based Peptides Targeting Spike Protein to Inhibit Porcine Epidemic Diarrhea Virus (PEDV) Infection. **2023**, 15, 381 0
- 118 Coronavirus Pandemics. **2023**, 143-222 0
- 117 Unveiling the prevalence and impact of diabetes on COVID-19. **2023**, 287-301 0
- 116 Primary factors that determine the severity of various infections and effective nutraceutical intervention strategies. **2023**, 63-72 0
- 115 Applications of genetic engineering in COVID-19. **2023**, 219-237 0
- 114 A SARS-CoV-2-Related Virus from Malayan Pangolin Causes Lung Infection without Severe Disease in Human ACE2-Transgenic Mice. 0
- 113 Effect of continuing the use of renin-angiotensin system inhibitors on mortality in patients hospitalized for coronavirus disease 2019: a systematic review, meta-analysis, and meta-regression analysis. **2023**, 23, 1
- 112 The effect of COVID-19 on patients with preexisting autoimmune diseases. **2023**, 495-528 0
- 111 Cerebrovascular disease associated with COVID-19 in the practice of a family doctor. **2023**, 40-45 0
- 110 Alterations in Gut Microbiota Composition in Patients with COVID-19: A Pilot Study of Whole Hypervariable 16S rRNA Gene Sequencing. **2023**, 11, 367 1
- 109 The lung employs an intrinsic surfactant-mediated inflammatory response for viral defense. 0
- 108 Tissue distribution of angiotensin-converting enzyme 2 (ACE2) receptor in wild animals with a focus on artiodactyls, mustelids and phocids. **2023**, 16, 100492 0

- 107 The role of spike protein entry inhibitors in the treatment of mild-to-moderate covid-19 in nonhospitalized patients. **2022**, 9, 52-59 ○
- 106 Antimalarials and macrolides: a review of off-label pharmacotherapies during the first wave of the SARS-CoV-2 pandemic. 59, ○
- 105 ACE2 in pulmonary diseases. **2023**, 285-316 ○
- 104 Morphological aspect of the angiotensin-converting enzyme 2. **2023**, 389-417 ○
- 103 S:D614G and S:H655Y are gateway mutations that act epistatically to promote SARS-CoV-2 variant fitness. ○
- 102 SARS-CoV-2 Angiotensin Converting Enzyme 2 (ACE2) Receptor Expression and Its Effects on COVID-19 Epidemiology in Children. ○
- 101 Endogenous IFITMs boost SARS-coronavirus 1 and 2 replication whereas overexpression inhibits infection by relocalizing ACE2. **2023**, 26, 106395 ○
- 100 A Brighton Collaboration standardized template with key considerations for a benefit/risk assessment for the Medigen COVID-19 protein vaccine. **2023**, 41, 2615-2629 ○
- 99 Adaptive evolution of the Spike protein in coronaviruses. ○
- 98 T-cell lymphocytopenia: An omnipresent predictor of morbidity and mortality in consequence of SARS-CoV disease and influenza A infections. **2023**, 165, 156163 ○
- 97 Macular optical coherence tomography angiography analysis in diabetes mellitus patients with a history of Covid-19. **2023**, 42, 103513 ○
- 96 Myocardial Injury in COVID-19 (Epidemiology, Influence on Prognosis, Pathogenesis, Treatment). **2022**, 105-120 ○
- 95 Spike-mediated viral membrane fusion is inhibited by a specific anti-IFITM2 monoclonal antibody. **2023**, 211, 105546 ○
- 94 Antibody isotype epitope mapping of SARS-CoV-2 Spike RBD protein: Targets for COVID-19 symptomatology and disease control. **2023**, 53, ○
- 93 Broadly neutralizing aptamers to SARS-CoV-2: A diverse panel of modified DNA antiviral agents. **2023**, 31, 370-382 ○
- 92 Susceptibility of domestic and companion animals to SARS-CoV-2: a comprehensive review. **2023**, 55, ○
- 91 Quantitative profiling of N-glycosylation of SARS-CoV-2 spike protein variants. **2023**, 33, 188-202 ○
- 90 Emerging role of microRNAs and long non-coding RNAs in COVID-19 with implications to therapeutics. **2023**, 861, 147232 ○

- 89 Inhibiting the Deubiquitinase UCHL1 Reduces SARS-CoV-2 Viral Uptake by ACE2. ○
- 88 Repurposing of US-FDA approved drugs against SARS-CoV-2 main protease (Mpro) by using STD-NMR spectroscopy, in silico studies and antiviral assays. **2023**, 234, 123540 ○
- 87 Host-Derived Cytotoxic Agents in Chronic Inflammation and Disease Progression. **2023**, 24, 3016 ○
- 86 Drugs swapping in coronavirus strains: a structural biology view. 1-8 ○
- 85 SARS-CoV-2 Spike Protein Activates Human Lung Macrophages. **2023**, 24, 3036 ○
- 84 Targeted photodynamic neutralization of SARS-CoV-2 mediated by singlet oxygen. ○
- 83 Suppression of angiotensin converting enzyme 2, a host receptor for SARS-CoV-2 infection, using 5-aminolevulinic acid in vitro. **2023**, 18, e0281399 ○
- 82 Fibroblast-expressed LRRC15 is a receptor for SARS-CoV-2 spike and controls antiviral and antifibrotic transcriptional programs. **2023**, 21, e3001967 2
- 81 Brain corticogenesis and cholesterol homeostasis promotes SARS-CoV-2 infection and replication. ○
- 80 SARS-CoV-2 leverages airway epithelial protective mechanism for viral infection. **2023**, 26, 106175 ○
- 79 Towards Quantum-Chemical Level Calculations of SARS-CoV-2 Spike Protein Variants of Concern by First Principles Density Functional Theory. **2023**, 11, 517 ○
- 78 Membrane cholesterol regulates the oligomerization and fusogenicity of SARS-CoV fusion peptide: implications in viral entry. **2023**, 25, 7815-7824 ○
- 77 Metabolomics as a powerful tool for diagnostic, pronostic and drug intervention analysis in COVID-19. 10, ○
- 76 Exploring the Role of ACE2 as a Connecting Link between COVID-19 and Parkinson's Disease. **2023**, 13, 536 1
- 75 Chromone-embedded Peptidomimetics and Furopyrimidines as Highly Potent SARS-CoV-2 Infection Inhibitors: A Molecular Docking Study. ○
- 74 SARS-CoV-2 Affects Both Humans and Animals: What Is the Potential Transmission Risk? A Literature Review. **2023**, 11, 514 ○
- 73 Diagnostic TR-FRET assays for detection of antibodies in patient samples. **2023**, 3, 100421 ○
- 72 Antibody-mediated cell entry of SARS-CoV-2. ○

- 71 Human ACE2 expression, a major tropism determinant for SARS-CoV-2, is regulated by upstream and intragenic elements. **2023**, 19, e1011168
- 70 Insights into the Scenario of SARS-CoV-2 Infection in Male Reproductive Toxicity. **2023**, 11, 510
- 69 Broadly effective ACE2 decoy proteins protect mice from lethal SARS-CoV-2 infection.
- 68 Analysis of the SARS-CoV-2 spike protein revealed that blocked receptor-binding domain antigenicity decreases the production of neutralizing antibodies in vivo.
- 67 Machine Learning Guided Design of High-Affinity ACE2 Decoys for SARS-CoV-2 Neutralization. **2023**, 127, 1995-2001
- 66 SARS-CoV-2 pandemics: An update of CRISPR in diagnosis and host-virus interaction studies. **2023**,
- 65 Significance of Conserved Regions in Coronavirus Spike Protein for Developing a Novel Vaccine against SARS-CoV-2 Infection. **2023**, 11, 545
- 64 COVID-19 and diabetes mellitus: Clinical and laboratory features in hospitalized patients. **2023**, 20, 14-17
- 63 A structural perspective on the evolution of viral/cellular macromolecular complexes within the arenaviridae family of viruses. **2023**, 79, 102561
- 62 Infections of the cardiovascular system. **2023**, 255-326
- 61 Association of COVID-19 with Comorbidities: An Update. **2023**, 6, 334-354
- 60 Can Probiotics, Particularly *Limosilactobacillus fermentum* UCO-979C and *Lactiseibacillus rhamnosus* UCO-25A, Be Preventive Alternatives against SARS-CoV-2?. **2023**, 12, 384
- 59 The Latest Cellular and Molecular Mechanisms of COVID-19 on Non-Lung Organs. **2023**, 13, 415
- 58 Using PyMOL to Understand Why COVID-19 Vaccines Save Lives. **2023**, 100, 1351-1356
- 57 SARS-CoV-2 Spike-Mediated Entry and Its Regulation by Host Innate Immunity. **2023**, 15, 639
- 56 COVID-19 and Cardiovascular Diseases: A Literature Review From Pathogenesis to Diagnosis. **2023**,
- 55 Preface. **2023**, xxxiii-xxxiv
- 54 Angiotensin II as a mediator of renal fibrogenesis. **2023**, 235-262

- 53 Pathogenesis Underlying Neurological Manifestations of Long COVID Syndrome and Potential Therapeutics. **2023**, 12, 816 ○
- 52 Low hanging fruit for combatting SARS-CoV-2?. **2023**, 24, ○
- 51 Effect of B12 and folate deficiency in hypomethylation of Angiotensin I converting enzyme 2 gene and severity of disease among the acute respiratory distress syndrome patients. **2023**, 37, ○
- 50 Potential use of renin-angiotensin-aldosterone system inhibitors to reduce COVID-19 severity. **2023**, 42, 373-383 1
- 49 Rescuing fertility during COVID-19 infection: exploring potential pharmacological and natural therapeutic approaches for comorbidity, by focusing on NLRP3 inflammasome mechanism.. ○
- 48 Cellular and Molecular Mechanisms of Pathogenic and Protective Immune Responses to SARS-CoV-2 and Implications of COVID-19 Vaccines. **2023**, 11, 615 ○
- 47 Pharmacological disruption of mSWI/SNF complex activity restricts SARS-CoV-2 infection. **2023**, 55, 471-483 ○
- 46 SARS-CoV-2 Is More Efficient than HCoV-NL63 in Infecting a Small Subpopulation of ACE2+ Human Respiratory Epithelial Cells. **2023**, 15, 736 ○
- 45 Angiotensin-converting enzymes as druggable features of psychiatric and neurodegenerative disorders. ○
- 44 Understanding the Renin-Angiotensin System in Coronavirus Disease 2019. **2023**, 79-93 ○
- 43 Comprehensive Bioinformatics analysis of angiotensin-converting enzyme 2 (ACE2). ○
- 42 The consequences of severe acute respiratory syndrome coronavirus-2 on acute kidney injury among iraqi patients. **2023**, 7, 48 ○
- 41 Implications of Renin-Angiotensin System in Health and Disease. **2023**, 3-15 ○
- 40 Replicating-Competent VSV-Vectored Pseudotyped Viruses. **2023**, 329-348 ○
- 39 Relationship between the ABO blood group and Rhesus factors with COVID-19 susceptibility. **2023**, 16, 297-303 ○
- 38 Identifying promising druggable binding sites and their flexibility to target the receptor-binding domain of SARS-CoV-2 spike protein. **2023**, 21, 2339-2351 ○
- 37 Exploiting Modeling Studies for Evaluating the Potential Antiviral Activities of some Clinically Approved Drugs and Herbal Materials against SARS-CoV-2: Theoretical Studies toward Hindering the Virus and Blocking the Human Cellular Receptor. 1-12 ○
- 36 Efficient virus detection utilizing chitin-immobilized nanobodies synthesized in *Ustilago maydis*. **2023**, 366, 72-84 ○

- 35 Identification of common molecular signatures of SARS-CoV-2 infection and its influence on acute kidney injury and chronic kidney disease. 14, ○
- 34 Clays in the Global War Against COVID-19: Why are They Preferable Over the Conventional Weaponry?. **2023**, 91-122 ○
- 33 Serum Angiotensin II as a Biomarker in COVID-19. **2023**, 917-940 ○
- 32 Complications of COVID-19 on the Central Nervous System: Mechanisms and Potential Treatment for Easing Long COVID. **2023**, 0 ○
- 31 Dietary fish intake increased the concentration of soluble ACE2 in rats: can fish consumption reduce the risk of COVID-19 infection through interception of SARS-CoV-2 by soluble ACE2?. 1-8 ○
- 30 Reviews of drug candidates for COVID-19. 36, 219-226 ○
- 29 Prevalence of COVID-19 outcomes in patients referred to opioid agonist treatment centers. 14, ○
- 28 Clinical Characterization and Outcomes of Patients with Hypercreatinemia Affected by COVID-19. **2023**, 11, 944 ○
- 27 Deciphering molecular mechanisms of SARS-CoV-2 pathogenesis and drug repurposing through GRN motifs: a comprehensive systems biology study. **2023**, 13, ○
- 26 Receptors and Cofactors That Contribute to SARS-CoV-2 Entry: Can Skin Be an Alternative Route of Entry?. **2023**, 24, 6253 ○
- 25 Coronavirus 19 (COVID-19) and Syndrome of Inappropriate Anti-Diuretic Hormone Secretion (SIADH): A Review of Literature. ○
- 24 SARS-CoV-2 Receptors and Their Involvement in Cell Infection. **2023**, 17, 1-11 ○
- 23 The SARS-CoV-2 Spike Protein Activates the Epidermal Growth Factor Receptor-Mediated Signaling. **2023**, 11, 768 ○
- 22 Uncovering the Role of N-Glycan Occupancy on the Cooperative Assembly of Spike and Angiotensin Converting Enzyme 2 Complexes: Insights from Glycoengineering and Native Mass Spectrometry. **2023**, 145, 8021-8032 ○
- 21 All-atom simulations of the trimeric spike protein of SARS-CoV-2 in aqueous medium: Nature of interactions, conformational stability and free energy diagrams for conformational transition of the protein. ○
- 20 Lithium Therapy in COVID-19 with Bipolar Affective Disorder: A Case Series. 025371762311613 ○
- 19 Molecular Understanding of ACE-2 and HLA-Conferred Differential Susceptibility to COVID-19: Host-Directed Insights Opening New Windows in COVID-19 Therapeutics. **2023**, 12, 2645 ○
- 18 Cryo-EM structures and binding of mouse and human ACE2 to SARS-CoV-2 variants of concern indicate that mutations enabling immune escape could expand host range. **2023**, 19, e1011206 ○

- 17 Lung Expression of Macrophage Markers CD68 and CD163, Angiotensin Converting Enzyme 2 (ACE2), and Caspase-3 in COVID-19. **2023**, 59, 714 ○
- 16 Oral Cavity and COVID-19: Clinical Manifestations, Pathology, and Dental Profession. **2024**, 173-190 ○
- 15 Nano-Drug Delivery Systems for COVID-19 Drug Delivery. **2023**, 295-309 ○
- 14 High-Affinity Neutralizing DNA Aptamers against SARS-CoV-2 Spike Protein Variants. **2023**, 3, 520-542 ○
- 13 Mathematical Study on Corona-Virus (COVID-19) Disease Transmission and Its Stability Through SEIR Epidemic Model. **2023**, 562-578 ○
- 12 Insight into the liver dysfunction in COVID-19 patients: Molecular mechanisms and possible therapeutic strategies. 29, 2064-2077 ○
- 11 Interfacial water molecules contribute to antibody binding to the receptor-binding domain of SARS-CoV-2 spike protein. 1-10 ○
- 10 Changes in intestinal morphology, number of mucus-producing cells and expression of coronavirus receptors APN, DPP4, ACE2 and TMPRSS2 in pigs with aging. **2023**, 54, ○
- 9 Effect of coronaviruses on blood vessel permeability: potential therapeutic targets. **2023**, 17, 175346662311622 ○
- 8 The 3'UTR region of the DNA repair gene PARP-1 May increase the severity of COVID-19 by altering the binding of antiviral miRNAs. **2023**, 583, 29-35 ○
- 7 The role of the renin-angiotensin-aldosterone system in the development of cardiovascular complications in COVID-19. **2023**, 14, 98-118 ○
- 6 IS THERE A SAFETY SIGNAL GENERATION FOR SUDDEN SENSORINEURAL HEARING LOSS FOLLOWING mRNA COVID-19 VACCINATION: NATIONWIDE POST-MARKETING SURVEILLANCE USING THE FRENCH PHARMACOVIGILANCE SPONTANEOUS REPORTING DATABASE (Preprint). ○
- 5 Diabetes as one of the long-term COVID-19 complications: from the potential reason of more diabetic patients susceptibility to COVID-19 to the possible caution of future global diabetes tsunami. ○
- 4 Routine placental histopathology findings from women testing positive for SARS-CoV -2 during pregnancy: Retrospective cohort comparative study. ○
- 3 Understanding the molecular mechanisms of statin pleiotropic effects. ○
- 2 Mechanisms and implications of COVID-19 transport into neural tissue. **2023**, 123-132 ○
- 1 DHFR Inhibitors Display a Pleiotropic Anti-Viral Activity against SARS-CoV-2: Insights into the Mechanisms of Action. **2023**, 15, 1128 ○